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The work in this dissertation focuses on protein and peptides engineering for 
improving therapies for applications in human health. First, we describe a directed 
evolution approach to engineer antibody fragments to bind to intracellular targets. An 
antibody fragment library was displayed using the twin arginine translocation inner-
membrane display pathway, in order to allow only antibodies that are well-folded in the 
reducing cytoplasmic environment to be screened for binding. Displayed libraries were 
screened for binding to the apoptosis inhibitor survivin, and scFv cytoplasmic solubility 
and specificity was characterized. Though the antibodies isolated through this method 
displayed strong intracellular folding and high binding to survivin, they exhibited non-
specific binding as well. We improved the screening approach by using whole-plasmid 
PCR to recover sequences of isolated antibodies.  Additional improvements to the 
screening process to increase stringency will allow better isolation of antibodies with high 
affinity and specificity for their target. 
In a rational design approach, we designed an antimicrobial peptide-based approach 
for the treatment of candidiasis. Candida albicans is a commensal organism that resides 
asymptomatically in the body. This opportunistic pathogen can overgrow and cause 
potentially fatal bloodstream infections. C. albicans biofilms that colonize implanted 
devices exhibit increased resistance to antimicrobial treatments and current antifungal 
treatments contribute to the rise of resistant strains of C. albicans or may cause toxicity. 
Thus, there is a clinical need for new or improved antifungal therapeutics to treat C. 
albicans infections. Histatin-5 (Hst-5) is an antimicrobial peptide secreted by the salivary 
glands that exhibits antifungal activity against C. albicans. Hst-5 can, however, be 
degraded by secreted aspartic proteases (Saps) produced by C. albicans cells, reducing its 
antifungal activity. Amino acid substitutions made to Hst-5 reduced the likelihood of 
proteolytic degradation to better maintain antifungal activity. Of these modifications, the 
K11R-K17R and E16R peptides showed enhanced antifungal activity in preventing C. 
albicans biofilm formation and eradicating preformed biofilms as compared to parent Hst-
5. The improvements to methods and experimental findings in this research contribute to 
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Chapter 1: Introduction to protein engineering 
1.1 Engineering proteins and peptides for enhancement of therapeutic 
potential 
Protein engineering is the design of proteins to improve the properties of an existing 
protein or to develop novel proteins to serve a desired function [1] . Engineered proteins 
have relevance in a variety of sectors including but not limited to pharmaceuticals, biofuels, 
food and agriculture, and manufacturing [2,3]. Of particular interest in the biomedical field 
is the use of proteins and peptides as therapeutic agents to treat disease. New and emerging 
methods allow for improved engineering of existing therapeutic proteins. For example, 
newer insulin analogs have enhanced properties over first-generation recombinant insulin 
as protein engineering and characterization methods have improved [4].  
The fastest-growing class of protein therapeutics is antibody-based drugs, which have 
been approved for use in treatment of cancer, rheumatoid arthritis, asthma, transplant 
rejections, and Crohn’s disease among other applications [4–8] and monoclonal antibodies 
are among these biopharmaceuticals. Since cell signaling pathways contributing to cancer 
progression are complex [9,10] there are many potential targets for antibody-mediated 
therapy. The approval for use of antibodies as cancer therapeutics in healthcare establishes 
their potential as therapeutic agents. 
Another emerging class of protein therapeutics is that of antimicrobial peptides, which 
are naturally found in a variety of organisms and serve as a defense against microbial 
pathogens [11,12]. These peptides are of particular interest due to recent increases in 
antibiotic-resistant bacteria and fungi, resulting in increased mortality rates and healthcare 
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spending [13,14]. There is a need for the development of new therapeutics for the treatment 
of bacterial and fungal disease. In this work, we focused on two methods of protein and 
peptide engineering for developing an antibody fragment to target cancer pathways and 
antifungal peptides for the treatment of fungal infections.  
1.2 Directed evolution approach 
Directed evolution is a widely-used protein-engineering method that mimics natural 
selection to generate and isolate proteins with desired properties [15,16], such as antibodies 
with high affinity to a particular target. To begin, a diversified library is generated or 
obtained. For example, the gene for a protein of interest can be amplified in a low-fidelity 
manner that produces a library of protein genes each with varying nucleic acid mutations. 
The protein library is then expressed and screened for desired properties. In an iterative 
process, well-performing library members are then subjected to subsequent rounds of 
diversification and screening to enrich for proteins with the best properties (Figure 1.1).  
This process relies on the generation of an adequate library size to increase the probability 
of isolating a protein with improved fitness. The quality of the library, which is largely 
determined by the parent protein sequence and method of mutagenesis, is also of 
importance [16]. 
The most commonly used methods for screening protein libraries are phage display 
and yeast surface display [17,18] though in a comparison of these methods, it has been 
found that yeast surface display provides better sampling of the library repertoire and is 
less labor-intensive than phage display [19,20]. These methods have been used to isolate 
high-affinity antibodies for a variety of targets[21–24]and allow for fine affinity 
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discrimination, particularly with use of yeast surface display and flow cytometry [25]. For 
example, yeast surface display has been used to engineer antibodies to target antigens such 
as T cell receptors, botulinum neurotoxin, and the proapoptotic protein Bax, among other 
targets [21,26]. Yeast surface display, phage display, and traditional bacterial surface rely 
on secretory protein expression pathways [27,28] in which unfolded proteins are 
translocated to an oxidizing environment for folding [27,28]. Thus, these display methods 
are limited in the engineering of proteins that need to be well-folded in the reducing 
cytoplasmic environment. In Chapter 2, we describe the use of the twin-arginine 
translocation (Tat) pathway, which has an intrinsic intracellular protein folding quality 
control mechanism, which allows for display of proteins that are properly folded 
intracellularly [29]. 
1.3 Rational design approach 
Rational design of proteins is the manipulation of protein sequence or composition 
in a hypothesis-driven manner for the purpose of enhancing desired properties [30]. This 
Figure 1.1 Directed evolution. An iterative process mimicking natural selection 
whereby a gene is mutated to generate a diverse library of genes that is screened 
for a desired property. 
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requires an educated prediction based on previous findings about which modifications will 
impart the desired effect on the engineered protein structure or function.  The study of these 
small, deliberate changes and their impact on protein structure, function, and kinetics can 
provide valuable insight for the engineering of additional proteins. Previous work 
demonstrates the ability to rationally modify proteins to alter physiochemical properties, 
pharmacokinetics, affinity, and immunogenicity [30–33].  
It is important to note that in recent years, both rational design and directed 
evolution have benefited from advances in computer simulations of molecular interactions 
that can aid in design of functional proteins. For example, the Rosetta Antibody server can 
predict the structure of antibody variable regions based on optimization of dihedral angles 
and free energy of conformations [34]. Additionally, the Rosetta Snug dock application 
can be used to assess antibody-antigen docking taking into account the conformational 
degrees of freedom of the antibody portions relevant to binding [35].  
1.4 Overview of thesis work 
In Chapter 2, we describe the use of directed evolution to generate and screen an 
antibody fragment library for binding the intracellular target survivin, an inhibitor of 
apoptosis protein, using a bacterial inner-membrane display method. In Chapter 3, we focus 
on improvement of this method to simplify the process and increase the likelihood of 
isolating antibodies that specifically bind the target antigen. Methods presented in Chapter 
4 serve as an alternative display and screening method for the isolation of antibodies that 
bind survivin. In chapters 5 and 6, we describe a rational design approach to modify the 
antimicrobial peptide histatin-5 for the treatment of Candida albicans biofilms. Finally, in 
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Chapter 7, we discuss future studies to continue the improvement of protein and peptide 

























Chapter 2: Directed evolution of a single chain variable 
fragment library for binding survivin 
2.1 Introduction  
Directed evolution is commonly used to engineering antibodies. Intracellular 
antibodies (intrabodies) are particularly challenging to engineer as they must be correctly 
folded in the reducing cytoplasmic environment to ensure proper function and binding. 
They cannot contain the disulfide bonds that typically contribute to correct antibody 
folding and structure, and thus, must be engineered for solubility and folding. In this 
chapter, we focused on a novel bacterial protein display technique to engineer antibody 
fragments that are well-folded in the cytoplasmic environment and bind an intracellular 
target that plays a crucial role in anti-apoptotic cancer pathways.   
2.1.1 Selection of target protein, survivin 
The United States Centers for Disease Control reports over 1 million new cases of 
invasive cancer and more than 582,000 cancer-related deaths per year, making cancer one 
of the deadliest pathologies [36]. While the phenotypic manifestation of different cancers 
varies, one hallmark spanning all cancer types is the increased viability of cancerous cells. 
In addition to a loss of mitotic cell cycle checkpoints and increased proliferation, malignant 
cells lack a fully functional apoptotic program. In normal cells, there is a delicate balance 
between pro-apoptotic proteins and inhibitor of apoptosis proteins (IAPs) whereby cell-
physiological stimuli lead to a shift in this balance that can allow the cell to undergo 
apoptosis if need be. However, in cancer cells, this balance is disrupted and a loss of pro-
8 
 
apoptotic protein function or an increase in anti-apoptotic protein expression or function 
allows cells to evade apoptosis [37].  
Survivin is an IAP that is overexpressed in many cancer cell types including but 
not limited to breast, lung, colon, prostate and bladder cancers [38–42]. Overexpression of 
survivin leads to decreased patient survival rates in several cancer types [43,44] and to a 
particularly aggressive prognosis and increased metastasis in colorectal carcinoma [44,45]. 
Survivin is an ideal intracellular cancer target since, unlike other IAPs, it is only 
overexpressed in neoplastic tissues, but not in differentiated normal tissue [43,46].This 
research addresses the need to understand survivin’s role in cancer pathology and aims to 
develop a therapy to directly target survivin. 
 
 
Survivin has a pro-mitotic function [43,47] which is in part illustrated by its 
ubiquitous expression in embryonic and fetal developmental stages [46,48], during which 
Figure 2.1 Dimeric bowtie structure of survivin. Each C-
terminal helical domain interfaces with the BIR domain of 
partnering monomer via hydrogen bonding. (PDB ID : 1E31) 
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high cell division rates are expected. In contrast, survivin has a very low level of expression 
in normal adult cells [49]. Survivin plays a key role cytokinesis as part of the chromosomal 
passenger complex among other mitotic phenomena and is a critical regulator of mitosis 
[50–52] with increased expression during the G2-M transition phase of the cell cycle [50] 
of proliferating cells. Many cancers are marked by increased cell proliferation which agrees 
with the presence of survivin and its ability to increase proliferation. Survivin also plays 
an anti-apoptotic role, as explained below, and although many studies have been conducted 
to elucidate its role, gaps remain in the understanding of survivin’s inhibition of apoptotic 
moieties. Thus, there is a need to target survivin to inhibit its pro-mitotic and anti-apoptotic 
functions. 
Survivin’s structure provides some insight as to which domains are relevant to its 
pro-mitotic functions. Similar to other IAPs, survivin possesses a baculovirus inhibitor of 
apoptosis protein repeat (BIR) domain. It also has a 65Ǻ long C-terminal helix domain that 
is essentially locked in position with respect to the BIR domain via hydrogen bonding and 
hydrophobic contacts [53](Figure 2.1). The crystal structure of bacterially expressed 
recombinant full-length human survivin indicates a 35 kDa dimeric structure, which is 
maintained in solution. It is suggested that the two dimerization interfaces contribute to 
localization to the spindle centrosome as well as recruitment of other BIR domain 
containing proteins for the purpose of forming larger functional units. Furthermore, it is 
postulated that the dimeric structure with extended helical arms may play a role in bridging 
proteins involved with microtubule organizing centers (MTOC) [53], to which survivin 
spatially and temporally localizes to during mitosis [54]. 
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While it has been speculated that survivin’s anti-apoptotic activity involves its 
inhibition of caspases, this has not been confirmed by structural studies [53]. Survivin’s 
caspase-inhibiting behavior may be due to its conserved BIR domain, which has been 
shown to be vital in targeting caspases in other IAPs [47,55]. Debate exists over whether 
or not survivin can directly bind to caspases, but evidence shows that it indirectly prevents 
caspase activation. Survivin binds to the X-linked inhibitor of apoptosis protein (XIAP) to 
prevent XIAP from forming a complex with the second mitochondrial activator of caspases 
(Smac) [43].  Smac’s role is to bind IAPs like XIAP to disrupt their interaction with 
caspases so that apoptosis may proceed. Survivin disrupts the formation of the Smac-XIAP 
complex such that XIAP instead binds to survivin. This survivin-XIAP complex inhibits 
the activation of caspase-9, whose activation is a crucial step in the apoptotic pathway 
[47,56,57]. A potential therapeutic strategy could be to prevent survivin from binding to 
XIAP.  
Regardless of whether or not survivin can directly inhibit caspases or if it needs to 
bind to another IAP to prevent caspase activation, it is clear that preventing protein-protein 
interactions between survivin and other apoptosis associated proteins can inhibit survivin’s 
function. A potential challenge in designing a molecule to block these interactions is that 
survivin has acetylation and phosphorylation-diversified functions inside the cell [43]. In 
fact, while survivin inhibits apoptosis cytoplasmically, nuclear survivin can inhibit cell 
survival and repress transcription of oncogenes [58]. It is clear that the functional role of 
survivin is very complex and not fully understood.  Thus, in this research, we sought to 
engineer a molecule to inhibit survivin’s protein-protein interactions to help elucidate 
survivin’s specific binding domains and its role in the apoptotic pathway. This approach 
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would allow direct binding and inhibition of survivin, which is an advantage to more 
indirect methods such as survivin expression knockdown which may impart undesired 
effects. While parts of survivin’s structure-function relationship have been determined, we 
aim to target the survivin dimer as a whole rather than targeting specific domains. This will 
allow isolation of a more diverse group of survivin-binding molecules which may exhibit 
different modes of survivin binding and inhibition. 
2.1.2 Structure and properties of single chain variable fragments (scFvs) 
scFvs comprise a variable light chain (VL) and a variable heavy chain (VH) of a 
full-length IgG connected by a flexible peptide linker (Figure 2.2). Each VL and VH 
contains four framework regions and three complementarity determining regions (CDRs). 
The CDRs are highly variable, loop-structured regions that are responsible for antigen 
specificity and binding [59]. All scFv regions can contribute to antigen specificity, 
however, in order of importance to antigen binding these regions are CDR3H, CDR2H, 
CDR3L, CDR1H, CDR1L, CDR2L, and framework residues [59]. Thus, mutations can be 
made to the entire scFv sequence or focused solely on CDRs of higher importance to 
antigen specificity. scFvs maintain all antigen specificity of a full-length IgG antibody but 
are smaller and easier to produce [60].  
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scFvs rely on domain association to maintain full antigen binding capabilities. One 
critical VH-VL domain interaction is an intradomain disulfide bond between two highly 
conserved cysteine residues. While most scFvs require this intradomain bond to fold to the 
native conformation and intradomain association, the correct native structure can in some 
cases be reached with the absence of disulfide bonds [61]. scFvs engineered for 
intracellular function can be well-folded and functional even in the reducing cytoplasmic 
environment and have been shown to demonstrate cytoplasmic solubility [29]. scFvs are 
strong candidates for use as intrabodies as scFv libraries can be generated with high CDR 
diversity which gives a higher chance of success in finding scFvs that bind survivin. In 
these studies we enrich and screen a naïve scFv library for binding to survivin and discuss 
methods to improve specificity with our choice of display and screening method. 
2.1.3 Tat inner-membrane display and screening of antibody libraries 
It is inherently difficult to engineer antibodies for intracellular function as the 
cellular cytoplasm is highly reducing [62] and prevents the formation of disulfide bonds 
Figure 2.2 IgG and scFv structure. An scFv 
antibody fragment comprises the heavy and light 
chains of a full-length IgG antibody, connected 
via a flexible peptide linker.  
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necessary for correct protein structure and function. Commonly used methods of yeast 
surface display and phage display rely on secretory pathway to display libraries for 
screening [19,27,28], and thus do not have a quality control mechanism that prevents the 
display of improperly folded proteins. This contributes to the isolation of intrabodies that 
show promising binding affinity but that lack the cytoplasmic solubility needed to be 
function intracellularly [63]. To develop scFvs that are functional in the cytoplasmic 
milieu, we engineered antibodies using the Escherichia coli twin-arginine translocation 
(Tat) pathway. The Tat pathway contains an intrinsic intracellular protein folding quality 
control mechanism that only allows soluble, correctly folded proteins to be transported 
from the E. coli cytoplasm, across the inner membrane, and into the periplasm [64,65] . 
Overexpressed Tat substrates (i.e. proteins targeted to the Tat pathway with an N-terminal 
fusion to the Tat signal peptide ssTorA) that are well folded in the cytoplasm form a long-
lived translocation intermediate with the N-terminus in the cytoplasm and the C-terminus 
in the periplasm [29]. This allows display of correctly folded Tat substrates, including 
antibody fragments, on the periplasmic face of the E. coli inner membrane. After removing 
the outer membrane by enzymatic digestion to generate spheroplasts, antibodies are 
exposed to the extracellular space (Figure 2.3). This allows Tat substrates displayed on the 
inner membrane to be screened for binding to a specific target. Importantly, harnessing the 
Tat pathway for cell-surface display ensures that only the antibodies in the library that are 
well folded in the cytoplasm will be interrogated for binding, allowing simultaneous 
engineering of binding affinity and intracellular folding. 
The intracellular protein folding quality control mechanism of the Tat pathway in 
E. coli limits transport across the inner cell membrane to proteins that are well folded in 
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the reducing cytoplasmic environment. By overexpressing a fusion of an scFv to the 
ssTorA signal sequence (the signal sequence from the TorA protein, which is naturally 
transported by the Tat pathway) [64], translocation is stalled, resulting in display of scFvs 
on the inner membrane [29]. After enzymatic disruption of the outer membrane, the 
displayed antibodies are made available for screening for antigen-binding activity. The 
ability to take advantage of the Tat pathway for display was shown by Karlsson et al. [29] 
(Figure 2.4). The scFv antibodies scFv13 and scFv13.R4 were fused to either the native 
ssTorA sequence or a modified ssTorA that lacks the arginine-arginine residue pair 
recognized by the Tat pathway. scFv13.R4 was engineered by Martineau et al. from scFv13 
through four rounds of directed evolution and is known to fold well in the cytoplasm [66]. 
This scFv was displayed on the inner membrane, but only when expressed as a fusion to 
the native ssTorA signal sequence. Contrarily, scFv13 is not well folded cytoplasmically 
[66], so it is not displayed well on the inner membrane, regardless of the signal sequence 
to which it is fused. Additionally, if the scFvs were expressed in cells that lacked the TatC 
protein, a vital component of the Tat machinery [64,67], display was not observed, showing 




Inner-membrane display can successfully isolate scFv antibodies with high levels 
of affinity for a target protein and high levels of cytoplasmic solubility. Additionally, 
subsequent rounds of directed evolution using inner-membrane display improve antibody 
characteristics1. To demonstrate this, an error-prone PCR library based on scFv13, which 
has a low level of binding affinity for β-galactosidase (β-gal), was panned against the target 
antigen β-gal. scFv 1-4 was isolated after one round of mutagenesis and panning and 
exhibited higher binding affinity to β-gal than scFv13 (Figure 2.4A) and a higher level of 
cytoplasmic solubility (Figure 2.4B).  
Figure 2.3‡ E. coli twin-arginine translocation pathway and periplasmic display. 
Proteins expressed as fusions to the Tat pathway signal sequence ssTorA are transported 
for inner membrane anchoring only if they are correctly folded in the cytoplasm. The outer 
membrane is then enzymatically digested, thus placing the membrane-anchored protein in 
the extracellular space, available for detection in expression and antigen binding assays.  
‡Figure originally published in J. Vis. Exp. (2016) 
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A new library, based on scFv 1-4, was made using error-prone PCR, and panning 
of this second-generation library against β-gal was done in the presence of purified, soluble 
scFv 1-4 as a competitor. After this second round of mutagenesis and panning, scFv 2-1 
and scFv 2-3 were isolated using the enzyme-linked immunosorbent assay (ELISA)-based 
secondary screening. These scFvs not only exhibited higher binding affinity for β-gal than 
scFv13, but also exhibited better binding than the first-round clone scFv 1-4. scFv 2-1 
exhibited β-gal binding comparable to that of scFv13.R4 (Figure 2.4A). scFv 2-3 also 
shows a further increase in cytoplasmic solubility compared to scFv 1-4, highlighting the 
simultaneous engineering of solubility and antigen-binding. Since affinity and soluble 
expression of the scFvs are screened for simultaneously, it is possible that a selected scFv 
has moderate solubility but high binding or vice versa. For example, scFv 2-1 has lower 
soluble expression than scFv 2-3, but it exhibits higher binding affinity to β-gal.  
The Tat display and screening method can be used on its own or in combination 
with yeast surface display to enrich for well folded library members. Here, we use the Tat 
display method to screen a library of scFvs for binding to survivin. The display and 
screening of a naïve library using this method highlighted challenges in engineering for 
antigen binding specificity and reinforce the use of inner-membrane displayed libraries for 



















































































scFv13.R4-FLAG, M = 15
ssTorA-scFv13-FLAG, M = 35
ssTorA(KK)-scFv13-FLAG, M = 38
ssTorA-scFv13-FLAG tatC, M = 30
ssTorA-scFv13.R4-FLAG, M = 346
ssTorA(KK)-scFv13.R4-FLAG, M = 57
ssTorA-scFv13.R4-FLAG tatC, M = 40
Figure 2.4‡ Properties of scFv variants isolated using inner-membrane display. (a) 
Target binding. scFvs were expressed in the cytoplasm of E. coli cells (i.e. not using Tat 
display) with a 6X-His tag and purified using nickel-nitrilotriacetic acid spin-columns. 
Binding of the purified scFvs to β-galactosidase was measured via ELISA. Purified scFvs 
were loaded onto β-galactosidase-coated ELISA plates, and the bound scFvs were detected 
with an anti-6X-His antibody. (b) Cytoplasmic expression. Soluble and insoluble 
fractions of the cell lysates from cells expressing the scFvs cytoplasmically were analyzed 
via Western blot probed with an anti-6x-His antibody. Total protein concentration was 
used to normalize sample loading. (c) Detection of displayed scFvs on the inner 
membrane. Flow cytometry analysis was performed to detect the display of poorly folded 
scFv13 and well-folded scFv13.R4 on the inner membrane. scFvs were fused to native 
ssTorA or ssTorA(KK), where the Arg-Arg pair in the ssTorA sequence was modified to 
Lys-Lys. The C-terminal FLAG epitope tags on the scFvs were detected with a fluorescein 
isothiocyanate (FITC)-conjugated anti-FLAG antibody. Cells without the TatC protein 
(ΔtatC) and ssTorA-scF13 without the FLAG tag were tested as controls. M indicates the 
median fluorescence value. 




2.2 Materials and methods 
2.2.1 Selection of parent scFv for library generation 
As previously discussed, intrabodies must be engineered for cytoplasmic solubility 
and intracellular folding. As such, a parent scFv with high cytoplasmic solubility is an ideal 
starting point for the generation of a diversified library. One such scFv is scFv13-R4, which 
exhibits high solubility and has been shown to bind β-gal with high affinity, implying that 
it is well folded. Cytoplasmic solubility is a desired property as it improves the chance that 
the scFv is correctly folded and functional in the highly reducing cytoplasmic environment. 
Since survivin is an intracellular target, this is of extreme importance. Thus, an scFv13-R4 
based library was selected as the parent scFv on which the library would be based.  
 
Figure 2.5 Binding of scFv-F4 to survivin. A concentration-
dependent ELISA was performed to observe binding of 
scFv13, scFv13-R4, and scFv-F4 to survivin. scFvs bound to 
survivin were detected with an anti-FLAG epitope antibody. 



























The initial selection of the scFv13-R4 library, screening, and isolation of a new 
parent scFv, scFv-F4, were previously performed as follows (Dr. Amy Karlsson, 
unpublished data). A naïve scFv13-R4 library was obtained from the Martineau lab (IRCM, 
Montpellier, France). This library was constructed by introducing variation to the CDR3 
regions of scFv13-R4, by performing PCR with degenerate NNK oligonucleotides such 
that resulting scFv library constituents had varying CDR3 length [66]. This library was 
displayed using the E. coli Tat display method and subtractive panning and positive 
panning (detailed below in Sections 2.2.2 – 2.2.3) were performed to eliminate non-
specifically binding library constituents and to enrich for scFvs that bind to survivin (Figure 
2.8). The resulting sublibrary was screened using an ELISA for binding to survivin 
(detailed below in Section 2.2.4). From the screening, one potential scFv variant of interest, 
scFv-F4, was isolated and showed higher concentration-dependent binding to survivin than 
other potentially interesting variants. In Figure 2.5, it can be seen that scFv-F4 exhibits 
higher binding signal to survivin than its parent scFv, scFv13-R4, or scFv13 from which 









2.2.2 Library construction 
scFv-F4 was further mutagenized to create a second-generation library as described 
below. 
2.2.2.1 Error-prone PCR 
The Tat inner-membrane display plasmid containing the gene for scFv-F4, pIMD 
inner-membrane display plasmid (lab stock) (Figure 2.6), was used as the template in PCR 
using the Mutazyme II low-fidelity polymerase as part of the Genemorph II Random 
Mutagenesis kit (Agilent), which introduces random nucleotide errors during 
amplification. Initial template concentration was optimized to give a theoretical error rate 
of 1 to 4 amino acid mutations per amplicon. 
The primers used amplify the scFv genes were the forward primer, with sequence 
5′-GCGATGTCTAGAGCCGAGGTGCAGCT-3′, and the reverse primer, with sequence 
5′-ATGTAGTTCGAATTAACCTTTATCGTCATCGTCTTTGTAGTCTGCGGCCGCA 
CCTAGGAC-3′. These amplify the scFv genes, including FLAG tag, with inclusion of a 
5′ XbaI and a 3′ BstBI site, to enable cloning into the pIMD vector. The ssTorA signal 
sequence is excluded from error-prone amplification to allow fair periplasmic display and 
representation of the library amplicons, which would not be possible if ssTorA regions 
contained mutations and were thus unable to confer periplasmic display. 
2.2.2.2 Plasmid construction  
The error-prone PCR amplification product was cleaned and digested with XbaI 
and BstBI and ligated into the pIMD vector at the XbaI and BstBI restriction enzyme sites. 
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2.2.2.3 Transformation of library into E. coli 
Test ligations and transformations were performed in order to determine the 
insert:vector ratio that resulted in the largest number of transformants in comparison to the 
vector only control. The ligation reaction was scaled up to give an estimated library size of 
at least 1 × 106 transformants. Following ligation, electrocompetent DH5α E. coli cells 
were transformed via electroporation as follows. Ligation reaction product was heated at 
65 °C for 15 minutes to heat-inactivate DNA T4 ligase, followed by desalting on a 
microdialysis membrane (Millipore).  On ice, per 30 μL of ligation reaction, 300 μL of 
electrocompetent DH5α was added and each 350 μL solution of cells and ligation product 
was added to a 2 mm electroporation cuvette. Cuvettes were pulsed in an electroporator 
Figure 2.6‡ pIMD plasmid map. This plasmid fuses the inserted 
antibody gene to a 5’ ssTorA signal sequence and a 3’ FLAG 
epitope tag, with all three in the same reading frame. Restriction 
enzyme sites are indicated. 
‡Figure originally published in J. Vis. Exp. (2016) 
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(Bio-Rad) using manufacturer recommend settings designated for bacteria and cuvette size 
(2500 V, 25 μF, 200 Ω.) To recover transformed cells, a flask was filled with 25 mL SOC 
for every 1 mL cells used, and each cuvette was rinsed with a total of 3 mL SOC, all of 
which was added to the flask. Cells were recovered for 1 hour at 37 °C. A 300 μL aliquot 
was removed from the recovery flask to prepare dilutions and plate onto LB agar + Cm 
plates, which will be used to determine library size. The absorbance at 600 nm was read 
from a 1 mL aliquot as another measure to determine library size based on cell density. The 
remainder of the recovery cell suspension was added to 250 mL LB + Cm + 0.2% glucose 
and grown at 37 °C for 3 hours. From this, 100 mL was removed and added to 400 mL LB 
+ Cm + glucose and grown overnight to expand the library. The remaining volume was 
used to prepare lab stocks of the library in a solution of LB + Cm + 0.2% glucose with a 
final concentration of 50% glycerol which were then stored at -80 °C. The overnight culture 
was used in a midiprep DNA extraction and library size was estimated from the number of 




× 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 ×
(𝑡𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 𝑐𝑢𝑙𝑡𝑢𝑟𝑒)  
The purified plasmid obtained from the midiprep of the DH5α library overnight 
was used to transform electrocompetent MC4100 strain E. coli in the same manner. 
Transfer into this strain is necessary as DH5α is a cloning strain, and MC4100 is optimized 
for better protein expression. 
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2.2.3 Panning of library to enrich for survivin-binding members 
To deplete the library for non-specifically binding members and to enrich for those 
that bind survivin, a panning of the scFv library was performed against non-specific targets 
followed by a panning against survivin (Figure 2.9). 
2.2.3.1 Biotinylation of survivin and other proteins 
Survivin (1 mg/mL stock concentration; MW = 33.490 kDa including calmodulin 
tag), β-gal (10 mg/ml stock concentration; MW = 465 kDa), and lysozyme (100 mg/mL 
stock concentration; MW = 14.4 kDa) were biotinylated.  Immediately before biotinylation, 
a 10 mM solution of EZ-link-Sulfo-NHS-LC-biotin (Thermo Fisher) was prepared by 
adding 360 μL ultrapure water to 2.0 mg of reagent. This solution was added to each 
reaction in a 20-fold molar excess, which was calculated from the following equations:  










𝑚𝑚𝑜𝑙 𝑏𝑖𝑜𝑡𝑖𝑛 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑  







𝜇𝐿 𝑏𝑖𝑜𝑡𝑖𝑛 𝑟𝑒𝑎𝑔𝑒𝑛𝑡 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑  
The calculated amount of 10 mM EZ-link-Sulfo-NHS-LC-biotin solution was 
added, followed by the addition of PBS to a total volume of 50 μL. Solutions were 




2.2.3.2 Immobilizing biotinylated survivin on streptavidin-coated magnetic beads 
This protocol for directly immobilizing a biotinylated protein-of-interest from cell 
lysate onto streptavidin-coated magnetic beads is based on the Dynabeads manufacturer 
protocol (Invitrogen) and on procedures in Tayapiwatana et al. [68]. Dynabeads biotin 
binder streptavidin-coated magnetic beads (Invitrogen) were prepared by resuspension and 
washing with PBS + 0.1% BSA. Supernatant was removed by incubated tubes containing 
beads on a magnet and carefully pipetting. Survivin, β-gal, and lysozyme were immobilized 
onto separate aliquots of washed beads by adding 100 μL of biotinylated protein (from step 
2.2.3.1) to 45 μL washed beads and PBS up to a total volume of 500 μL and incubated at 
room temperature for 30 minutes while rotating. Beads were collected and washed 4 times 
with PBS + 0.1% BSA and were then resuspended in 1 mL PBS + 0.1% BSA. 
2.2.3.3 Spheroplasts with periplasmic-anchored scFvs 
Spheroplasting of E. coli expressing library scFvs is necessary to make 
periplasmically anchored scFvs available for binding interactions as it permeabilizes the 
outer membrane (Figure 2.7). One freezer aliquot of the MC4100 scFv-F4 library was 
thawed and grown in 250 mL LB + Cm at 37°C for 3 hours. The cultures were transferred 
to 20°C and grown for 18 hours, allowing the scFvs to be expressed.  Following overnight 
expression 1×1010 cells were harvested and centrifuged. The pellet was rinsed with ice-
cold fractionation buffer (3.0 mL 1M Tris-HCl (pH = 8.0) + 20.0 g sucrose + 200 μL 0.5 
M Na2EDTA + sterile water to final volume of 100 mL) and then resuspended in 
fractionation buffer supplemented with lysozyme. While slowly vortexing, 1 mM EDTA 
was added in a dropwise manner and the solution was incubated at room temperature for 
20 min. Ice cold 0.5 M MgCl2 was added and incubated on ice for 10 minutes. The sample 
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was centrifuged and the supernatant, which contains the dilute periplasmic fraction, was 
carefully removed. The remaining spheroplast pellet was then resuspended in 1 mL ice-
cold PBS.  
2.2.3.4 Negative panning  
The spheroplast-displayed library against magnetic beads coated in a nonspecific 
protein was implemented in order to deplete the library of non-specific binders. A sample 
of 4 × 109 spheroplasts was added to 8 × 108 lysozyme-coated beads and the volume was 
adjusted to 4 mL by adding PBS + 0.1% BSA. The reaction was split into 4 aliquots and 
Figure 2.7‡ E.coli cells and spheroplasts. (a) Untreated E. 
coli cells are cylindrical in shape. (b) Spheroplasting E. coli  
using EDTA and lysozyme causes rupturing of the outer 
membrane and the spheroplasts are spherical in shape. 
Differential interference contrast microscopy images were 
obtained using a 100X objective on an inverted microscope. 
‡Figure originally published in J. Vis. Exp. (2016) 
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gently rotated at 4 °C for 4 hours. Following incubation, the tubes were placed on a magnet 
and the supernatant containing the unbound spheroplast population was collected and used 
in a new negative panning preparation with fresh lysozyme-coated beads and the panning 
was repeated. Negative panning was repeated a third and fourth time with β-gal coated 
beads. 
2.2.3.5 Positive panning, PCR amplification, and library construction 
Immediately following negative panning, the collected supernatant, which contains 
any remaining unbound spheroplasts, was used to prepare panning reactions with survivin-
coated beads. Reactions were incubated at 4 °C while gently rotating for 5 hours. 
Polymerase chain reaction (PCR) to amplify the scFv genes of plasmids contained in the 
bead-bound spheroplasts was performed. Bead-bound spheroplasts were prepared for PCR 
by washing with PBS + 0.1% BSA followed by resuspension in 25 μL water. Multiple 
identical PCR reactions were prepared as seen in Table 2.1 and boiled at 98 °C for 15 
minutes prior to adding polymerase. High fidelity Phusion polymerase (New England 
Biolabs) was used to ensure errors that could change the scFv sequence could not occur. 
The PCR was completed using the thermal cycler program in Table 2.2. PCR products 
were pooled, cleaned using a PCR cleanup kit, and scFv genes were cloned into the pIMD 








Table 2.1 PCR reaction preparation for amplification of scFv library 
from bead bound spheroplasts 
Reagent Volume (μL) 
Washed beads with bound spheroplasts 5.0 
40 mM (10 mM each) dNTP mix 0.4 
Forward primer “MD 6283” (33 μM) 0.75 
Reverse primer “MD 6284” (33 μM) 0.75 
5X Phusion HF buffer 10.0 
Water 32.6 
Phusion polymerase (added after boiling step) 0.5 
Total 50.0 
 
Figure 2.8 Subtractive and positive panning. Spheroplasts expressing antibody library 
variants are incubated with magnetic beads coated with non-desired target to deplete the 
library of antibodies that bind non-specifically. Spheroplasts remaining in solution are 
incubated with survivin-coated magnetic beads. Antibody genes from bead-bound 




2.2.4 Library secondary screening 
An initial screening on the binding activity of library variants was performed in 
order to isolate potentially interesting clones to further characterize. The MC4100 panned 
scFv-F4 library was plated onto 20 μg/mL Cm LB agar plates and grown at 37 °C. Sterile 
flat-bottom 96-well culture plates were filled with 200 μL per well with 20 μg/mL Cm LB 
media. Individual colonies from the library plate were picked using a pipette tip and used 
to inoculate individual wells of the culture plate. Controls included were wells with cells 
harboring scFv-13, scFv-R4, and scFv-F4 containing plasmids, as well as a negative 
control well with no inoculation. Plates were incubated at 37 °C for 4-6 hours at 350 rpm 
on a microplate shaker until OD600 = 0.6. Cell suspension from wells was spotted as an 
array onto a 15 cm LB + Cm agar plate, which was incubated at 37 °C. This enables 
recovery of specific clones after the screening assay is completed. Plates were further 
incubated at 37 °C shaking overnight to promote growth and induction of scFv expression. 
A high-binding polystyrene ELISA plate was coated with 50 μL of a 1 μg/mL survivin 
solution and incubated at 4 °C overnight. The ELISA plate was emptied and blocked with 
2% milk in PBS for 2 hours. Cells in the growth plate were lysed by the addition of 20 μL 
PopCulture reagent (EMD Millipore) per well and incubated at room temperature while 
shaking for 15 minutes. The ELISA plate was washed 4 times with 0.05 % PBST followed 
Table 2.2 Thermal cycler protocol for PCR amplification of scFv 
library from bead bound spheroplasts 
Step Temperature (°C) Duration 
1 98 30 seconds 
2 98 30 seconds 
3 62 30 seconds 
4 72 25 seconds 
5                                              Repeat steps 2 – 4  30 times 
6 72 8 minutes 




by a transfer of 50 μL from each well of the cell lysis plate to the ELISA plate. Plates were 
incubated at room temperature for 2 hours then washed as before. The conjugated primary 
anti-FLAG (HRP) antibody was prepared at a 1:10000 dilution in 2% milk PBST and 50 
μL of the antibody solution was added to each ELISA plate well and incubated at room 
temperature for 2 hours. Plates were washed as before and 200 μL of SigmaFast OPD (o-
phenylenediamine dihydrochloride) HRP substrate (Sigma Aldrich) was added to each well 
an incubated for 1 hour at room temperature in the dark. The reaction was quenched by 
addition of 50 μL 3 M H2SO4 per well and absorbance at 492 nm was measured. Data was 
analyzed by first subtracting background signal and then comparing absorbance values for 
each well to that of the average absorbance of the scFv-F4 wells as a higher signal indicates 
higher binding of expressed scFvs clones to survivin. Interesting clones were selected on 
this basis to further characterize their survivin-binding properties. 
2.2.5 Library tertiary screening 
This assay was performed in order to determine the binding properties of interesting clones 
at different dilutions in order to characterize binding to survivin. Cells were inoculated 
from the spotted agar plates from step 2.2.4 into 5 μL LB + Cm each and grown overnight 
at 37 °C. ELISA plates were coated with survivin as described in step 2.2.4. Plates were 
blocked with PBS + 0.1% BSA for 2 hours at room temperature then washed with PBST. 
Cell lysates were prepared by centrifuging overnight samples, adding BugBuster 
MasterMix (EMD Millipore) as directed in the manufacturer protocol, and centrifuging at 
16,000 ×g for 20 minutes at 4 °C to separate soluble cell lysate from insoluble cell debris. 
Two-fold dilutions of cell lysate were performed, using PBS + 0.1% BSA as a diluent such 
that all wells contained 50 μL of lysate. Samples were incubated for 1.5 hours at room 
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temperature then washed with PBST as before. A 1:10,000 dilution of Anti-6XHis (HRP 
conjugated) antibody was prepared in PBS-BSA and 50 μL was added per well and 
incubated for 1.5 hours, followed by a PBST wash as before. HRP substrate was prepared 
as directed in manufacturer instructions and 200 μL was added to each well on the ELISA 
plate and incubated for 30-45 minutes in the dark. To quench the reaction, 50 μL of 3M 
H2SO4 was added to each well and mixed by pipetting. The absorbance at 492 nm was 
measured. 
2.2.6 Expression and binding characterization of isolated clones 
A Western blot was performed to determine the level of soluble scFv expression of 
newly-isolated library members as compared to scFv-R4 and scFv-F4 which have high 
soluble expression. For this experiment, genes encoding scFvs were expressed using the 
pET21 expression vector that expresses protein in the cytoplasm. Thus, scFvs will no 
longer be anchored in the periplasm, and will be partitioned into either the lysis buffer 
(soluble fraction) or remain in the cell debris (insoluble fraction). 
Standard molecular cloning techniques were used to clone the genes encoding for 
scFv13, scFv13-R4, scFv-F4, and selected isolated scFvs into the pET21 expression 
plasmid, which expresses proteins with a C-terminal 6XHis tag. BL21-DE3 E. coli were 
transformed with the recombinant plasmids via electroporation as previously described. 
BL21-DE3 cells with no plasmid were included as a control. Cells were grown at 37 °C 
overnight, subcultured to OD600= 0.5-0.8 and induced with IPTG at 20 °C overnight. Cells 
were transferred to microcentrifuge tubes and centrifuged at 16,000 × g for 5 minutes. The 
supernatant was removed and 5 mL\g cell pellet of BugBuster MasterMix was added to 
each sample and resuspended. Samples were incubated at room temperature for 20 minutes 
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while gently rotating then centrifuged at 16,000 × g at 4 °C for 20 minutes to pellet the cell 
debris. The supernatant containing the soluble fraction of protein was collected and the 
total protein concentration was measured at A280. Samples were diluted with BugBuster 
MasterMix to normalize by total protein concentration. SDS loading buffer was added and 
samples were boiled at 98 °C for 5 minutes, and then loaded onto an Any kD Mini-
PROTEAN TGX precast protein gel (Bio-Rad) for gel electrophoresis. Protein was 
transferred to a polyvinylidene difluoride membrane, which was then stained with a 
horseradish peroxidase (HRP)-conjugated anti-6XHis antibody and incubated with HRP 





Figure 2.9‡ ELISA-based secondary screenin. (a) To grow and express 
antibodies, wells of a culture plate are inoculated with individual library variants 
from the sublibrary enriched during panning. (b) An ELISA plate is coated with 
target antigen. (c) Library variants are screened using the ELISA-based 
secondary screen described. Upon analysis of data obtained from the secondary 
screen, variants of interest are selected and characterized further via 
concentration-dependent ELISA using cell lysates. 
‡Figure originally published in J. Vis. Exp. (2016) 
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2.3 Results and discussion 
2.3.1 scFvs isolated through inner-membrane display and screening are soluble 
In order for intrabodies to function properly, they must be soluble and correctly 
folded in the cytoplasmic environment. Insolubility of intrabodies results in aggregation 
that can renders them non-functional [63]. To determine whether or not isolated scFvs are 
cytoplasmically soluble, the soluble fraction of newly-isolated variants was compared to 
that of scFv-F4 and scFv13-R4. Similar levels of soluble protein expression are observed, 
which indicates that the Tat inner-membrane display and screening method is not 
selecting against this property and that solubility of library variants is maintained because 
insoluble library members are not displayed for screening (Figure 2.10). As expected, 
scFv13 exhibits lower soluble expression levels as previously observed by Karlsson et al. 
[29]. Since scFvs need to be soluble in the cytoplasm, this property is imperative to their 
function. These results demonstrate the application of the Tat inner membrane display 
system as a tool to engineer intrabody solubility. 
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2.3.2 Isolated scFvs are non-specific and do not exhibit saturable binding 
Library scFv variants of interest were isolated and further characterized for 
surviving-binding capabilities and showed high ELISA signal that increased with 
increasing scFv concentration. However, saturable binding was not seen as higher scFv 
concentrations were used, which may be indicative of nonspecific binding or aggregation 
of scFvs (Figure 2.11A). While a saturable binding curve is not a requirement, it suggests 
that the binding signal seen is predominantly from scFvs binding specifically to the antigen. 
Since there is a finite amount of antigen present, binding that does not show saturation at 
higher scFv concentrations is indicative of scFvs nonspecifically binding to each other such 
that the signal is amplified. It could also indicate that an isolated scFv is binding to multiple 
epitopes on a single antigen, which indicates some level of nonspecificity.   
Figure 2.10 Soluble fraction of cytoplasmically expressed scFvs. scFv13, 
scFv13-R4, and scFv-F4 controls were compared to X25 and X30 scFv library 
isolates for soluble expression. Genes encoding each scFv were cloned into the 
pET21 (+) a plasmid and expressed as a fusion to a polyhistidine tag in BL21-DE3 
E. coli. Samples were normalized by total protein concentration prior to gel loading 
and detected using an ant-6XHis antibody in a Western blot assay. 
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Additionally, when the same scFvs were tested via ELISA for binding to 
nonspecific targets such as β-gal and lysozyme (method in Section 3.2.4), similar binding 
patterns and absorbance intensities were seen, indicating that isolated scFvs bind to all 
targets, including survivin, nonspecifically (Figure 2.11B). This nonspecific binding is an 
undesirable property as for therapeutic purposes, it is imperative that the antibody binds 
only survivin, as binding other proteins may disrupt other pathways and cellular properties 
that may change the properties of the cancerous cells in undesirable ways. 
 A potential reason for the high binding signal seen in the secondary screen that led 
the pursuit of the scFvs that bind nonspecific targets with high affinity is binding avidity. 
The secondary screen relies on the data from just one well with an uncontrolled number of 
cells, and thus an uncontrolled number of displayed scFvs, to convey information about 
that particular scFv binding affinity for survivin. It is possible that some wells contain more 
cells and thus, more scFv copies, which can lead to an inaccurate comparison of two scFvs 
with equal binding affinity. Additionally, the secondary screening assay involved the use 
of surface-immobilized antigen, which can also increase avidity due to a high local 
concentration of available antigen binding sites. As the survivin is not oriented on the 
surface in any particular way during the bead-coating process, there will also be a higher 
number of scFvs that can bind as there are more potential antigen epitopes that isolated 
scFvs may bind.  
A strategy was employed to elucidate implications of secondary screen apparent 
binding signal as it relates to specificity. We hypothesized that those variants showed very 
high secondary screen signal may be doing so due to scFv crowding or avidity and that 
scFvs showing mid-range signals may be more accurately representative of scFv binding 
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strength. Following secondary screening, the variants were grouped into three bins based 
on the A492 signal and scFvs from each bin were compared to those of other bins in a 
specificity ELISA (data not shown). It was found that the differences in secondary screen 
signal did not convey differences in specificity among scFv variants as those from different 
signal bins showed similar non-specific binding behavior. 
We hypothesize that the non-specific properties of scFvs isolated from the library 
may be a result of reduced library quality and choice of parent scFv. While scFv-F4 was 
selected due to its high binding signal to survivin and the fact that its parent scFv, scFv13-
R4, exhibited high cytoplasmic solubility [29], its intrinsic binding affinity for β-gal may 
be difficult to overcome when targeting other antigens. However, as the scFv also bound 
to lysozyme, to which scFv13-R4 does not bind, this is likely not the case. The issue may 
be caused by overall library quality, that is determined by functional library size and not 
by apparent library size [69]. Preferences for mutation and high percentage of stop codon 
mutations could result in a poor sampling of possible scFv mutants. We reviewed a 
sampling of scFv library member sequences throughout these studies and all were unique, 
in frame with the ssTorA signal sequence, and a low percentage contained stop codons 
(data not shown.) As high-affinity antibodies have been isolated from non-immunized 
libraries with some groups indicating specificity of isolated antibodies [70,71], however, it 







Figure 2.11 Binding of scFv variants. (a) A concentration-dependent ELISA 
was performed on variants of scFv-F4 to observe binding to survivin. Variant 
names begin with “X”. (b) To observe specificity, a concentration-dependent 
ELISA was performed using variants of scFv13-R4 on ELISA plates coated 
with either survivin or lysozyme. BL21-DE3 cells expressing scFvs were 
lysed and lysates were serially diluted in an ELISA plate coated with survivin 
or lysozyme. scFvs were detected with an HRP-conjugated anti-FLAG 
antibody and incubation with HRP substrate, followed by absorbance 
measurement at 492 nm. Closed icons indicate samples binding to survivin 
and open icons indicate samples binding to lysozyme. Variant names begin 
with “Var”. Samples labeled with (lysozyme) indicate their binding to 






































Overall, scFvs isolated from the scFv-F4 library using Tat inner-membrane display 
and screening exhibited high binding to survivin. They also showed high binding to non-
specific targets, which is not ideal when aiming for binding to a specific intracellular target. 
While the underlying cause of this nonspecific behavior has yet to be determined, these 
results clearly indicate a need to characterize the specificity of antibodies derived from all 
library display and screening protocols.  
Still, isolated scFvs were soluble, indicating that they are likely well folded in the 
cytoplasmic environment which highlights the capability of the Tat inner membrane 
display system as a vital tool to engineering intrabody solubility. Additional modifications 
to the screening protocol will improve the specificity of isolated antibodies. These results 
highlight that advantages of the Tat inner-membrane display and screening method for the 
isolation of soluble intrabodies and necessitate the improvement of the methods for the 
screening of a naïve library to increase intrabody specificity. 
Furthermore, these results emphasize the general need to assess specificity when 
screening a large library, particularly one that is non-immunized. Non-specific binding, 
both intracellularly and extracellularly, could result in detrimental off-target effects and 
greatly reduce the ability to use such antibodies as therapeutics. Specificity is often 
overlooked when engineering for antigen binding affinity; however, our results 




Chapter 3: Improving antibody library construction and 
screening assays 
3.1 Introduction 
Specificity of binding is an issue, particularly in dense cytoplasmic milieu. 
Nonspecific binding of intrabodies can lead to undesired off-target effects. In our studies, 
we found that it was difficult to isolate scFvs that specifically bound to survivin and not to 
other proteins. Additionally, the screening method of Tat-displayed libraries is a low-
throughput method, and thus any techniques that can shorten the timescale of screening 
would be beneficial. For this reason, we sought to implement techniques to increase the 
stringency and streamline the screening process to remove time-consuming steps. 
3.2 Methods of improvement 
3.2.1 Whole plasmid PCR 
3.2.1.1 Determination of feasibility of whole plasmid PCR 
In the interest of simplifying the protocol and saving time, we sought to eliminate 
a cloning step by utilizing whole plasmid PCR. Previously, scFv genes were amplified via 
PCR, digested with restriction enzymes and ligated back into the vector plasmid. 
To ensure whole plasmid PCR can be performed, purified pIMD-scFv13 plasmid was used 
to set up a PCR reaction with various sets of primers that are in conserved regions of the 
vector, for example, the origin of replication. Five sets of primers (Table 3.1) were tested 
to see which gave the best results in addition to variance of the type of polymerase, Phusion 
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or Q5 (New England Biolabs), used for primer sets that benefited from adjustment in 
annealing temperature. In each set of primers, the forward and reverse primers were 
designed to anneal to the template end-to-end, on complementary strands, such that when 
amplified, the entire plasmid will be accounted for (Figure 3.1).  Primers were 
phosphorylated at the 5′ end with T4 Polynucleotide Kinase (PNK) (New England Biolabs) 
to ensure re-circularization can occur. The template DNA used to test amplification was 
pIMD-scFv13 and each reaction was set up as shown in Table 3.2 and using the thermal 
cycler program in Table 3.3. Following PCR, 5 μL of each PCR product was run on an 
agarose gel alongside uncut plasmid template controls to determine size. The remainder of 
each product was cleaned using a PCR cleanup kit (Promega) and ligation was performed 
at 16 °C overnight at a low template concentration of 1 ng/μL to re-circularize the DNA 
(Table 3.4).   
 
Figure 3.1 Whole plasmid PCR. End-to-end primers that anneal to a common plasmid feature are 





Table 3.1 Whole plasmid PCR primer sets 















































promoter of the E. coli cat gene  







Table 3.2 PCR reaction preparation for PCR amplification of 
whole plasmids 
Reagent Volume (μL) 
Plasmid template (0.5 ng) 0.9 
Phosphorylated forward primer (10 μM) 2.5 
Phosphorylated reverse primer (10 μM) 2.5 
5X polymerase-appropriate reaction buffer 10 
40 mM dNTP mix 1 









3.2.1.2 Whole plasmid PCR on spheroplasts 
We then sought to show that whole plasmid PCR can be performed on recovered 
spheroplasts. Following a panning of library spheroplasts against survivin-coated beads, 
beads were collected and used to set up PCR reactions. Each PCR reaction was prepared 
as in Table 3.2 but instead of purified plasmid template, 5 μL of beads collected from 
panning were used and the volume of sterile water was adjusted. Only the primer set 2 (P-
127 + P-128) was tested. PCR product was run on an agarose gel alongside PCR product 
from amplification of solely the scFv gene region to compare size. 
Table 3.4 Preparation of a ligation reaction to recircularize linear 
whole plasmid PCR product 
Reagent Volume (μL) 
Linearized PCR product (200 ng) Dependent on concentration 
10X T4 DNA ligase buffer 20 
T4 DNA ligase 1 
Sterile water To a total of 200 μL 
 
Table 3.3 Thermal cycler protocol for PCR amplification of whole 
plasmids 
Step Temperature (°C) Duration 
1 98 30 seconds 
2 98 10 seconds 
3 Ta 30 seconds 
4 72 1 minute, 30 seconds 
Repeat steps (2 – 4) 35 times 
5 72 6 minutes 




3.2.2 Recovery of plasmids from spheroplast 
3.2.2.1 Determining minimum spheroplast concentration for direct transformation 
of E.coli  cells 
FACS sort cell suspensions of different cell densities were simulated by 
spheroplasting E. coli and resuspending them in PBS (Table 3.5). Samples were 
centrifuged at 16,000 ×g at 4 °C for 10 minutes and 900 μL of the supernatant was carefully 
removed by pipetting. To each sample, 500 μL of sterile water was added to lyse the 
spheroplasts. Each sample was then sterile filtered through a 0.2 μM filter to remove any 
residual cells and de-salted on a microdialysis membrane (EMD Millipore). MC4100 cells 
were transformed by addition of 20 μL of filtered, de-salted lysates to 50 μL E. coli and 
transformation via electroporation as previously described. Each reaction of transformed 
cells was recovered for 1 hour at 37 °C in 400 μL SOC media. For each condition, 380 μL 
of recovery was plated on 15 cm LB agar + Cm plates and incubated at 37 °C overnight. 
The number of CFUs per plate was counted. No replicates were performed initially.  
3.2.2.2 PCR amplification of spheroplasts 
 To assess whether or not spheroplasts at low concentrations that are not bound to 
magnetic beads can be used in PCR amplification reactions, the following experiment 
was performed. MC4100 E. coli containing pIMD-F4-FLAG plasmid were grown and 
spheroplasts were prepared as previously described. Spheroplasts were diluted to 
concentrations of 1 × 104 cells/mL, 1 × 106 cells/mL, or 1 × 108 cells/mL in 1 mL PBS 
each. Samples were centrifuged at 4 °C at 11,000 × g for 20 minutes and 500 μL of 
supernatant was removed by pipetting. To each sample, 2 mL of sterile water was added 
to lyse the spheroplasts.  Samples were then sterile filtered through a 0.2 μm filter to 
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eliminate E. coli that were not spheroplasted or lysed, which could contaminate results. A 
small volume from each was collected at this step to use as a comparison to test the 
necessity of performing a cleanup of the lysed spheroplasts. A PCR cleanup kit was used 
to concentrate the remaining filtered samples, which were eluted into a volume of 35 μL.  
 Whole PCR reactions were prepared for each starting spheroplast concentration, 
with either 75 μL pre-PCR cleanup sample, 5 μL post-PCR cleanup sample, or 20 μL 
post-PCR cleanup sample using primer set 2 (P-127 and P128). A positive control was 
prepared using purified plasmid DNA. A negative control was prepared with water 
instead of DNA or spheroplast. Taq polymerase (New England Biolabs) was used as it 
showed better amplification of at low DNA template concentrations as compared to 
Phusion polymerase.  
3.2.3 Increasing stringency 
scFvs isolated by screening the inner membrane-displayed library did not bind 
specifically to survivin and showed similar binding to nonspecific targets of β-gal and 
lysozyme (Section 2.3.2). To improve the likelihood of isolating scFvs that specifically 
bind survivin, we sought to alter the panning and screening protocol by manipulating 
conditions through the use of non-specific proteins, additional blocking reagents or 
competitive inhibitors. 
3.2.3.1 Inclusion of a non-specific target, competitive inhibitor, additional blocking 
reagents in panning reactions 
 To increase the probability that potentially interesting library members bind to 
survivin immobilized on beads specifically, a variety of conditions were manipulated 
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during panning reactions. Panning reactions were prepared as described in Section 2.2.3 
with the addition of 40 μg of β-gal per reaction. Simultaneously, the addition of additional 
BSA, milk, and Tween 20 was varied. 
 An experiment was performed to determine the effects of supplementation with 
0.05 mg/mL soluble β-gal during the lysate incubation step of the secondary screening 
process. Potentially interesting clones were selected for further characterization. To 
determine the effect of this modification on saturable binding, ELISAs to observe binding 
to survivin were performed that included isolated members from the secondary screen with 
β-gal and members isolated from screening without β-gal supplementation. Three variants 
that exhibited saturable binding profiles were selected for further characterization to 
determine their specificity. ELISAs were performed using these variants against survivin 
and the nonspecific target lysozyme, including scFv13-R4 and scFv-F4 as controls. 
Additionally, to compare blocking capabilities of different reagents, lysates dilutions were 
prepared in either PBST + 50 μg/mL BSA or PBST + 2 % w/v milk. 
In a separate experiment, soluble scFv-F4-6XHis was included as a competitive 
inhibitor in panning reactions. This would serve as a method to allow only scFvs that bind 
survivin with higher affinity than scFv-F4 to compete scFv-F4 off of survivin and 
contribute to a binding signal. BL21-DE3 E. coli transformed with pET21-scFv-F4-6XHis 
were grown overnight at 37 °C then subcultured to OD600 = 0.5 and were induced with 
IPTG and grown at 20 °C overnight. Cells were lysed using a cell disruption system 
(Avestin) and purification was performed using immobilized metal affinity 
chromatography (IMAC) on a Next Generation Chromatography system (Bio-Rad). 
Collected fractions containing soluble scFv-F4-6XHis were sequentially dialyzed into 20 
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mM Tris supplemented with 100 mM EDTA (pH = 8.5), 20 mM Tris (pH = 8.5), and finally 
PBS (pH = 7.4). Purity and molecular weight were confirmed by gel electrophoresis and 
Coomassie staining. Panning reactions were prepared as described in 2.2.3 with the 
addition varying volumes of soluble scFv-F4-6XHis per reaction. 
3.2.3.2 Additional negative panning steps to improve elimination of non-specific 
library members 
Another method modification to improve specificity was the addition of multiple 
negative panning steps. Originally, there was no inclusion of the negative panning steps 
detailed in Chapter 2.2.3.4 other than panning the spheroplast library against beads that 
were not yet coated with anything other than streptavidin. See 2.2.3.4 for sequential 
negative panning protocol. 
3.2.4 Specificity ELISA 
Specificity of isolated antibodies is often overlooked but needs to be assessed when 
engineering intrabodies for therapeutic purposes to prevent any off-target effects that may 
be unfavorable [72]. To assess the specificity of isolated antibody fragments for binding 
survivin, those antibodies that showed promising binding activity were assessed. 
Performing this assay after making modifications to the panning and screening protocols 
provides a correlation between the inclusion of competitive or blocking factors and the 
specificity of isolated scFvs. 
Survivin and a non-specific target (i.e. β-gal, lysozyme, or BSA) were coated onto 
high-binding polystyrene 96-well ELISA plates at 4 °C overnight and an ELISA was 
performed as described in 2.2.5 with dilutions of one replicate of scFv sample lysate added 
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to wells coated with survivin and the other added to wells coated with non-specific target. 
Survivin was coated at 1 μg/mL, β-gal was coated at 4 μg/mL, and lysozyme was coated 











3.3 Results and discussion 
3.3.1 Whole plasmid PCR recovers plasmid from purified plasmid and 
spheroplast lysate 
Gel electrophoresis of purified linearized whole plasmid PCR product and 
recircularized whole plasmid PCR product showed bands around the correct size of 2970 
bp, with the recircularized plasmid running slightly larger which is expected as supercoiled 
plasmid tends to run smaller than linearized ladder DNA (Figure 3.2). These results 
indicate that plasmids can successfully be fully amplified.  
Figure 3.2 Whole plasmid PCR using purified plasmid template. Sizes of linear product 
obtained from whole plasmid PCR reactions 1 – 5 from Table 3.1 (Lanes 5 – 9) were 
compared to that of undigested, purified plasmid template (Lanes 2 – 3). Arrow indicates 
approximate correct size of 2970 bp as determined by the DNA ladder (Lane 1). Red color 
on DNA band indicates signal saturation. 
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It was also found that whole plasmid PCR can be performed successfully on 
plasmids taken from spheroplasts. Whole plasmid PCR performed on purified plasmid 
from spheroplasts was ran on an agarose gel and again bands were present at the correct 
size of 2970 bp (Figure 3.3). This enables the elimination of cloning step to reinsert 
recovered scFv genes into the vector plasmid, thus shortening the time needed to screen 
the library. It should be noted that whole plasmid PCR done on spheroplasts did result in 
some amplification of smaller products (below 500 bp) and some larger products (above 6 
kb) which can be removed by excision of the correct band from the gel followed by cleanup 
prior to recircularization. The addition of this step would still entail fewer overall steps in 
the library amplification process.  
Figure 3.3 Whole plasmid PCR using lysed spheroplasts as template. Spheroplasts 
containing plasmid of interest were lysed and lysis product was used to prepare whole 
plasmid PCR reactions as described in 3.2.1.2. Sizes of product were compared to that of 
a positive control product from whole plasmid PCR of purified plasmid. Red arrow 




Both of these methods of whole plasmid PCR save time in the course of library 
construction as they eliminate the need to produce and purify large amounts of vector 
plasmid and additional restriction enzyme digestion steps needed to ligate library gene 
inserts into the vector. Typically, it takes 1 to 2 weeks to perform these steps, which would 
need to be performed multiple times throughout the directed evolution process as the 
library is enriched and new libraries are constructed from isolated scFvs. Thus, 
implementing these changes can eliminate months’ worth of plasmid purification, 
digestion, and cloning procedures. This additional time that the user gains can be allocated 
to screening additional variants or further characterization. 
3.3.2 E. coli are transformed with spheroplast lysate to recover plasmid 
As an alternative to conducting screening in ELISA plates, there is the potential to 
us fluorescence activated cell sorting (FACS) to screen and sort individual scFv-displaying 
spheroplasts for survivin binding. However, this sorting process would return a solution 
containing a low concentration of spheroplasts, which are very difficult to recover in liquid 
or agar media. This is because spheroplasts are essentially damaged in that their outer 
membrane has been removed, which naturally makes it difficult for cell survival and 
growth and prevents cell division [73]. In order to determine whether or not spheroplasts 
could be recovered, without the need for an additional PCR and cloning step, we sought to 
find the minimum sorted spheroplast concentration that could be used to directly transform 
E. coli that could then be recovered and grown. This value can help to determine the 
quantity of spheroplasts that need to be analyzed and sorted via FACS. 
It was determined that at simulated sorting concentration outputs of less than 1 × 
106 cells/mL, there was no growth of transformed E. coli cells on LB agar plates (Table 
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3.5). At spheroplast concentrations higher than 1 × 106 cells/mL, transformed E. coli cells 
showed adequate colony growth, though still at amount lower than expected given the 
theoretical number of cells plated. This recovery is still an improvement in the method as 
it eliminates multiple steps needed to recover the library gene sequences that show high 
survivin binding.  
From the PCR results, amplification of whole plasmid was seen for initial 
spheroplast concentrations of 1 × 106 cells/mL and 1 × 108 cells/mL when either pre-PCR 
cleanup DNA or a small volume of post-PCR cleanup DNA was used to prepare the PCR 
reaction (Figure 3.3). A higher volume of post-PCR cleanup DNA yielded no product; 
however, this may be optimized further in the future. 
Again, the implementation of this technique decreases the total time needed to 
construct a library from a panned sublibrary or new parent scFv. By eliminating the need 
to perform PCR or ligation, the library construction process is streamlined. This saves 
approximately 2 weeks total time from each library construction procedure which equates 
to a few months of time saved in the iterative library screening and construction process. 
Table 3.5 Correlation of spheroplast sample cell density to transformed E. 
coli CFU/mL 
Simulated FACS sort retrieval 
density (spheroplasts/mL) 
Transformed E. coli CFU/mL 
Negative control (sterile water) 0 
0 0 
5 × 103 0 
1 × 104 0 
5 × 104 0 
1 × 105 5 
1 × 106 47 
1 × 107 159 
1 × 108 1537 




3.3.3 Increasing assay stringency modulates scFv binding behavior does not 
result in improved specificity 
Method modifications that increased the stringency of the screening assay changed 
the binding behavior of isolated scFvs but did not improve the likelihood that selected 
clones specifically bind survivin.  The addition of β-gal in the secondary screen improves 
discrimination of clones with better binding to survivin. When soluble β-gal was 
supplemented during the lysate incubation step of the secondary screen, the tertiary screen 
results indicated that fewer isolated variants showed high binding to survivin as compared 
to those isolated from secondary screens where no soluble β-gal was supplemented (Figure 
3.4). Additionally, for those clones from the β-gal supplemented screening that did show 
high binding to survivin, a concentration-dependent binding profile that was relatively 
saturable was seen. This is indicative that including β-gal as a competitor limits the number 
of false positive signals seen when performing a concentration dependent ELISA, which 
will prevent the pursuit of those clones. Though more studies need to be conducted, 
observing even one scFv that demonstrates saturable binding gives confidence that utilizing 
a soluble competitor allows for clones with better binding profiles to bind the target 
antigen. 
Furthermore, comparing binding of these scFvs to survivin under different diluent 
conditions, using PBST + 50 μg/mL BSA showed concentration-dependent binding 
profiles that appeared more saturable than those obtained using PBST + 2 % milk as a 
diluent (Figure 3.5). This may indicate that milk blocks binding more effectively at lower 
scFv concentrations until a certain threshold at which high binding signal is seen. Perhaps 
the reason for this difference in behavior between the two diluents is due to the profile of 
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proteins present in each. Milk has a heterogeneous distribution of protein sizes whereas 
BSA is homogeneous in protein size. Thus, milk may block more sites as large proteins 
binding to sites on the antigen can prevent the binding of scFvs, thus effectively blocking 
scFv binding. However, use of BSA will likely offer more reproducible results as the 
molecular weight is consistent and will bind in a more predictable manner. 
Ultimately, when isolated scFvs were examined for specificity, binding to both 
survivin and the nonspecific lysozyme target was still seen, indicating that increased 
secondary screen stringency does not have a profound effect on the specificity of isolated 
antibodies (Figure 3.6). This may be a property of this particular library and may not be 




   
Figure 3.4 Effect of supplementary soluble β-gal on saturable binding. (A), (B) An ELISA 
to determine binding to survivin was performed on scFv-F4 library variants pmt17 – pmt35 
which were isolated from secondary screen in which no soluble β-gal was included. (C) An 
ELISA to determine binding to survivin was performed on scFv-F4 library variants pmt36 – 
pmt47 which were isolated from secondary screen in which soluble β-gal was included. scFv-




Based on these results, we sought to modify the screening protocol to include 
soluble scFv-F4 as a competitive inhibitor during the panning and secondary screening 
steps. However, the purification of soluble scFv-F4 was challenging due to aggregation 
and precipitation. Though purified scFv-F4-6XHis was achieved through IMAC 
purification, a high level of protein precipitation was observed during buffer exchange 
procedures and size exclusion chromatography (SEC) revealed a secondary peak indicating 
presence of aggregates (data not shown.) The optimization of this purification will allow 
the use of soluble scFv-F4 in future assay modification experiments.  
Figure 3.5 Effect of lysate diluent on binding profile. (A) An ELISA for binding 
survivin was performed using 2 % w/v milk in PBST as a diluent during the lysate 
incubation step. (B) An ELISA was performed using PBST + 50 μg/mL BSA as a 




3.3.4 Specificity of screening assay may be dependent on library quality and 
parent antibody 
We speculated that it may not be feasible to achieve high specificity for survivin 
from a naïve (or β-gal targeted) library using the Tat inner-membrane display method.  In 
previous work done by Karlsson et al. scFv-R4 was found to bind the target antigen β-gal 
[35]. To check whether or not the isolates from their scFv13-based library were specific, a 
specificity ELISA was done on isolates 1-4, 2-1, and 2-3, and an scFv13-R4 control to 
compare their binding to β-gal to their binding to the nonspecific protein target lysozyme. 
It was found that clones 1-4, 2-1, and 2-3 showed a high level of binding to the target 
antigen β-gal, and a very low level of binding to lysozyme (Figure 3.7). This indicates that 
specific antibody fragments can be isolated using Tat inner-membrane display and 
Figure 3.6 Effect of supplementary soluble β-gal on specificity. An ELISA was 
performed to compare binding of isolated scFvs to survivin to their binding to the 
nonspecific target lysozyme. BL21-DE3 E. coli expressing scFv variants and controls 
scFv-13, scFv13-R4, and scFv-F4 were lysed and serially diluted in an ELISA plate 
coated with survivin or lysozyme. scFv binding was detected by incubation with an 
HRP conjugated anti-FLAG antibody and incubation with HRP substrate and 
absorbance at 492 nm was measured. 
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screening, but perhaps that it is contingent upon the quality and properties of the initial 
library. These particular clones were isolated from a library based off of scFv13 which has 
some low level of binding to β-gal which may contribute to the generation of other library 
members that have inherent β-gal binding. For our library, we began with an scFv13-R4 
based library, which may be the reason behind isolated clones binding β-gal, as scFv13-R4 
has inherent binding affinity for β-gal. This does not, however, explain why isolated scFvs 
also bind other nonspecific targets such as lysozyme. Specific antibodies have been isolated 
from naïve libraries using other display methods [74–77], so there is a need for further 
optimization of the Tat inner-membrane display method for the isolation of intrabodies that 
specifically bind their target antigen.  
 
Figure 3.7 Tat inner-membrane display and screening for selection of specific 
antibodies. scFv clones R4, 1-4, 2-1, and 2-3 isolated by Karlsson et al. [29] were used 
in a concentration dependent ELISA to compare their binding signals to β-gal and the 




Overall, the modifications made will allow for better characterization of isolated 
clones and save time when performing the screening and library construction protocols The 
addition of β-gal to the secondary screen improved the binding profile of isolated clones, 
which exhibited more saturable binding at higher scFv concentrations. This information 
will be useful in future experiments to eliminate those clones that would otherwise show a 
high false positive signal. Since the soluble β-gal behaves as a competitor for antibody 
binding, it should eliminate those clones that have nonspecific binding properties, 
particularly those that bind β-gal. 
The choice of blocking agent in the lysate incubation step of the tertiary screen 
ELISA also had an effect on the binding profiles and the use of PBST + BSA allowed for 
discernable differences in binding amongst isolated scFvs. While this may not aid in 
improving specificity of clones, once specific clones are isolated, it will assist in 
discriminating between clones that show very similar levels of binding to the target antigen. 
This will enable better resolution of antigen binding which will in turn, allow comparison 
of antibodies with minute differences in binding.  
The implementation of whole plasmid PCR and direct transformation of E. coli 
with spheroplast lysate will decrease the overall time it takes to construct a library from a 
panned sublibrary. With this advancement, libraries can be constructed more quickly which 
will enable faster and more comprehensive sampling of the library as this allows for more 
time to be allotted for the screening portion of the procedure.  
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 Despite these improvements, the scFvs isolated from this particular library still 
displayed nonspecific binding which can be improved upon with additional modifications 
to increase stringency, choice of library basis, or an alternative display and screening 
method. In Chapter 4, we discuss an approach to implement changes to the library basis 














Chapter 4: Directed evolution of a single domain antibody 
library for binding survivin 
4.1 Introduction 
 Based on the results in Chapters 2 and 3, in order to proceed with the development 
of an antibody fragment to target survivin, we developed an alternative engineering 
approach. We sought to decrease the time spent on the initial library screening process and 
to improve the likelihood that isolated antibodies are specific to our target. We chose to 
use yeast surface display and screening using flow cytometry, which is a commonly used 
antibody engineering method [78–81] and has even been used in the isolation of high-
affinity antibodies from naïve libraries [77,82]. Yeast surface display and FACS screening 
has been used to isolate antibodies that bind a variety of clinically relevant targets 
[71,74,83,84], which makes it suitable for engineering therapeutic antibodies. 
The high-throughput nature of flow cytometry screening and will allow for faster 
screening of large libraries as compared to the ELISA-based screening method previously 
described. However, because yeast surface display does not intrinsically screen for 
intracellular folding, this will serve as an initial screen to isolate antibodies to bind survivin. 
Isolated antibodies would then be displayed and screened using the Tat inner-membrane 
display for affinity maturation. 
 Additionally, we explored a different antibody fragment because of challenges we 
encountered in the engineering of a naïve scFv library. A library of single domain 
antibodies derived from camelid species was chosen for screening. The properties of these 
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antibody fragments that make them ideal candidates for intracellular function are outlined 
below in Section 4.4.1.  
 In an interest to improve the antibody engineering and screening method, we 
decided to also display scFvs using yeast surface display so that results could be compared 
to those obtained with display of single domain antibodies. The results of this comparison 
would help to discern which display and screening method yields intrabodies with desired 
antigen-binding affinity, specificity, and cytoplasmic solubility properties. Insights 
collected from the results of this comparison could be used to develop a general method of 
intrabody engineering for applications other than targeting survivin. 
4.1.1 Structure and properties of single domain antibodies 
Single domain antibodies are small antibodies with a molecular weight of 
approximately 15 kDa [85], which is significantly smaller than that of scFvs and antigen-
binding (Fab) fragments. Single domain antibodies demonstrate high stability and 
solubility, ease of library cloning and selection, and high expression in yeast [86]. Camelid 
single domain VHHs are the heavy chain portion of a full length heavy-chain camelid IgG 
(Figure 4.1) that are derived from camelid species that innately produce functional 
antibodies lacking light chains. VHHs are highly stable and soluble and possess properties 
that make them suitable candidates for therapeutic applications [85]. VHH domains are 
similar to VH domains of scFv fragments in that they comprise four framework regions 
and three CDRs with high sequence homology between VH and VHH frameworks. One 
key difference is that four amino acid positions typically conserved in VHs are substituted 
with more hydrophilic residues in VHHs. At least one of these mutations is important in 
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stabilizing the single-domain nature of VHHs as the hydrophilic nature of these residues, 
in comparison to hydrophobic residues in these positions in traditional VH domains, 
contributes to a higher expression level. VHH fragments are easy to produce because they 
are able to fold without a requirement for domain association [85]. VHHs have comparable 
affinity to scFvs, as well as high stability, solubility and expression [21]. Additionally 
VHHs present less intracellular aggregation than other antibody formats [87] and are highly 
stable [88]. VHHs may also be tethered or arranged to give multi-valent effects if necessary 
[85]. 
VHHs have already been shown to demonstrate therapeutic potential. Gueorguieva 
et. al. have generated camelid VHH intrabodies with specificity to Bax, a proapoptotic 
protein implicated in oxidative-stress-induced apoptosis extant in several 
neurodegenerative diseases [21]. The group constructed a naïve llama single domain 
library from llama blood leukocytes via RNA extraction, polymerase chain reaction (PCR), 
Figure 4.1 Camelid antibody structures. VHHs 
are heavy chain single domain antibody 
fragments derived from heavy-chain IgG 
antibodies from camelid species. 
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and cloning into a phage display vector [89]. This phage library was panned and screened 
for binding to Bax and six distinct binders were identified and characterized for Bax 
inhibition in vitro and in vivo in a human neuroblastoma cell line. These anti-Bax VHHs 
phenotypically transform neuroblastoma cells to become resistant to oxidative-stress-
induced apoptosis, thus effectively demonstrating the potential of VHH intrabodies in 
therapeutic applications [21]. Other previous work has demonstrated the ability to isolate 
antigen-specific VHHs from immune [90,91], non-immune [71,89,92], and semisynthetic 
[93] libraries using a variety of display methods [85]. Given their promising characteristics, 
we chose to engineer VHHs for use as intrabodies. 
4.1.2 High-throughput screening 
Yeast surface display is a well-developed method in the antibody engineering field 
[78–81] and has been used in the isolation of high-affinity antibodies from naïve libraries 
[77,82]. In conjunction with FACS screening, this display method has been used to isolate 
antibodies that bind the mycotoxin aflatoxin B1 [74], the toxin ricin [83], haptens [94], and  




Yeast surface display entails use of a display plasmid that expresses proteins of 
interest in a fusion scaffold. The fusion scaffold comprises the Aga2 cell wall anchor 
protein, followed by an HA epitope tag, the protein of interest, and concluded by a C-
terminal myc epitope tag [19,80,95] (Figure 4.2). The scaffold is transported out of the cell 
via a secretory mechanism and the Aga2 protein links to the a-agglutinin Aga1 cell surface 
protein via two disulfide bridges. Surface display is induced and not constitutive; thus, 
library bias is eliminated. However, each yeast cell displays approximately 5 × 104 copies 
of the fusion scaffold, so avidity binding effects must be surveilled [80].  
Yeast surface display is advantageous for engineering antibodies for eventual use 
in human cells as it relies on eukaryotic post translational machinery, which more closely 
Figure 4.2 Yeast surface display. Antibodies are expressed 
as fusion scaffold to an N-terminal Aga2 protein and HA tag 
and C-terminal myc tag. The secreted scaffold binds to cell 
surface protein Aga1 via disulfide bonding to Aga2. The 
surface-bound antibody can then be detected in expression 
and antigen binding assays. 
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resembles modifications of mammalian cells than bacterial cells employ [80]. This 
essentially compensates for the fact that yeast surface display libraries typically have 
diversity an order of magnitude lower than bacterial or phage display libraries. 
Additionally, screening of a yeast surface display library using fluorescence-activated cell 
sorting (FACS) is high throughput, quantitative, and allows for precise discrimination of 
fluorescence signal allows for screening of a library to two targets simultaneously [20,80]. 
Yeast surface display has one particular limitation in intrabody engineering 
applications. Yeast surface display, phage display, and traditional bacterial surface display 
rely on secretory protein expression pathways [19,27,28]. In the secretory pathway, 
unfolded proteins are translocated from the cytoplasm to the endoplasmic reticulum in 
yeast or to the periplasm in bacteria, both of which are oxidizing [96,97]. Folding then 
ensues in an oxidizing environment such that antibodies are able to form disulfide bonds 
that would otherwise not form in the cytoplasm [61,98]. Therefore, intrabody libraries 
screened for antigen binding using these methods would potentially contain many 
antibodies that do not fold correctly intracellularly as the entire library repertoire, and not 
just the antibodies that fold correctly intracellularly, is assayed for antigen binding. When 
using these methods, antigen binding and cytoplasmic solubility must be engineered 
separately and iteratively.  However, this can be mitigated by passing the screened 
sublibrary through a pathway that does possess a protein folding quality control 
mechanism, such as the Escherichia coli twin-arginine translocation pathway previously 
described in Chapter 2. 
Here we describe the process of preparing VHH and scFv libraries for yeast surface 
display. While the preparation of these libraries presented some challenges and needs 
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optimization, the side-by-side comparison of intrabodies isolated from these two methods 
will allow for improvement of engineering antibodies specifically for intracellular targets.  
4.2 Materials and methods 
4.2.1 Selection of library basis 
The “Nomad #1” semisynthetic hyperdiversified llama VHH library was a gift from 
the Hayhurst lab at the Texas Biomedical Research institute. It was previously shown by 
Goldman et al. that high-affinity antibodies can be isolated from this library using phage 
display techniques [93]. 
4.2.2 Optimization for library screening 
To assess whether or not differences in antibody binding can be determined via 
flow cytometry techniques, an optimization was performed to compare binding of scFv13 








4.2.2.1 Cloning scFv13 and scFv13-R4 into yeast surface display vector 
The genes encoding scFv13 and scFv13-R4 were cloned into the pCTcon2 yeast 
surface display vector between the NheI and BamHI restriction enzyme sites using standard 
molecular cloning techniques. The recombinant ligation products were used to transform 
DH5α E. coli and a DNA miniprep was used to purify plasmids, which were then sequenced 
for accuracy. 
4.2.2.2 Transformation of S. cerevisiae 
The EBY100 strain Saccharomyces cerevisiae (ATCC) was transformed with 
purified pCTcon2-scFv13 and pCTcon2-scFv13-R4 plasmids using the Frozen EZ Yeast 
Transformation II Kit (Zymo Research). Transformed yeast were grown on SD-CAA 
minimal media agar plates, to promote selective growth of cells containing the pCTcon2 
plasmid, which has a gene to produce tryptophan. 
Figure 4.3 pCTcon2 plasmid map. Antibody genes are 
cloned between NheI and BamHI restriction enzyme sites 
such that they are fused to genes encoding the Aga2 
protein and HA and c-myc tags. Expression of protein 
scaffold is mediated by galactose. 
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4.2.2.3 Flow cytometry optimization 
This optimization was performed to determine quantities of antibodies needed to 
discern between high-binding and low-binding scFvs via flow cytometry. An individual 
colony was selected from each plate and used to inoculate SD-CAA media and grown at 
30 °C overnight. An EBY100 plasmid –free control was inoculated into YPD media.  
Subcultures were inoculated at a density of 1 × 107 cells/mL in 15 mL of SD-CAA media 
and grown for 3.5 hours. Cultures were centrifuged at 4 °C at 3,000 × g for 5 minutes to 
remove media. Protein expression was induced by resuspending each culture in 15 mL SG-
CAA media and growing at 20 °C overnight. The following day, 1 × 107 cells per sample 
were placed into microcentrifuge tubes and centrifuged at 4 °C at 14,000 × g for 1 minute, 
then resuspended in 100 μL of PBS + 0.1% BSA. Cells were prepared for flow cytometry 
as follows. 
To confirm expression of full-length Aga2-HA-scFv-c-myc, 1μL of Anti-HA tag 
[16B12] (mouse) (Abcam) and 1 μL of Chicken Anti-c-MYC (Gallus Immunotech Inc.) 
primary antibodies were added to each sample and gently rotated at room temperature for 
1 hour. Cells were centrifuged and resuspended as before in PBS + 0.1% BSA, then 1 μL 
of Alexa Fluor 488 goat anti-mouse IgG (H+L) and 1 μL of Alexa Fluor 647 goat anti-
chicken IgG (H+L) (Life Technologies) secondary antibodies were added and samples 
were gently rotated at 4 °C for 30 minutes while protected from light. 
To assess binding to β-gal, 5 μg of biotinylated β-gal was added to a new set of 
samples in addition 1 μL Chicken Anti-c-MYC antibody and gently rotated at room 
temperature for 1 hour. Following centrifugation and resuspension in fresh PBS + 0.1% 
BSA, 1 μL of Neutravidin Dylight 488 (Thermo Fisher) and 1 μL of Alexa Fluor 647 goat 
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anti-chicken IgG (H+L) were added and samples were gently rotated at 4 °C for 30 minutes 
while protected from light. 
All samples were centrifuged and rinsed once with 1 mL of PBS + 0.1% BSA 
before being resuspended in 500 μL of PBS + 0.1% BSA and transferred to 5 mL round-
bottom tubes. Flow cytometry was performed (BD FACS Canto II) using FITC and APC 
channels to detect Alexa Fluor 488 and Alexa Fluor 647 fluorescence, respectively, and 
data was analyzed using FlowJo software. 
4.2.3 Library construction 
4.2.3.1 VHH library construction for yeast surface display 
To transfer the Nomad library, which will hereafter be referred to as the “VHH 
library,” to an appropriate platform for yeast surface display, the following was performed. 
The Nomad library format received had the VHH genes situated between 2 discontinuous, 
non-identical SfiI sites in the pECAN21 plasmid vector. PCR was performed to amplify 
the VHH genes including the SfiI sites, cleaned, and digested with SfiI.  Digested product 
was then ligated into pCTcon2 and pIMD plasmids which were previously modified to 
contain SfiI sites. It is important to note that vector plasmids were propagated in the non-
methylating INV110 strain of E. coli (Thermo Fisher) prior to digestion, as the SfiI enzyme 
can only digest non-methylated DNA. Ligation product was used to transform DH5α E. 
coli using the previously-described electroporation protocol in 2.2.2.3 and a representative 
sample of the library was plated on LB agar plates supplemented with ampicillin. Colonies 
were selected, grown, and midiprepped and purified plasmid for each was sent for 
sequencing to confirm insert sizes and sequence uniqueness. 
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4.2.3.2 scFv library construction for yeast surface display 
 The original scFv13-R4 library was also cloned into the pCTcon2 vector. The scFv 
genes were amplified via PCR with the addition of a 5′ NheI and 3′ BamHI site, and the 
PCR product was cleaned and digested with NheI and BamHI restriction enzymes. The 
digested product was ligated into pCTcon2 vector that had been previously digested with 
the same two enzymes. Ligation product was used to transform DH5α E. coli using the 
previously-described electroporation protocol in 2.2.2.3 and a representative sample of the 
library was plated on LB agar plates supplemented with ampicillin. Colonies were selected, 
grown, and midiprepped and purified plasmid for each was sent for sequencing to confirm 
insert sizes and sequence uniqueness. 
4.3 Results and discussion  
4.3.1 Flow cytometry needs further optimization 
 In order to determine if differences in antigen binding can be observed through flow 
cytometry screening, scFv13 and scFv13-R4 were expressed using yeast surface display 
and expression and β-gal binding was analyzed. S. cerevisiae expressing scFv13 and those 
expressing scFv13-R4 showed high fluorescent signal for antibodies binding the HA and 
c-myc tags, indicating full length expression of the Aga2-HA-scFv-c-myc fusion. When 
comparing fluorescent signal due to binding of β-gal, slight differences between scFv13 
and scFv13-R4 were seen. A larger difference was expected to be seen, indicating the need 
for optimization of antibody concentrations, washing steps, or cell density. 
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4.3.2 Generation and cloning of VHH library into yeast surface display vector 
requires optimization 
 The cloning of the VHH library into the pCTcon2 yeast surface display vector 
presented complications. Over 10 sets of primers were designed, including degenerate 
primers previously used to amplify the library [93]. For primers that only presented one 
binding site throughout the entire plasmid template sequence, PCR products contained 
additional bands, indicating non-specific binding of primers. Two sets of adequately 
specific product were generated, although these results could not be replicated, despite 
using the exact same conditions, reagents, and thermal cycler protocol. Additionally, when 
the pCTcon2 vector with added SfiI sites was propagated in non-methylating E. coli, SfiI 
digestion was successful initially, but later attempts to digest the same aliquot of DNA with 
the same aliquot of SfiI restriction enzyme resulted in a very low level of digestion, even 
when digested overnight. The minimal amount of PCR product and vector that were used 
in cloning led to the generation of a library with approximately 105 members, which is not 
an adequately large library size for screening. However, sequencing revealed that VHH 
inserts are full length (~ 420bp) and have unique sequences. Based on the challenged 
encountered in amplification and cloning of the VHH library, this needs to be optimized. 
4.3.3 Generation and cloning of VHH library into yeast surface display vector 
requires optimization 
 The scFv library inserted into the yeast surface display vector was of a more 
appropriate size of approximately 108 variants, as compared to the VHH library. Upon 
examination of sequencing results, it was observed that truncated scFv genes of varying 
sizes were being inserted between the NheI and BamHI sites. The PCR amplified scFv 
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genes were checked for size by gel electrophoresis and were found to be approximately 
750 base pairs, which is the correct, full-length size. There are no additional NheI or BamHI 
restriction enzyme sites within the pCTcon2 vector and it is improbable that every clone 
that was assessed had an additional BamHI site that could explain the truncated insertion. 
We hypothesized that the error may lie in some ligation or cellular process that is causing 
incomplete insertion of full-length scFv genes. Due to the challenges of cloning the 
scFv13-R4 library into the yeast surface display vector, this needs to be optimized. 
4.4 Conclusion  
 Comparison of different modalities of screening and display of an antibody library 
can elucidate factors that are important when designing an intrabody engineering strategy. 
Differences in solubility, stability, specificity, and binding behavior of isolated antibodies 
are important factors to consider when selecting a display and screening method. Though 
the preparation of the VHH and scFv libraries presented challenges, we created the plasmid 
frameworks to prepare these libraries in the future, perhaps with some modifications to 
ensure proper library amplification and adequate library size for screening purposes. 
With an appropriate choice of library format and by utilizing different methods of 
display and screening, it will be possible to isolate intrabodies with high affinity and 
specificity for their target antigen. An important factor in managing the feasibility of such 
a project is ensuring that the transfer of a library from one display plasmid to another is 
seamless. Some suggestions for improving this method are to introduce the same restriction 
enzyme sites to flank the intrabody gene in any display plasmids, use enzymes that are 
active at the same temperature such that double digests can be performed. The use of a tool 
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such as Primer-BLAST could also be beneficial to prevent any mispriming and nonspecific 
amplification during PCR. Keeping these modifications in mind will serve to improve the 

































Chapter 5: Antifungal peptides for treatment of C. albicans 
5.1 Introduction 
5.1.1 Selection of C. albicans as a therapeutic target 
The normal human flora comprises a variety of bacterial and fungal organisms [99]. 
Candida species are fungal organisms present on skin and mucosal surfaces in healthy 
people. However, Candida species are commensal organisms and opportunistic pathogens 
as they can cause infections such as mild rashes, oral thrush, genital yeast infections, and 
potentially life-threatening systemic infections. Susceptibility to infection is of greater 
concern in immunocompromised patients, such as those with human immunodeficiency 
virus (HIV), diabetes, or those undergoing chemotherapy [100].  Given growing concerns 
over hospital acquired infections amidst increasing numbers of drug-resistant strains, it is 
imperative to develop novel therapeutics to treat Candida infections.  
 The most common species of Candida present in clinical isolates is C. albicans 
[101]. C. albicans is a diploid organism and is capable of taking on different forms. It can 
exist as oval-shaped yeast, budding yeast, pseudo-hyphae, and hyphal forms. C. albicans 
can also form biofilms under certain physiological conditions which can colonize surfaces 
such as implants, catheters, and dentures [102]. C. albicans biofilms comprise yeast, 
pseudohyphal, and hyphal forms of C. albicans embedded in extracellular matrix. 
Additionally, cells in biofilms have been found to have increased resistance to treatment 
due to increased virulence and changes in expression of cell membrane components, which 
are described in more detail below [103–105]. 
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 Current treatments for C. albicans infections include azoles, amphotericin B, and 
capsofungin, and while effective, they pose some limitations. Amphotericin B, while robust 
in its treatment of C. albicans, causes kidney toxicity [101,106], which makes it a poor 
choice for repeated candidiasis. Amphotericin B functions by binding ergosterol [107] and 
azoles function by preventing the formation of ergosterol, which is an important component 
of the fungal cell membrane [108]. Topical azole antifungal agents have been paramount 
in the treatment of mucosal candidiasis in immunocompromised patients [106]. However, 
increasing usage of antifungal agents has given rise to antifungal-resistant C. albicans. In 
a 2013 report published by the Centers for Disease Control and Prevention, it was noted 
that fluconazole-resistant Candida infections posed a serious threat to human health, with 
nearly 7% of bloodstream Candida isolates exhibiting resistance [14]. Thus, there is a clear 
need for alternative methods of candidiasis treatment that are both safe and effective. 
5.1.2 Histatin-5 as an antifungal agent 
C. albicans has a tendency to colonize the oral cavity and infection of the oral cavity 
is commonly seen in those with compromised immune systems [100]. The human body has 
defense mechanisms in the form of antifungal salivary peptides and proteins that can 
prevent overgrowth of C. albicans.  
Histatins are a family of histidine-rich peptides that are secreted from human 
salivary glands [109] that possess a variety of functions within the human oral cavity. They 
play a role in formation of acquired enamel pellicle on teeth, maintenance of mineral-
solution dynamics in saliva, and antimicrobial activity against strains of Streptococcus 
mutans among other functions [110]. 
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One of the most interesting properties of histatins is their potency against C 
albicans. Histatins inhibit C albicans germination and cause C. albicans cell death at 
physiological concentrations [111–113]. Of these, histatin-5 (Hst-5) is of particular interest 
as it has the strongest antifungal activity against C. albicans [109,113]. Hst-5 has been 
indicated in the maintenance of C. albicans at non-virulent levels [114] and kills C. 
albicans in vitro at physiological concentrations of 15 to 30 μM [115]. Hst-5 has an 
identical sequence to the N-terminal proteolytic fragment of histatin 3 [116,117]. Hst-5 is 
present at reduced levels in HIV-positive patients [118,119] indicating a connection 
between reduced Hst-5 and lack of maintenance of C. albicans at commensal levels in 
immunocompromised patients. 
 
Hst-5 is a 24-amino acid, cationic peptide that has the propensity to form an α-
helical structure in non-aqueous solutions and maintains an unstructured form in aqueous 
solutions [110]. Hst-5 is weakly amphipathic, and this lack of strong amphipathicity 
prevents spontaneous insertion into microbial membranes. This is consistent with findings 
that indicate lack of pore formation in the Hst-5 antifungal mechanism [120]. Previous 
research has focused on making modifications to full-length and truncated versions of Hst-
5 in order to determine the effects that charge, hydrophobicity, and amino acid side chain 
Figure 5.1 Histatin-5 sequence and antimicrobial fragment. The minimal antimicrobial 
fragment comprises residues 4 – 15 as determined by Rothestein et al. [120]. 
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properties have on the propensity of α-helical structure formation. Substitution of the four 
charged amino acid types (lysine, arginine, histidine, glutamic acid) with glycine residues 
resulted in significantly decreased antifungal activity [121–123], suggesting that side chain 
charge is an important factor in antifungal activity of Hst-5.  
Other studies were conducted in which Hst-5 peptides were synthesized and 
assessed for antifungal activity in order to determine the minimal sequence required for 
antifungal activity comparable to full-length Hst-5 [121,124,125]. It was determined that 
the P-113 fragment consisting of residues 4-15 is the minimal sequence required and in 
fact, has higher antifungal activity than non-truncated Hst-5 [121].  
The proposed antifungal mechanism of Hst-5 differs from that of other 
antimicrobial peptides, which tend to form pores in the cell membrane [118,126,127]. In 
fact, the α-helical structure important for spontaneous insertion into microbial membranes 
does not appear to be of importance in Hst-5 antifungal activity, as disruption of helical 
formation did not result in a loss of activity [122]. Instead, Hst-5 enters the cell and causes 
an imbalance of ATP, potassium, and magnesium that causes cell volume loss and thus, 
cell death [115,117,120]. More specifically, Hst-5 binds to C. albicans cell wall β-glucans 
and fungal heat shock proteins Ssa2 and Ssa1 in an energy-independent manner to promote 
its localization with a transport complex [115,128]. Hst-5 is translocated into the cell via 
fungal polyamine transporters Dur3 and Dur31 in a nonlytic, energy-dependent manner 
[115,120]. It is also indicated that Hst-5 uptake can be endocytic in nature as Hst-5 localizes 
inside vacuoles at low physiological Hst-5 concentrations but is found in the cytoplasm at 
high concentrations, which requires a high cationic charge on Hst-5. C. albicans in which 
Hst-5 showed vacuolar localization remained viable, while those with cytoplasmic 
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localization were non-viable [120]. The presence of Hst-5 intracellularly causes 
depolarization of the cytoplasmic and/or mitochondrial membranes [127,129], that can 
allow direct transfer of Hst-5 into the cytosol [127]. Thus, Hst-5 uptake in C. albicans may 
be a combination of transporter-mediated uptake, receptor-mediated endocytosis, and 
direct transfer across the membrane [115].  
5.1.3 Secreted aspartic proteases 
Secreted aspartic proteases (Saps) are a family of enzymes that are part of the 
repertoire of hydrolytic enzymes secreted by C. albicans. Saps serve to protect C. albicans 
from death and to evade immune response through various protective mechanisms such as 
inactivation of complement receptors on macrophages, lysosomal permeabilization, and 
degradation of protective proteins and peptides [130,131]. Of the ten Saps, Sap1 through 
Sap8 are secreted to the extracellular environment and Sap9 and Sap10 are attached to the 
cell wall by a glycosylphosphatidylinositol anchor [132,133]. Distribution of Sap 
expression and function in C. albicans is dependent on factors such as pH and morphology 
of cells [133–136]. Sap7, Sap9, and Sap10 have higher activity in physiologically relevant 
pH ranges, and of these, Sap9 has been found to be highly expressed in C. albicans strains 
present in patients with vaginal and oral candidiasis [137]. Sap2 is highly expressed by C. 
albicans and its interactions with Hst-5 have been recently studied [114,138]. 
5.1.4 Proteolytic susceptibility of Hst-5 to Saps 
Studies directed at analyzing cleavage site amino acid preferences of Saps reveal 
that Saps prefer basic or large, hydrophobic residues [134,135,139]. While these studies 
elucidate some information, they do not take into account the effect that modifications 
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further from the cut site, that may affect cleavage site accessibility, may have on proteolytic 
cleavage by Saps. It has been shown that Hst-5 can undergo proteolytic cleavage by Sap2, 
Sap9, and Sap10 at physiological pH conditions [114] and by the other seven Saps at pH 
conditions at which each Sap has optimal activity [130]. Degradation of Hst-5 by Saps 
leads to reduced antifungal activity[114], and thus, improving the proteolytic stability of 
Hst-5 could improve its half-life and antimicrobial function. Prevalence of Saps and their 
cleavage site preferences are important factors to consider in the rational design of Hst-5 
mutants that can resist proteolytic cleavage by Saps, while maintaining their antifungal 
properties. 
5.2 Previous experiments 
The experiments and results discussed in Section 5.2 were performed by Dr. 
Svetlana Ikonomova and are provided as background and motivation for experiments in 
Chapters 5 and 6. 
5.2.1 Rational design of Hst-5 peptides 
In studies conducted by Meiller et. al. and Bochenska et. al. a lysine residue was 
observed on either side of the Sap cleavage site [114,130], indicating the potential 
importance of lysine as a recognition or target residue for Saps. This is corroborated by 
findings that Saps may prefer hydrophobic or basic residues, as lysine is basic 
[134,135,139]. Due to this apparent importance of the presence of lysine at Sap cleavage 
sites, modifications were made to substitute lysines at four different locations (K5, K11, 
K13, and K17) with either an arginine or a leucine. Since charge plays an important role in 
Hst-5 function, arginine was chosen in order to preserve the positive charge at the modified 
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residue positions. Leucine was selected as a substitute in order to remove the positive 
charge incurred by lysine, as this could affect how the modified Hst-5 peptides interact 
with the aspartic acid residues present in the Sap active sites. Modified peptides are shown 
in Table 5.1.  
5.2.2 Peptides and enzymes 
Unmodified and modified Hst-5 peptides were commercially synthesized 
(GenScript) with purity ≥95% and trifluoroacetic acid salt removal by exchange with 
hydrochloride. Purified recombinant Sap2 and Sap9 (produced with GPI anchor) were 
produced in Pichia pastoris and were a gift from Dr. Bernard Hube at Friedrich Schiller 
University in Germany.  
Table 5.1 Hst-5 and variants with single leucine or arginine substitutions 
Peptide Sequence 
  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
Hst-5 D S H A K R H H G Y K R K F H E K H H S H R G Y 
K5R - - - - R - - - - - - - - - - - - - - - - - - - 
K5L - - - - L - - - - - - - - - - - - - - - - - - - 
K11R - - - - - - - - - - R - - - - - - - - - - - - - 
K11L - - - - - - - - - - L - - - - - - - - - - - - - 
K13R - - - - - - - - - - - - R - - - - - - - - - - - 
K13L - - - - - - - - - - - - L - - - - - - - - - - - 
K17R - - - - - - - - - - - - - - - - R - - - - - - - 
K17L - - - - - - - - - - - - - - - - L - - - - - - - 
*Dash indicates residue unchanged from parent Hst-5. Letter R or L indicates that parent residue at that position 




5.2.3 Proteolytic degradation of Hst-5 and variants by Saps 
The degradation of Hst-5 and modified peptides by incubation with purified recombinant 
Sap2 or Sap9 was examined. Briefly, Hst-5 or variants (final concentration of 150 μg/mL) 
were each mixed with Sap2 or Sap9 (3.13 μg/mL or 6.25 μg/mL) in 1 mM NaPB and 
incubated at 37 °C for 2 hours. A Hst-5 control was prepared with NaPB with no Saps. 
Tricine sample buffer containing 2% β-mercaptoethanol was added to each and samples 
were boiled at 100 °C for 10 minutes. The sample buffer added to the control Hst-5 
contained Coomassie Blue G-250 in order to visualize the location of the peptides during 
the electrophoresis process. Degraded and non-degraded peptides were separated by gel 
Figure 5.2† Degradation of Hst-5 and modified peptides by purified (A) Sap9 and (B) 
Sap2. Peptides (150 g/mL) were incubated with Sap9 (3.13 g/mL) or Sap2 (6.25 g/mL) 
for 2 h at 37 °C. Following gel electrophoresis, and the relative amounts of intact peptide 
(upper band) and degraded peptide (lower bands) were quantified by densitometry and 
compared. Error bars represent standard error of the mean (n = 3). A one-way ANOVA test 
and Dunnett’s multiple comparison test was performed. Asterisks indicate the level of 
statistical significance against parent Hst-5 incubated with Sap: * for p< 0.05, ** for p< 0.01, 
*** for p< 0.001, and **** for p< 0.0001. The lower band in the Hst-5 control lanes is due 
to Coomassie dye.  
†Figure originally published in FEBS J. (2018) 
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electrophoresis in 10 – 20% Tris-tricine gels (Bio-Rad). Gels were then fixed in a 10% 
acetic acid/40% methanol/50% water mixture for 30 minutes followed by staining with 
Bio-Safe Coomassie stain (Bio-Rad) for 1 hour. Gels were washed with water three times 
and imaged on a ChemiDoc imager (Bio-Rad). Three replicates of the assay were 
performed. Densitometric analysis was done with Image Lab software (Bio-Rad) to 
determine the percent intact peptide, where the upper band was considered intact and lower 
bands considered degraded peptide.  A one-way ANOVA tests with p< 0.05 and Dunnett’s 
multiple comparison tests with the Hst-5 sample as the control were performed to assess 
statistical significance.  
Densitometric analysis revealed that arginine and leucine substitutions at the K17 
site led to an increased resistance to degradation by Sap9 and Sap2, as compared to Hst-5 
(Figure 5.2). In fact, no degraded peptide was seen for K17L and K17R Hst-5 variants 
when incubated with Sap2. Modifications of lysine residues to leucine residues at positions 
other than K17L (i.e. K5L, K11L, and K13L) led to an increase in degradation by Sap9 as 
compared to Hst-5 and no intact peptide could be seen for the K13L samples. However, 
when treated with Sap2, substitution of lysine with leucine residues improved resistance to 
degradation when compared to Hst-5 for K5R, K11R, and K17R modifications but this 
effect was not seen for the K13R peptide. The results demonstrate the ability to visualize 
and quantify peptide degradation by Saps via gel electrophoresis and densitometric analysis 
as well as the effect that modification of lysine residues has on the resistance to degradation 
by Sap2 and Sap9. These results establish that single amino acid changes can impart large 
impacts on the structure and behavior of peptides.  
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5.2.4 Antifungal activity assay 
5.2.4.1 Antifungal activity assay performed with intact peptides 
In making modifications to improve resistance to proteolytic degradation, it was of 
importance to consider the maintenance or improvement of antifungal activity for Hst-5 
variants. Thus a antifungal activity assay was performed to determine the antifungal 
properties of the modified peptides on planktonic C albicans. 
Briefly, C. albicans was inoculated into YPD and grown at 30 °C overnight. The 
following day it was subcultured and grown until OD600 = 1 – 1.2. Cells were washed three 
times with 2 mM NaPB and diluted to either 5 × 105 cells/mL or 5 × 107 cells/mL. Three 
biological replicated with two technical replicates were performed for each cell density 
condition. Serial dilutions of Hst-5 and modified peptides were prepared in water, and 
20 L of each peptide was mixed with 20 L of diluted cells and incubated in round-bottom 
96-well culture plate at 30 °C for 30 minutes. Final peptide concentrations ranged from 0-
50 μM for experiments using the lower cell density and 0-200 μM for those using the higher 
cell density. 
Following incubation, 320 L of 1 mM NaPB was added to each well and another 
dilution was performed to dilute the peptide concentration and cell density. A calculation-
based estimate of 250 cells were inoculated into respective wells of round-bottom culture 
plates containing a 1:1 ratio of YPD media and 1 mM NaPB, amounting to a total volume 
of 200 L once diluted cells were added. Sterility and background control wells were 
included that contained only YPD and NaPB that would assist in determining percent 
reduction in viability. Plates were incubated at 30 °C overnight while shaking. The 
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A one-way ANOVA test with p< 0.05 and Dunnett’s multiple comparison tests with 
the Hst-5 sample as the control were performed to assess statistical significance. 
 At the lower C. albicans concentration of 2.5×105 cells/mL, the modified Hst-5 variants 
showed only slight observable differences in antifungal activity and all exhibited an 
increased percent reduction in viability with increasing peptide concentration (Figure 
5.3A). The minimum inhibitory concentration for 50% growth (MIC50) value was 
calculated for all peptides and it can be seen that MIC50 values for variants differ from that 
of Hst-5 by a maximum of one dilution factor. 
Figure 5.3† Antifungal activity of Hst-5 and modified peptides. Peptides were serially diluted 
and incubated with either (A) 2.5×105 cells/mL or (B) 2.5×107 cells/mL of C. albicans for 30 
minutes at 30 °C. Error bars represent standard error of the mean (n = 6). MIC50 values for the 
peptides are shown. 
†Figure originally published in FEBS J. (2018) 
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At the higher C. albicans cell concentration of 2.5×107 cells/mL, the Hst-5 variants 
again follow a trend similar to parent Hst-5 with increasing percent reduction in viability 
with increasing peptide concentration (Figure 5.3B). The MIC50 values for all peptides 
increased for this higher cell concentration, which is expected as the peptide concentration 
was not increased as well. At the lower cell concentration, all growth inhibition curves are 
fairly similar, however, at the higher cell concentration, the differences in percent reduction 
in viability between cells treated with the different peptides are increased. From these 
curves and from the MIC50 values, it is seen that K11R shows enhanced antifungal activity 
over that of Hst-5, however, it should be noted that MIC50 values for all modified peptides 
are still within one dilution factor from that of Hst-5. Since the K11 residue resides within 
the previously-identified active fragment of Hst-5 [121],  modifications to this residue will 
likely modulate antifungal properties of the peptide. It is of interest to note that despite the 
large enhancement in proteolysis resistance the K17L and K17R modifications imparted 
on the peptide, neither of these modifications resulted in improved antifungal activity. This 
may be the result of the short incubation time in the antifungal activity assay which is not 
yet optimized with Sap proteolysis kinetic properties. Substitution of lysine residues within 
Hst-5 with leucine or arginine maintains or improves antifungal activity as previously 
reported [125]. Additionally, in some cases, these modifications improve resistance to 
proteolytic degradation by Saps. 
5.2.4.2 Antifungal activity assay performed with degraded peptides 
It was also of importance to look at the antifungal activity of degraded peptide 
fragments as it is possible to have antifungal activity retained via a smaller active fragment, 
or that resistance to degradation prolongs the antimicrobial lifetime of an active peptide. In 
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this experiment, Hst-5 and Hst-5 variants, at a concentration pf 150 μg/mL, were first 
degraded by incubation at 37 °C for 2 hours with purified Sap9 or Sap2, at 6.25 μg/mL or 
18 μg/mL respectively. This increase in Sap concentration was done in order to amplify 
differences in antifungal activity caused by degradation, which may otherwise not be seen 
with low Sap concentrations and only partial degradation. This was followed by heat-
inactivation of the Saps at 100 °C for 5 minutes and then using the degraded peptides in 
the antifungal activity assay as described in 5.2.4.1. A one-way ANOVA tests with p< 0.05 
and Dunnett’s multiple comparison tests with the Hst-5 sample as the control were 




 It was observed that while incubation with Sap2 cause Hst-5 to lose nearly all of its 
antifungal activity, incubation with Sap9 only resulted in a loss of approximately 60% 
when compared to non-degraded Hst-5 (Figure 5.5).  The K17R and K17L peptides showed 
a very minimal loss in antifungal activity, despite being exposed to Saps which is consistent 
with their apparent high resistance to proteolytic degradation as observed even at these 
high Sap concentrations (Figure 5.4). Interestingly, the K11R peptide showed some 
retention of antifungal activity after incubation with Saps and showed significantly higher 
Figure 5.4† Degradation of Hst-5 and modified peptides by high concentrations of purified 
(A) Sap9 and (B) Sap2. Peptides (150 g/mL) were incubated with Sap9 (6.25 g/mL) or Sap2 
(18 g/mL g/mL) for 2 h at 37 °C. Following gel electrophoresis, and the relative amounts of 
intact peptide (upper band) and degraded peptide (lower bands) were quantified by densitometry 
and compared. Error bars represent standard error of the mean (n = 3). A one-way ANOVA test 
and Dunnett’s multiple comparison test was performed. Asterisks indicate the level of statistical 
significance against parent Hst-5 incubated with Sap: * for p< 0.05 and **** for p< 0.0001. The 
lower band in the Hst-5 control lane in (B) is due to Coomassie dye. 
† Figure originally published in FEBS J. (2018) 
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resistance to degradation than Hst-5. These results indicate that there are several factors 
that play a role in determining the antifungal potency of peptides. 
 
Figure 5.5† Antifungal activity of Hst-5 and modified peptides following incubation with 
Sap9 and Sap2. The peptides (150 g/mL) were incubated with either (A) Sap9 (6.25 g/mL) 
and (B) Sap2 (18 g/mL) for 2 h at 37 °C. Samples were serially diluted and incubated with 
2.5×105 cells/mL C. albicans for 30 minutes at 30 °C. Error bars represent standard error of 
the mean (n = 6).  
† Figure originally published in FEBS J. (2018) 
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5.2.6 Peptide degradation by C. albicans 
 The extent to which peptides were degraded by whole C. albicans cells was also 
examined in order to determine whether or not it is accurate and representative to use 
purified Saps in degradation experiments. C. albicans was inoculated overnight and 
subcultured as previously described in Section 5.2.4.1. Cells were washed three times with 
100 mM NaPB and diluted to a concentration of 2 × 109 cells/mL in 100 mM NaPB. The 
cells were prepared in this high ionic strength solution to prevent internalization of peptides 
such that the peptides would be available extracellularly to be susceptible to degradation 
by Saps. Peptides were prepared at a concentration of 300 μg/mL in sterile water. For each 
peptide, an equal volume of cells and peptides were mixed and the solution was incubated 
at 37 °C for 2 hours. Three biological replicates were performed for each peptide. Cells 
were removed by centrifugation and tricine sample buffer was added to the supernatant. 
Samples were boiled at 100 °C for 10 minutes. Gel electrophoresis, Coomassie staining, 
and densitometric analysis was performed as described in 5.2.3. A one-way ANOVA tests 
with p< 0.05 and Dunnett’s multiple comparison tests with the Hst-5 sample as the control 
were performed to assess statistical significance. 
 Consistent with findings from degradation experiments with purified Sap2 and 
Sap9, the K17L and K17R peptides showed improved resistance to degradation by C. 
albicans cells as compared to Hst-5 (Figure 5.6).  Interestingly, the results for K5R and 
K5L suggest that both Sap2 and Sap9 influence degradation as K5L shows improved 
resistance and K5R shows no change as compared to Hst-5. These are consistent with the 
degradation pattern seen for these K5 peptides with Sap2 and Sap9, respectively. While the 
patterns of peptide degradation following incubation with C. albicans reflect results seen 
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with Sap2 and Sap9 incubation, there may be other Saps contributing to peptide 
degradation. However, since the degradation patterns resemble those from experiments 
with purified Saps, it can be assumed that results will be similar regardless of if whole cells 
or purified Saps are used. To differentiate between effects of Sap2 and Sap9, an experiment 
with just the culture supernatant would need to be performed. 
5.2.7 Mass spectrometry analysis 
Mass spectrometry (MS) was used to determine peptide cleavage sites and relative 
amounts of fragments produced following degradation by Saps. Briefly, peptides were 
incubated with Sap9 or Sap2, desalted, and supplemented with the peptide MRFA as an 
Figure 5.6† Degradation of parent Hst-5 and Hst-5 variants by C. albicans. Peptides (150 
g/mL) were incubated with C. albicans (1×109 cells/mL) for 2 h at 37 °C. Following gel 
electrophoresis, the amount of intact peptide (upper band) and degraded peptide (lower bands) 
were quantified by densitometry and compared. Error bars represent standard error of the mean 
(n = 3). A one-way ANOVA test and Dunnett’s multiple comparison test was performed. 
Asterisks indicate the level of statistical significance against parent Hst-5 incubated with cells: 
** for p< 0.01 and **** for p< 0.0001.The lower band in Hst-5 control lane is due to Coomassie 
dye. 
 




internal control for MS. Mass spectra were acquired and molecular weight calculation and 
fragment prediction was performed. MS/MS spectra were processed to identify peptides 
and the fragments produced from each, including the relative abundance of each fraction 
as compared to the MRFA control.  
 Overall MS results are in agreement with gel electrophoresis degradation analysis 
in regards to relative abundance of intact peptide for each peptide. For example, following 
incubation with Sap9 and MS, both K17R and K17L showed the highest signal from intact 
peptide, which is confirmed by earlier densitometry results (Figure A1). It is important to 
note that parent Hst-5 was cleaved on the C-terminal side of the K17 residue, but that 
modification of this lysine to either arginine or leucine prevented this cleavage from 
occurring. In fact, for Hst-5, the signal for the fragment from residues 1 – 17 was much 
higher than that of the intact peptide. For Hst-5, cleavage on either side of the lysine at 
position 13 and between histidine residues at positions 18 and 19 was also observed. 
Generally, arginine-substituted peptides showed higher relative amounts of intact peptide 
than their leucine-substituted counterparts. Substitutions also have the ability to shift the 
cleavage site preference or, as seen for K13R, and to affect the peptide as a whole, as seen 
by increased amount of intact peptide seen for K11R. This indicates that substitutions can 
affect the overall cleavage of the peptide and not just at the substitution site. 
 Incubation with Sap2 resulted in intact peptide being the most observed size for 
parent Hst-5 (Figure A2). This effect was observed for all peptides and corroborates the 
differences observed between Sap9 and Sap2 gel electrophoresis results. Whereas with 
Sap9, K17R and K17L mutations protected this site from cleavage, with Sap2, cleavage 
was observed on the C-terminal side of the K17 site. MS data suggests that Sap2 greatly 
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prefers lysine over other residues at cleavage sites, regardless of the charge of amino acid 
substitutions made. These results confirmed gel electrophoresis results and allowed for the 
design of new modified Hst-5 peptides. 
5.2.8 Additional modification of Hst-5 peptides and results 
Based on the results of the first set of modifications, a new set of Hst-5 variants 
was designed [140]. Since the glutamic acid at residue position 16 is the only negatively 
charged amino acid in Hst-5, this was selected as one site for modification to either an 
arginine, to change the charge to be positive, or to leucine, to remove the charge. 
Modifications to the lysine at position 13 were also explored since it was found that the 
K13L modification made the peptide highly susceptible to Sap9, despite maintaining 
antifungal activity. The K17R peptide proved to be highly resistant to degradation and 
maintained antifungal activity and the K11R enhanced antifungal activity. Therefore, these 
modifications would be combined in order to observe any synergistic effects. 
Modifications assessed included K13H, K13E, E16R, E16L, and K11R-K17R and 




 The K11R-K17R peptide was highly resistant to degradation by Sap2 and Sap9 as 
over 88% remained intact following incubation with Saps. Conversely, E16R and E16R 
showed increased degradation with both Saps as compared to parent Hst-5 (Figure 5.7A 
and B). The benefit of arginine substitution is again observed as the E16R peptide shows 
better resistance than the E16L peptide. The substitutions at K13 showed almost no intact 
peptide remaining following Sap9 incubation, though they showed a similar percentage of 
intact peptide remaining as compared to Hst-5 when incubated with Sap2. The identity of 
the higher molecular weight band observed in the K13H lane is unknown and was 
disregarded. Degradation results observed after incubation of peptides with whole C. 
albicans cells showed a similar pattern of degradation (Figure 5.7C). 
Table 5.2 Hst-5 and variants with one or two residue substitutions 
Peptide
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Hst-5 D S H A K R H H G Y K R K F H E K H H S H R G Y
K13H - - - - - - - - - - - - H - - - - - - - - - - -
K13E - - - - - - - - - - - - E - - - - - - - - - - -
E16R - - - - - - - - - - - - - - - R - - - - - - - -
E16L - - - - - - - - - - - - - - - L - - - - - - - -
K11R-K17R - - - - - - - - - - R - - - - - R - - - - - - -
Sequence
a
*Dash indicates residue unchanged from parent Hst-5. Letter R or L indicates that parent residue at that 





Figure 5.7§ Extent of proteolysis of parent Hst-5 and Hst-5 variants by purified (A) 
Sap9 and (B) Sap2. Peptides (50 μM) were incubated with either Sap9 (3 μg/mL) or Sap2 
(0.05 μg/mL), respectively for 2 h at 37 °C. Following gel electrophoresis, the amount of 
intact peptide (upper band) and degraded peptide (lower bands) were quantified by by 
densitometry and compared. Error bars indicate standard error of the mean (n = 6).  A one-
way ANOVA test and Dunnett’s multiple comparison test was performed. Asterisks 
indicate significance relative to parent Hst-5: ns for no significance, *** for p< 0.001, and 
**** for p< 0.0001. (C) Extent of degradation for Hst-5 and its variants after 
exposure to C. albicans cells. Peptides (50 μM) were incubated with C. albicans cells 
(1×109 cells/mL) for 2 hours at 37 °C. Following gel electrophoresis, the amount of intact 
peptide (upper band) and degraded peptide (lower bands) were quantified by by 
densitometry and compared.The source of the additional band in the K13H lane is 
unknown and not included in the analysis. Error bars indicate standard error of the mean 
(n = 6). A one-way ANOVA test and Dunnett’s multiple comparison test was performed. 
Asterisks indicate the level of statistical significance relative to parent Hst-5: ns for no 
significance, ** for p< 0.01, and **** for p< 0.0001. 





 An antifungal activity assay revealed that both E16R and E16L peptides showed enhanced 
antifungal activity as compared to parent Hst-5 despite being highly degraded by purified 
Saps and whole C. albicans cells (Figure 5.8). This indicates that some subset of 
degradation fragments produced for these two peptides are antifungal in nature. 
Interestingly, the K13E peptide showed decreased antifungal activity, which in conjunction 
with the E16 peptide results, suggests that a positively-charged residue is preferred over a 
negatively-charged residue to maintain or enhance antifungal activity. Following 
degradation by Sap2 or Sap9, degraded peptides were assessed for antifungal activity. 
Though E16R and E16L peptides were completely degraded by high concentrations of 
Saps (Figure 5.9A and B), they maintained a high level of antifungal activity (Figure 5.9C).  
The K11R-K17R peptide showed very high antifungal activity, most likely as a result of 
its synergistic effect of enhanced activity via the K11R mutation and resistance to 
degradation via the K17R mutation. These results considered when selecting peptides for 
experiments on C. albicans biofilms as described in Chapter 6. 
Figure 5.8§ Antifungal activity of Hst-5 and modified peptides. The peptides (50 μM) were 
serially diluted and incubated with 2.5×107 cells/mL C. albicans for 30 minutes at 30 °C. Error 
bars indicate the standard error of the mean (n = 6). MIC50 values for the peptides are shown. 





Figure 5.9§ (A) and (B) Extent of proteolysis of parent Hst-5 and Hst-5 variants by higher 
concentrations of purified Sap9 and Sap2. Peptides (50 μM) were incubated with Sap9 (6 
μg/mL) or Sap2 (0.2 μg/mL), respectively for 2hours at 37 °C. Following gel electrophoresis, 
the amount of intact peptide (upper band) and degraded peptide 9lower bands) were quantified 
by densitometry and compared. Error bars indicate standard error of the mean (n = 4). A one-
way ANOVA test and Dunnett’s multiple comparison test was performed. Asterisks indicate 
the level of statistical significance relative to parent Hst-5: **** for p< 0.0001. (C) Antifungal 
activity of the peptides after incubation with or without Sap9 or Sap2. Peptides (50 μM) 
were incubated with Sap9 (6 μg/mL), Sap2 (0.2 μg/mL), or 1 mM NaPB buffer for 2 h at 37 °C. 
Then, peptides were serially diluted and incubated with 2.5×105 cells/mL C. albicans for 30 
min at 30 °. Error bars indicate the standard error of the mean (n = 4). 





5.3 Materials and Methods 
5.3.1 Peptide degradation by C. albicans culture supernatant 
To confirm the presence and proteolytic activity of fully-secreted active Saps from 
C. albicans, an experiment was designed and performed to determine peptide degradation 
by C. albicans culture supernatant. An overnight culture of C. albicans was inoculated in 
YPD and grown at 30 °C overnight. The following day, a subculture was started and grown 
to an OD600 = 0.8 – 1 and from this, a second subculture of 25 mL was started and grown 
overnight for 17.5 hours to ensure adequate Sap expression and secretion. This additional 
subculturing step was performed in order to maintain consistency in the number of cells 
among biological replicates, which affects total protein expression. Cells were removed by 
centrifugation and 20 mL of the culture supernatant was transferred to a 10 kDa MWCO 
column and centrifuged at 20 °C for 20 minutes. Buffer exchange was performed by adding 
20 mL of 2 mM NaPB and centrifuging, which was performed three times. The remaining 
solution was resuspended in 2 mM NaPB to a final volume of 17.5 mL.  
Equal volumes of buffer-exchanged culture supernatant and peptide were mixed 
and incubated at 37 °C for 2 hours. Tricine sample buffer was added and samples were 
boiled at 100 °C for 10 minutes. Gel electrophoresis, Coomassie staining, and 
densitometric analysis were performed as described in 5.2.3. Three biological replicates 
with two technical replicates each were performed. A one-way ANOVA tests with p< 0.05 
and Dunnett’s multiple comparison tests with the Hst-5 sample as the control were 




5.4.1 Saps found in C. albicans culture supernatant degrade Hst-5 and variants 
The densitometric analysis performed on peptides degraded by culture supernatant 
revealed a pattern of degradation consistent with results from experiments using purified 
Saps (Figure 5.10). Both K17L and K17R peptides showed improved resistance against 
degradation, which is in agreement with previous findings. With this assay, the high 
resistance of these two peptides is highlighted, as there remains 72% intact peptide for 
K17R and 35% for K17L, compared to 10% or less intact peptide remaining for all other 
peptides. With the culture supernatant experiment, subtle differences between K17R and 
K17L can also be seen as there may be other enzymes present in the supernatant that may 
have a preference for leucine over arginine at cut sites. The supernatant should only contain 
secreted Saps, and results are consistent with this. For example, the K5R peptide shows 
more resistance to degradation when incubated with supernatant than when incubated with 
C. albicans, which confirms initial findings that K5R is more resistant to Sap2 than to 
Sap9. The K11R-K17R peptide also exhibited high resistance to degradation, which was 
expected due to the resistance imparted by the K17R modification. The K13H and E16R 
peptides provided some protection against degradation by C. albicans supernatant as 
compared to Hst-5; however, K13H and E16L did not impart any protection against 
proteolysis.  The differences in results from this assay as compared to the assay in which 
peptides were incubated with C. albicans cells demonstrate that both cell wall-anchored 





These findings demonstrate that specific modifications to the Hst-5 sequence 
protect from proteolytic degradation by purified Saps, whole C. albicans cells, and C. 
albicans culture supernatant. Resistance to degradation correlates with maintained or 
increased antifungal activity, though some degradation fragments appear to have high 
antifungal activity. These results contribute to what is known about Sap cleavage site 
preferences and properties of antimicrobial fragments, which can be used in further 
modification of Hst-5 or for the design of additional antifungal peptides. To further our 
Figure 5.10† Degradation of Hst-5 and modified peptides by C. albicans culture 
supernatant.  Peptides (150 μg/mL) from the first group of modifications (Table 5.1)  
(A) or the second set of modifications (Table 5.2) (B) were incubated with culture 
supernatant for 2 hours at 37 °C. Following gel electrophoresis, the percent intact peptide 
(upper band) and percent degraded peptide (lower bands) were quantified and compared. 
Error bars indicate standard error of the mean (n = 3).  A one-way ANOVA test and 
Dunnett’s multiple comparison test was performed Asterisks indicate the level of 
statistical significance relative to parent Hst-5: **** for p < 0.0001, * for p < 0.05 
† Figure A originally published in FEBS J. (2018) 
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understanding of the antifungal capabilities of the Hst-5 variants, we explored their use in 














Chapter 6: Antifungal peptides for treatment of C. albicans 
biofilms 
6.1 Introduction 
6.1.1 Properties of C. albicans biofilms 
C. albicans is an opportunistic pathogen that asymptomatically inhabits oral, 
gastrointestinal, and urogenital tracts in the human body. C. albicans has the ability to form 
biofilms on biotic and abiotic surfaces such as implants and catheters. Biofilm colonization 
of such surfaces is a major contributor to urogenital tract and bloodstream infections, which 
can be deadly [141]. Hospital-acquired infections of C. albicans are on the rise as overuse 
of antibiotics suppresses normal species of the microbiota and high usage of implants, 
catheters, and endotracheal tubes allows opportunity for infection [142–144]. 
The process of C. albicans biofilm formation begins by cell wall mediated 
adherence of yeast cells to a surface between 0 to 11 hours of growth. This is followed by 
a period during which blastospores proliferate and begin to produce a carbohydrate-rich 
extracellular matrix (ECM) [103]. During the maturation phase, cells form pseudohyphae 
and hyphae sand are encased by additional ECM [103], although cells are still able to 
disperse to invade other areas [141]. As C. albicans is a dimorphic organism, it exists in 
biofilms in budding yeast, pseudohyphal, and hyphal forms [142,145] (Figure 6.1). The 
latter two filamentous forms, while fundamentally different [145], share a genetic 
regulation factors that contribute to increased virulence. For example, both filamentous 
forms can exert mechanical force [146], which enables tissue penetration and invasion. 
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In fact, genes controlling virulence factors, and those controlling hyphal 
morphogenesis are co-regulated, implying that hyphal formation contributes to the 
virulence of C. albicans [146]. The most prevalent regulator of hyphal morphogenesis is 
the transcription factor Efg1p which is also responsible for the regulation of genes encoding 
Saps and adhesins. This expression that coincides with hyphal projection growth allows 
the cells to have a degradative and adhesive defense system while using the mechanical 
strength of hyphae to invade tissue, colonize surfaces, or escape epithelial cells following 
internalization [146]. 
Additionally, a small portion of clinically isolated strains of C. albicans yeast can 
undergo an epigenetic switch between white and opaque cells that is linked to the mating 
cycle of the cells [147]. It has been found that over 95% of C. albicans clinical isolates are 
heterozygous for the Mating Type Like (MTL) locus, meaning that they cannot mate unless 
they undergo homozygosis at the mating locus [141,147]. Interestingly, it has been found 
that biofilms formed from MTL-heterozygous C. albicans are ninefold more viable than 
those formed by MTL-homozygous cells and are more impermeable [141]. This may 
suggest that the majority of clinical infections are caused by MTL-heterozygous C. 
albicans as it serves as a protective factor in biofilm survival. 
In biofilms, C. albicans cells assume different properties from when they are 
planktonic. They are less susceptible to antimicrobial agents and MICs values were found 
to increase up to 20,000-fold for C. albicans in biofilms as compared to planktonic cells 
[104]. One of the main factors contributing to the increased antibiotic resistance of C. 
albicans biofilms as compared to planktonic cells is the phase-specific role of efflux pumps 
and membrane sterols. The CDR1, CDR2, and MDR1 genes encode for membrane-
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localized efflux pumps that pump drugs out of fungal cells and are characteristic or the 
multidrug resistant phenotype of C. albicans [103,105]. Membrane sterols that contribute 
to cell wall permeability also contribute to fluconazole resistance. Mukherjee et al. assessed 
fluconazole resistance of wild-type efflux pump gene knockout strains of C. albicans and 
also assessed the membrane composition of biofilm and planktonic C. albicans. Results 
suggest that efflux pumps impart azole-resistance only during early phases of biofilm 
formation, and that changes in membrane sterol composition contribute to resistance in 
mature biofilm development phases [103]. Ramage et al. found that the CDR1 and CDR2 
mRNA transcript expression was higher for early-phase sessile C. albicans in biofilms than 
for planktonic yeast, implicating their importance in fluconazole-resistance of biofilms in 
particular [105]. Comparison of temporal changes of membrane ergosterol levels between 
planktonic and biofilm C. albicans established that between 6 to 12 hours of growth the 
levels decreased 18% and 50%, respectively [103]. This indicates differences in 
fluconazole-resistance between planktonic and hyphal cells found in biofilms are partly 
due to membrane composition. 
Another factor contributing to the increased resistance of C. albicans biofilms to 
antibiotics is the composition of the extracellular matrix. Al-Fattani et al. describe a method 
by which C. albicans cells were grown under conditions that caused excess production of 
extracellular matrix material. These cells were found to be more resistant to amphotericin 
B than those grown in normal, static conditions. Additionally, to simulate conditions that 
may be present on catheter surfaces, the group performed the same experiment using a 
mixed culture of C. albicans and a slime-producing strain of Staphylococcus epidermidis 
and found the biofilm to be completely resistant to amphotericin B and fluconazole, even 
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under static conditions [148]. Thus, the use of an alternative therapy, such as antifungal 
peptides, could prove beneficial to overcome the limitations of current treatments. 
6.1.2 Selection of antifungal peptides for the treatment of C. albicans biofilms 
Previous work from other groups has demonstrated the use of peptides to treat C. 
albicans biofilms. Peptides based on KABT-AMP and uperin 3.6 showed the ability to 
eradicate biofilms, as decreasing biofilm metabolic activity was observed as peptide 
concentrations were increased from 1 – 4 times the MIC50 value for planktonic cells. 
Unfortunately, these peptides showed significant toxicity on two normal human epithelial 
cell lines, which puts limitations on their use in therapeutic applications [149]. Karlsson et 
al. demonstrated the use of β-peptides, constructed with β-amino acid oligomers, against 
C. albicans biofilms. They observed 80% reduction in biofilm metabolic activity when 
using peptide concentrations that were 1 – 16 times the MIC50 for planktonic cells [150]. 
Additionally, they demonstrated the ability to incorporate these β-peptides into poly- L-
glutamic acid/poly- L-lysine polyelectrolyte multilayer films, which led to a 74% decrease 
Figure 6.1 Microscopy of treated and untrteated C. albicans biofilms. (A) 
Untreated biofilm where primarily hyphal and pseudohyphal C. albicans are seen. (B) 
Biofilm grown in the presence of 0.75 mM E16R peptide that shows primarily yeast 
form C. albicans. Differential interference contrast microscopy images were obtained 
using an inverted microscope. Scale bars shown are 50 μm in length. 
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in biofilm metabolic activity and a decrease in hyphal cell elongation [151]. Other work 
has demonstrated the use of peptides, including non-amphipathic varieties, that have 
antifungal properties or that prevent the adhesion of C. albicans to surfaces [152–154]. 
Since Hst-5 is naturally occurring in the saliva, it serves as an ideal template for 
peptide design for therapeutic purposes. As detailed in previous chapters, specific 
modifications made to Hst-5 resulted in increased resistance to degradation and 
maintenance of antifungal activity against planktonic C. albicans cells. We chose to assess 
the ability of parent Hst-5, E16R, K11R-K17R peptides to eradicate C. albicans biofilms. 
The K11R17R peptide was selected for its combined modifications of improved antifungal 
activity (K11R) and high resistance to degradation by Saps (K17R). The E16R peptide was 
selected because previous results showed that despite being very susceptible to 
degradation, it maintained high antifungal activity (Figure 5.9). Hst-5 was used as a control 
for comparison to determine if modifications also demonstrate enhanced properties when 
treating C. albicans biofilms, which also contain more resistant pseudohyphal and hyphal 
cells. 
6.2 Materials and methods 
6.2.1 Planktonic candidacidal assay 
This assay was used to assess the antifungal properties of Hst-5, E16R, and K11R-
K17R peptides against planktonic C. albicans to confirm previous results prior to using the 
peptides against biofilms (Figure 6.2).  C. albicans was grown overnight at 30 °C in YPD. 
Cells were subcultured until OD600 = 1 to 1.2 and cells. Briefly, cells were washed with 2 
mM NaPB by centrifugation and resuspension and resuspended in 1 mL of 2 mM NaPB. 
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The OD600 was measured and a cell suspension of 5 × 107 cells/mL in 2 mM NaPB was 
prepared. Twofold serial dilutions of peptides were prepared in water 2X final 
concentration, with the highest 2X concentration being 800 μM) and 20 μL peptide was 
added to the appropriate well of a 96-well round-bottom plate, followed by 20 uL diluted 
cells per well. Amphotericin B was used as a control with 4.7 μM as the highest final 
concentration in the first well. For each peptide or drug, three biological replicates with 
two technical replicates each were performed (i.e. 6 total replicates each). 
Plates were incubated at 30 °C for 30 minutes and then the reaction was slowed by 
adding 320 μL 1 mM NaPB per well. Samples were diluted futher in YPD supplemented 
with NaPB to ~250 cells per well. These diluted samples were loaded into the appropriate 
wells of a new 96-well round-bottom plate and grown overnight at 30 °C at 350 rpm on a 
microplate shaker. Cells were resuspended and the absorbance at 600 nm was measured on 
a microplate reader. The percent reduction in viability was calculated as follows: 
 
% 𝑟𝑒𝑑𝑢𝑐𝑡𝑖𝑜𝑛 𝑖𝑛 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = [1 −
(𝑂𝐷𝑤𝑖𝑡ℎ 𝑝𝑒𝑝𝑡𝑖𝑑𝑒 − 𝑂𝐷𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑)
(𝑂𝐷𝑛𝑜 𝑝𝑒𝑝𝑡𝑖𝑑𝑒 − 𝑂𝐷𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑)




6.2.2 Biofilm formation assay 
This assay was performed to determine the ability of peptides to prophylactically 
prevent C. albicans biofilm formation. C. albicans was grown overnight in YPD at 37 °C.  
Twofold serial dilutions of peptides were prepared in water at 2X the desired final 
concentration with the highest 2X concentration being 12 mM. Cells were washed twice 
with PBS and diluted to a density of 10 × 106 cells/mL in RPMI-1640 medium. RPMI-
1640 is a defined media that contains amino acids and mimics the composition of human 
fluids [155].To each well of a 96-well high-binding polystyrene ELISA plate, 50 μL of the 
appropriate peptide dilution was added followed by 50 μL of cells. Amphotericin B was 
used as a positive control for antifungal activity. Again, for each peptide or drug, three 
biological replicates with two technical replicates each were performed. For each row (i.e. 
each replicate) a no peptide control and an empty control well were included. Plate edges 
were sealed with parafilm and plates were incubated at 37 ° for 24 hours. Growth was 
quantified using a metabolic colorometric assay. A solution of 0.5 g/L 2,3-bis(2-methoxy-
4-nitro-5-sulfo-phenyl)-2H-tetrazolium-5-carboxanilide (XTT) in PBS supplemented with 
1 μL 10 mM menadione in acetone was prepared and protected from light. Biofilms were 
Figure 6.2 Candidacidal assay. C. albicans cells are incubated with peptide, then diluted and grown 
overnight. Cell growth is measured and compared to that of cells without peptide treatment in order to 
determine the percent reduction in viability that peptide treatment imparts on cells. 
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washed three times with PBS and 100 μL of XTT/menadione solution was added to each 
well, including the empty well control in each row. Films were incubated in the dark at 37 
°C for 1.5 hours. Plates were centrifuged at 2,000 × g for 5 minutes and 75 μL of 
supernatant from each well was transferred to the corresponding well of a new 96-well flat-
bottom plate. The absorbance at 490 nm was measured and the percent reduction was 
calculated as follows: 
% 𝑟𝑒𝑑𝑢𝑐𝑡𝑖𝑜𝑛 𝑖𝑛 𝑚𝑒𝑡𝑎𝑏𝑜𝑙𝑖𝑐 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 = 100 ×  
(𝐴490
490 −  𝐴490







6.2.3 Biofilm susceptibility assay 
This assay was used to determine if peptides exhibit antifungal activity against 
preformed biofilms. As described in Section 6.2.2, cell suspensions of C. albicans were 
prepared at a density of 1 × 106 in 1:2 RPMI-1640 medium and 100 μL was placed into 
each well of an ELISA plate, with the exception of the final column to serve as an XTT 
control. Again, three biological replicates and two technical replicates per peptide or drug 
were used. For each row (i.e. each replicate) a no peptide control and an empty control well 
were included.  Plate edges were sealed with parafilm and incubated at 37 °C for 24 hours. 
Biofilms were washed 3 times with PBS. Twofold serial dilutions of peptides were 
prepared in 1:2 RPMI-1640 medium at the desired final concentrations with the highest 
concentration being 12 mM. 100 μL each was added to the appropriate wells of the ELISA 
plate and incubated for 24 hours at 37 °C. Biofilms were washed the XTT assay was 
performed as in 6.2.2. 
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6.2.4 Cytotoxicity analysis of peptides 
Peptide solutions were made by resuspending lyophilized peptide in 1 mM NaPB 
buffer to a final concentration of 200 μM each. HEK293T cells were cultured in 12-well 
tissue culture plates to 90%-100% confluency in Dulbecco’s modified Eagle’s medium 
(DMEM) with high glucose (ThermoFisher Scientific, Waltham, MA), 10% FBS 
(ThermoFisher Scientific), and 1% Penicillin-Streptomycin 10,000 U/ml (ThermoFisher 
Scientific). Cell media was replaced with serum-free media 16 hours prior to peptide 
incubation. Cells were rinsed with PBS and incubate with 1mL of peptide solution for 30 
minutes at 37°C. 1 mM NaPB buffer and ethanol controls were included. 250 μL of 0.25% 
Trypsin-EDTA was added to each well and incubated for 5 minutes at 37°C. Each sample 
was centrifuged at 200×g for 5 minutes and supernatant was aspirated. Cells were 
resuspended in 250 μL PBS and transferred to flow cytometry tubes. The cell culture, 
peptide incubation, and preparation of samples for flow cytometry detailed above were 
performed by Mary Doolin. 
Cells were resuspended by pipetting and 1 μL of 1 mg/mL propidium iodide was 
added immediately before data acquisition on the flow cytometer (BD FACS Canto II). 
Data was acquired for each sample for 75 seconds at a high flow rate. Analysis was 
performed by establishing APC-/APC+ gating between two population peaks, viable and 
non-viable, on the ethanol control APC-A histogram in FlowJo. This analysis was applied 
to all groups, resuspended in 250 μL of PBS, and transferred to the respective flow 
cytometer tubes. A one-way ANOVA statistical test was performed using GraphPad Prism 
software to assess statistical significance. 
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6.2.5 Incorporation of peptides into polyelectrolyte multilayer films 
 Biofilms colonize surfaces such as catheters and implants inside the body. 
Therefore, we hypothesize that treating these surfaces with antimicrobial agents that are 
released in a controlled manner can prevent colonization by C. albicans cells. One such 
method is the incorporation of antifungal peptides into polyelectrolyte multilayer (PEM) 
films that can be directly assembled on surfaces. PEMs are fabricated by the alternating 
deposition of polyanions and polycations in a layer-by-layer manner. Previous research 
demonstrates the incorporation of antifungal peptides into these films and the maintenance 
of peptide antifungal activity against planktonic C. albicans [156] and biofilms [151,157]. 
 To optimize conditions for the engineering of Hst-5 peptide-loaded films, different 
film fabrication methods were compared. Silicon substrates were cut into 15 mm × 5 mm 
chips and cleaned with acetone, ethanol, methanol, and water and dried under a filtered air 
stream. Substrate chips were treated with oxygen plasma to impart charge on the substrate 
surface. A solution of 50 mM polyethylenimine (PEI, MW = 50,000, Sigma) was prepared 
in 25 mM NaCl and 5 mM HCl in water. A solution of 50 mM sulfonated polystyrene (SPS, 
MW = 70,000, Sigma) in 25 mM NaCl in water. PEI and SPS were deposited onto the chip 
by (1) soaking the chip in the PEI solution for 5 minutes, (2) washing the chip twice by 
soaking in water for 1 minute per wash, and (3) soaking the chip in the SPS solution for 5 
minutes, (4) washing the chip twice by soaking in water for 1 minute per wash. Steps (1) 
through (4) were repeated until 10 bilayers were formed. The fabrication of these PEI/SPS 
base layers was performed on a DR3 dipping robot (Riegler & Kirstein GmbH). 
Preparation of silicon chips and base layer coating was performed by Haleigh Eppler and 
Dr. Qin Zeng. 
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 Solutions of poly-L-glutamic acid sodium salt (PGA, MW = 50,000, Sigma), poly-
L-lysine hydrobromide (PLL, MW = 15,000 – 30,000, Sigma), and Hst-5 were prepared at 
1 mg/mL each in 20 mM NaCl in water.  Two film preparation conditions were performed 
with 2 replicates each. For each condition, the film was fabricated by (1) soaking the 
substrate chip in the first solution for 5 minutes, (2) washing the chip twice by soaking in 
water for 1 minute per wash, (3) soaking in the second solution for 5 minutes, and (4) 
washing the chip twice with water as before. For the trilayer method, there was an 
additional (5) soaking the substrate chip in the third solution, and (6) washing the chip 
twice with water as before. For each condition, this schema was repeated until 8 bilayers 
or trilayers were deposited, and thickness measurements were taken after every 2 bilayers 
or trilayers. Film thickness measurements were taken at 5 points along the center of each 
chip using an ellipsometer (Gaertner Scientific). 
A control condition was performed by alternating deposition of PGA and PLL , 
which is known to generate films. As modeled after previous antifungal loaded PEMs 
[151], a trilayer condition was tested by alternating between the PGA solution, the Hst-5 
solution, and the PLL solution. The mean thickness and standard error for each condition 
was calculated after every 2 bilayers or trilayers and from this, the mean base layer 
thickness was subtracted. 
6.3 Results 
6.3.1 Modified peptides exhibit enhanced antifungal activity 
To assess the antifungal capabilities of the K11R-K17R and E16R peptides, a 
planktonic Candidacidal assay was performed. The results showed patterns in antifungal 
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activity for Hst-5, E16R, and K11R-K17R at varying peptide concentrations that confirm 
earlier results (Figure 6.3). It is of interest to note that at all relevant peptide concentrations, 
the percent reduction in viability was higher for the modified peptides than for unmodified 
Hst-5. This could indicate that either modified peptides have enhanced antifungal 
properties or that their resistance to degradation by Saps allows antifungal fragments to 
remain active. Small error bars at all concentrations, and particularly for K11R-K17R and 
E16R peptides imply that these results are reproducible and consistent. A higher error for 
the Hst-5 peptide is seen at lower peptide concentrations which is due to the large number 
of cells present, which causes some variability when measuring cell growth by absorbance. 
These results are consistent with previous planktonic assay results shown in Chapter 5, and 
highlight the benefits that single residue modifications can impart on the antifungal 
capabilities of peptides such as Hst-5. 
 
Figure 6.3 Planktonic Candidacidal assay. Planktonic C. albicans cells were 
grown in the presence of histatin-5, E16R or K11R-K17R peptide. An XTT 
assay was performed to determine cell metabolic activity of the cells and the 
percent reduction in metabolic activity, as compared to untreated cells, was 
calculated. Error bars represent standard of the mean with n = 6. 
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6.3.2 Histatin-5 and modified peptides inhibit biofilm formation 
To determine the capabilities of Hst-5 and modified peptides in the preventing 
growth of biofilms, a biofilm formation assay was performed. The results for the biofilm 
formation assay indicate that Hst-5, E16R, and K11R-K17R exhibit antifungal properties 
and can prevent the formation of biofilms (Figure 6.4). Once again, at relevant 
concentrations, E16R and K11R-K17R performed better than Hst-5 in terms of reduction 
of metabolic activity, indicating that the modifications impart beneficial effects on the 
antifungal activity of the peptides. Again, error bars are small, indicating that results are 
consistent and reproducible. It is important to note that the peptide concentrations needed 
to show reduction in metabolic activity for cells where biofilm formation is being induced 
is in the millimolar range, whereas concentrations in the micromolar range were enough to 
show antifungal activity against planktonic C. albicans. This reiterates the higher resistance 
of C. albicans biofilms to antifungal agents as compared to their planktonic counterparts 
and emphasizes the need for improving therapy. Though these concentrations may appear 
high, only a high local concentration at the surface is needed for preventing biofilm growth. 
Additional mammalian cell cytotoxicity studies using millimolar concentrations of peptide 
will be performed in the future and the immunogenicity of the peptides will be tested. The 
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results from this assay are a good indication that biofilm formation can be prophylactically 
prevented with the use of Hst-5 or modified peptides. 
 
6.3.3 Histatin-5 and modified peptides show antifungal activity against 
preformed biofilms 
While preventing biofilm formation is ideal, another mode of therapeutic use of 
antifungal peptides is to treat preformed biofilms (Figure 6.5). Here, when peptides were 
incubated with preexisting C. albicans biofilms, there was a marked reduction in metabolic 
activity. In this case, the modified peptides showed enhanced antifungal activity against C. 
albicans over Hst-5, except at the highest concentrations where Hst-5 performed equally 
or better than E16R and K11R-K17R. It is of interest to note that while K11R-K17R and 
E16R both show very small error bars, that Hst-5 shows large error bars, and that this is 
Figure 6.4 Biofilm formation assay. C. albicans biofilms were grown for 24 hours 
in the presence of histatin-5, E16R, or K11R-K17R peptide. An XTT assay was 
performed to determine metabolic activity of the cells. The percent reduction in 
metabolic activity, as compared to untreated cells, was calculated. Error bars 
represent standard of the mean with n = 6. 
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specific to this assay. One possible explanation could be how the degradation kinetics of 
Hst-5 compared to those of K11R-K17R. From preliminary kinetic analysis (data not 
shown) it seems that E16R degrades much more quickly than Hst-5, and as speculated 
before, we believe that one of the degradation fragments of E16R has antifungal 
capabilities. Thus, E16R likely degrades quickly and in a consistent manner. In 
comparison, Hst-5 degrades more slowly and as degradation is dependent on Saps from C. 
albicans cells, there will likely be more variability which contributes to the high error seen. 
K11R-K17R is not readily degradable by Saps, which means that it will perform in a 
consistent manner, as suggested by the small error bars. The results of this assay 
demonstrate the therapeutic potential for Hst-5 and modified peptides to be used to treat 
preexisting biofilms that have formed on surfaces. 
In microscopy images taken of treated C. albicans biofilms vs. untreated biofilms, 
we observed a distinct lack of hyphal cell formation in treated samples (Figure 6.1). There 
were still a few yeast form cells in treated samples, which indicate that there were still 
potentially live cells present, and that few, if any, were pseudohyphal or hyphal in nature. 
This observation may be of interest as it may indicate that Hst-5 and its variants in part 
function by preventing hyphal growth, and since hyphal cells are more resistant to 
antifungals, demonstrating this capability would be compelling to the treatment of fungal 
disease.  In Chapter 7, we discuss the potential for using this information to elucidate the 






6.3.4 Peptides are not cytotoxic to mammalian cells 
To ensure that modified peptides did not cause significant mammalian cell 
cytotoxicity, incubation of peptides with HEK293T cells was performed and the percent of 
non-viable cells was quantified using propidium iodide staining and flow cytometry. 
Propidium iodide can only enter cells when the cellular membrane is destabilized, 
indicating a damaged, non-viable cell. The percent PI-positive cells for each modified 
Table 6.1 Cytotoxicity analysis of Hst-5 and variants 
Peptide % PI-positive cells ± SEM 
1 mM NaPB control 5.106 ± 1.385 
Hst-5 7.215 ± 1.025 
E16R 10.74 ± 3.625 
E16L 5.252 ± 0.7552 
K11R-K17R 4.626 ± 0.8321 
K13E 6.328 ± 1.3 
K13H 4.687 ± 1.083 
 
Figure 6.5 Biofilm susceptibility assay. C. albicans biofilms were grown for 
24 hours and then incubated with histatin-5, E16R, or K11R-K17R peptide for 
24 hours. An XTT assay was performed to determine metabolic activity of the 
cells. The percent reduction in metabolic activity, as compared to untreated 
cells, was calculated. Error bars represent standard of the mean with n = 6. 
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peptide was compared to that of a 1mM NaPB buffer control with a one-way ANOVA tests 
with p< 0.05 and Dunnett’s multiple comparison tests with the Hst-5 sample as the control 
were performed to assess statistical significance. No significant differences were observed 
(Table 6.1), indicating that peptides are no more cytotoxic than buffer alone. Additionally, 
the percent PI-positive cells for each modified peptide was compared to that of Hst-5 and 
no significant differences were observed. These results demonstrate that peptides are not 
cytotoxic to mammalian cells and that the peptide modifications to not cause changes in 
cytotoxicity from the parent Hst-5. Additional testing with millimolar peptide 
concentrations will be performed to ensure that concentrations used in biofilm assays are 
not toxic to mammalian cells. 
 
6.3.5 Peptides can be incorporated into PEMs 
Preliminary results indicate the ability to incorporate Hst-5 into PGA/PLL 
polyelectrolyte multilayer films. The growth of the PEMs fabricated in the trilayer method 
show a generally positive growth as the number of deposited trilayers increases, with an 
increase of 408 Ȧ from the initial base layer thickness (Figure 6.6). The PGA/PLL control 
also showed film growth, but at a lower level than the Hst-5 incorporated trilayers, which 
is expected. It should be noted that large error bars seen are likely an artifact of inadequate 
base layer homogeneity which led to differences in film thickness at different locations on 
each chip, which are particularly apparent when more layers are deposited. The deposition 
of base layers will be optimized to promote homogeneous film growth. 
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Optimizing concentrations of PGA, PLL, and Hst-5 will allow for more consistent 
growth with an increasing number of trilayers. Additionally, ensuring base layers are 
properly and homogeneously built onto the chip surface will allow for more consistent 
polyelectrolyte deposition and less variability in measurements. With these initial results 
confirming that peptide can be incorporated into films, more studies should be performed 
to characterize these films and their ability to prevent biofilm formation. These studies are 




Figure 6.6. Thickness of fabricated polyelectrolyte multilayer films. Films were 
fabricated as described in Section 6.2.5 by alternating deposition of poly-L-glutamic 
acid, poly-L-lysine, and histatin-5. Film thickness was measured at 5 points per sample 
after every 2 bilayers or trilayers on an ellipsometer and averaged. Error bars show 





 Hst-5 and the variants E16R and K11R-K17R can be used to prevent formation of 
C. albicans biofilms and to eradicate preformed biofilms. The modified peptides exhibit 
enhanced antifungal activity as compared to parent Hst-5 in the treatment of both 
planktonic cells and biofilms. Hst-5 and modified peptides are not toxic to mammalian 
cells, which makes the suitable agents for therapeutic purposes. Hst-5 and its variants are 
attractive candidates for treating fungal disease in humans as Hst-5 is natively produced 
and present in the oral cavity. The non-foreign nature lends itself to greater tolerance and 
some predictability of properties and immunogenicity of modified variants. 
  The incorporation of these antimicrobial peptides into PEMs will allow the coating 
of implantable surfaces to prevent C. albicans growth and fungal disease. Peptide loaded 
films can be used to coat a variety of surfaces such as prostheses and catheters, which will 
confer a high local surface concentration of peptide. This can effectively prevent biofilm 
formation on implantable devices as the peptide release rate can be adjusted. As the risk of 
C. albicans infection is higher immediately after implantation, such a coating would release 
peptide initially and eventually degrade when the risk of biofilm growth decreases over 
time. In Chapter 7, we discuss studies that will facilitate the use of peptide loaded PEMs 































PART III: SUMMARY AND 






Chapter 7: Summary and recommendations for future work 
7.1 Summary 
The work presented in this dissertation contributes new methodology, novel 
insights, and potential therapeutic agents to the protein and peptide engineering field.  
 With our intrabody engineering work, we demonstrated the ability to isolate highly 
soluble scFvs from a naïve library using Tat inner-membrane display and screening. We 
found that screening of naïve libraries using this method requires optimization as the 
isolated scFvs exhibited nonspecific binding behavior. In our efforts to increase assay 
stringency to improve the properties of isolated scFvs, we found that inclusion of a soluble 
competitor during the screening process altered the overall properties of isolates. Upon 
further characterization, those scFvs isolated from screening in which a soluble competitor 
was included exhibited more saturable binding curves and greater discrimination between 
binding signal of different library members. This reduces the number of false positives and 
nonsaturable binding seen in concentration dependent ELISAs. Additionally, we found that 
choice of blocking agent as a diluent when incubating lysates affects the binding of scFvs 
at higher concentrations, which is an important consideration during isolate 
characterization. 
 We also implemented modifications to the library cloning process that shorten the 
time it takes to generate new libraries from enriched sublibraries or isolated antibodies. 
Whole plasmid PCR eliminates the need to perform plasmid purification and restriction 
enzyme digest digestion to prepare vector backbone. We also demonstrated the ability to 
perform whole plasmid PCR on plasmid DNA directly from lysed spheroplasts. 
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Additionally, we were able to transform E. coli with plasmid from spheroplast lysate, 
which eliminates the need to amplify plasmids, though additional work needs to be 
performed to determine if libraries generated in this manner are comparable in diversity to 
those generated using cloning methods. The implementation of these protocol 
modifications will save valuable time when repeatedly panning and constructing libraries, 
which will allow for a shorter timescale to discovery of high binding antibodies. These 
findings and method improvements will help to shape a general protocol for intrabody 
engineering that promotes antigen specificity and cytoplasmic solubility.  
 In our work with antifungal peptides, we demonstrated that specific modifications 
to Hst-5 made modified peptides more resistant to degradation by Saps found on C. 
albicans cells and in the culture supernatant. We also established the use of three of these 
peptides, Hst-5, E16R, and K11R-K17R, for the prevention of C. albicans biofilm 
formation and eradication of preformed biofilms. It was seen that the antifungal activity of 
the modified peptides was enhanced as compared to Hst-5. Results also indicate that K11R-
K17R and E16R behave in a more predictable and consistent manner as compared to parent 
Hst-5, likely due to differences in the kinetics of peptide degradation by C. albicans 
secreted Saps and the properties of their respective fragments. The results from this work 
contribute to the knowledge of current antimicrobial peptides and can be used in the 
engineering of additional peptides. 
Based on our work, we have several recommendations for future studies to build 




 7.2Improving library screening for the isolation of intrabodies 
7.2.1 Improving library quality 
7.2.1.1 Use of an immunized library 
 Our first suggestion is to explore the use of an immunized library as a starting point 
for affinity maturation using the Tat inner-membrane display method. To obtain an 
immunized library, the target antigen is introduced into an animal (e.g. a llama) whereby 
the antibodies are generated in response to this antigen. Antibodies are isolated by 
extracting mRNA from lymphocytes from the animal and then genes encoding antibody 
fragments can then be cloned into the selected display vector. Immunization is 
advantageous because of the intrinsic clonal expansion and affinity maturation that occurs 
when an immunogen is introduced into the animal’s body. This results in a library that is 
made of many members that already have at least a low level of binding to the antigen. 
Using Tat inner-membrane display to further affinity mature an immunized library is 
valuable for intrabody engineering applications as it will deplete the library of poorly 
soluble members. 
7.2.1.2 Use of a commercial anti-survivin antibody 
 Commercially available monoclonal antibodies targeted towards survivin for 
research purposes are available. One option to improve the quality of the library is to use 
such an existing antibody as a template for the library. This would ensure that the parent 
antibody has some specificity for survivin, which will be further engineered. In this 
approach, it would be necessary to receive the gene sequence from the commercial 
antibody manufacturer and determine the heavy chain and light chain regions in order to 
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generate an scFv or other antibody fragment from the full length IgG. The isolated fragment 
would then be mutagenized to generate a library to display and screen against survivin. 
Binding affinity and specificity for survivin would be characterized. 
7.2.1.3 Modifications to the antibody fragment frameworks to improve solubility 
The highly reducing cytoplasm of mammalian cells prevent the formation of 
stabilizing disulfide bonds normally needed for antibodies and antibody fragments to fold 
and function correctly. It has been shown that an scFv framework that has been modified 
to eliminate cysteines that form disulfide bonds allows for isolation of scFvs that are well 
folded and stable [158]. We suggest extending this framework modification to VHHs, as 
they are already more stable than scFvs and show great potential for use as intrabodies. 
In VHHs, there are two conserved cysteines at residue positions 22 and 92 in the 
framework FR1 and F3 regions, respectively, that are prone to forming disulfide bonds. 
Site-directed mutagenesis can be performed to substitute the framework cysteine residues 
at positions 22 and 92 with alanine residues. Alanine residues are typically used for 
cysteine substitution are small and are not likely to cause major structural changes. This 
would prevent the formation of this disulfide bond and decrease the likelihood that a 
promising VHH would show low solubility upon further characterization. We would 
expect that a VHH library based on a framework that is non-reliant on stabilizing disulfide 
bonds will produce VHHs with greater cytoplasmic solubility earlier in rounds of directed 
evolution than a library based on a traditional VHH framework. 
An alternative method to improving the solubility of antibody fragments, including 
both VHHs and scFvs, is to pack the core of the folded proteins with hydrophobic residues. 
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The inclusion of more hydrophobic residues on the interior and more hydrophilic residues 
on the exterior of the folded protein may confer additional thermal stability and solubility 
to the antibodies. This method would rely on an analysis of existing antibody fragment 
framework structures. Such an approach would entail engineering the solubility first, and 
then following this with library construction, display, and screening to engineer binding 
affinity and specificity. 
7.2.2 Increasing assay stringency 
 As we demonstrated in our work, modifications to the screening assay can change 
the binding behavior of isolated antibodies and allow better discrimination between 
isolates. Therefore, we suggest continuing along this route to systematically modify the 
panning and screening protocols and compare outcomes. One suggestions for improvement 
is the inclusion of soluble parent antibody in various steps of the protocol so that library 
antibodies have to bind more strongly to the antigen than the parent scFv in order to remain 
bound and be recovered. Specifically related to the survivin antigen, we recommend 
improving the purification of scFv-F4 for use as a soluble competitor. We also recommend 
assessing the extent to which adding additional negative panning steps affects the presence 
of false positives in the library secondary screening process. Elimination of false positives 
early on will save time and resources that would not need to be spent on further 
characterization of such antibodies. 
7.2.3 Modifications to survivin target 
The commercially available recombinant human survivin used in our work had an 
N-terminal calmodulin tag which was nearly as large as monomeric survivin itself. As such, 
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it is quite possible that libraries were being screened for binding to epitopes on the 
calmodulin tag rather than on the survivin protein. We suggest the use of a recombinant 
survivin protein with either no tag or a smaller tag to prevent antibodies from binding to 
non-target domains.  
Orienting survivin in unidirectiontionally during surface coating for binding assays 
may promote isolation of antibodies that bind to specific domains. One potential method 
for achieving this is to express survivin as a fusion to the biotin carboxyl carrier protein 
(BCCP) or its minimal substrate, AviTag. These can be biotinylated in vivo [159], purified, 
and immobilized onto streptavidin-coated plates in a method similar to that developed by 
Ikonomova et al. for immobilization of scFvs [160]. This method would orient the survivin 
molecules once the biotin-streptavidin non-covalent bond is formed as the terminus bearing 
BCCP will be bound to the surface. Other methods for orienting survivin can also be 
explored. 
7.3 Understanding histatin-5 cell entry mechanisms and potential as a 
candidacidal therapy 
7.3.1 Oriented CD 
 As detailed in Chapter 5, Hst-5 does not cause pore formation when it enters C. 
albicans and enters the cell through a combination of energy dependent and energy 
independent mechanisms. While it is known that Hst-5 is unstructured in aqueous solution 
and helical in hydrophobic solutions, more information about the structure of Hst-5 near 
the cell surface is warranted. We suggest performing oriented circular dichroism (OCD) to 
gather information about the secondary structure of Hst-5 and variants near synthetic 
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oriented lipid multibilayers [161]. This method relies on the assumption that the dipole 
moment of the transition of amide bond is polarized either parallel or perpendicular to the 
helical axis [162]. The orientation of the helical peptide with respect to the lipid multilayer 
is conveyed through the OCD spectra produced. Understanding the direction at which Hst-
5 approaches the membrane will contribute to our knowledge of its entry mechanism and 
provide additional amino acid targets for modification. 
7.3.2 Formation of peptide-loaded PEMs to coat implantable surfaces 
 We demonstrated the success of Hst-5 and modified peptides in treating C. albicans 
biofilms. While our results for incorporation of Hst-5 into PGA/PLL PEMs are 
preliminary, once it is demonstrated that the films can be fabricated, we suggest the 
following set of experiments. Peptide-loaded films should be characterized for thickness 
and peptide incorporation. Thickness measurements can be performed during layer-by-
layer formation as described in Chapter 6.2.5 and peptide incorporation can be confirmed 
by taking absorbance measurements of PEMs fabricated with fluorescently-labeled 
peptide. The stability of the films in RPMI-1640 media should also be assessed as their use 
in these growth conditions is necessary. Most importantly, the antifungal activity of the 
films should be assessed by inducing biofilm formation in the presence of peptide-loaded 
films and then quantifying cell viability with an XTT metabolic or PI stain. Growth of 
biofilms on coated substrates will be compared to their growth on the surrounding surface 
and on untreated samples via the metabolic assay and visual comparison using bright field 
microscopy. Additional details for designing and performing these assays is described by 
Karlsson et al. [151]. Establishing the maintenance of antifungal activity will serve as a 
foundation for in vivo studies involving PEM-coated implantable surfaces. The information 
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gained from these studies will continue the advancement of applying Hst-5 and its variants 
toward therapeutic purposes. 
7.3.3 Assessment of Hst-5 and modified peptides ability to prevent hyphal 
formation 
 As described in Chapter 6, there was lack of hyphal cell formation in treated 
samples of the biofilm formation assay, though a few yeast form cells were still seen. It is 
of interest to determine whether or not Hst-5 and its variants prevent C. albicans biofilm 
formation by preventing hyphal cell growth that contributes to the network-structure of 
biofilms. The dense network formed by hyphal cells, which later become encapsulated by 
extracellular matrix, is one of the contributing factors to the increased resistance of C. 
albicans in this form. It could be speculated that preventing these connections would inhibit 
the ability of the cells to form such a network, thus reducing their resistance to treatment. 
Therefore, developing an assay to assess mRNA transcripts in response to peptide 
treatment at varying time points would help to elucidate whether or not peptide in part 





Figure A1† Relative mass spectrometry signal intensity of intact peptide (gray) and peptide 
fragments produced by incubation of parent Hst-5 and Hst-5 variants (modified residue in 
red) with 3.13 g/mL Sap9. The values on each fragment indicate the signal for the fragment 
relative to the signal for an internal standard. Fragments with signals greater than 0.01 
relative to the standard are shown. The relative signal is the mean with standard error (n = 
3). 







Figure A2† Relative mass spectrometry signal intensity of intact peptide (gray) and peptide 
fragments produced by incubation of parent Hst-5 and Hst-5 variants (modified residue in 
red) with 6.25 g/mL  Sap2. The values on each fragment indicate the signal for the 
fragment relative to the signal for an internal standard. Fragments with signals greater than 
0.01 relative to the standard are shown. The relative signal is the mean with standard error 
(n = 3). 
†Figure and caption originally published in FEBS J. (2018) 
133 
 
Publications and Presentations 
Accepted publications 
Moghaddam-Taaheri P and Karlsson AJ. “Protein labeling in live cells for 
immunological applications.” Bioconjugate Chemistry. doi: 
10.1021/acs.bioconjchem.7b00722. (2018). 
Ikonomova SP, Moghaddam-Taaheri P, Wang Y, Jabra-Rizk MA and Karlsson AJ. 
“Engineering improved variants of the antifungal peptide histatin 5 with reduced 
susceptibility to Candida albicans secreted aspartic proteases and enhanced 
antimicrobial potency.” FEBS J. doi: 10.1111/febs.14327 (2017). 
Moghaddam-Taaheri P, Ikonomova SP, Gong Z, Wiesnieski J, and Karlsson AJ. 
"Bacterial inner-membrane display for screening a library of antibody fragments." J Vis. 
Exp. (116), e54583, doi:10.3791/54583 (2016). 
Publications under preparation 
Moghaddam-Taaheri P, Ikonomova SP, Eppler H, and Karlsson AJ. “Histatin 5 
variants inhibiting Candida albicans biofilm formation.” In preparation. 
Ikonomova SP, Moghaddam-Taaheri P, Doolin M, Wang Y, and Karlsson AJ. 
“Histatin 5 variants with improved resistance to degradation by Candida albicans 
secreted aspartic proteases.” In preparation. 
Presentations (presenting author underlined) 
Moghaddam-Taaheri P, Ikonomiva S and Karlsson AJ. “Antifungal peptide variants 
with reduced degradation by fungal proteases and improved antifungal activity against 
planktonic and biofilm cells.” AIChE Annual Meeting, Pittsburgh, PA, October 2018. 
In preparation. (Poster) 
Dearring R, Yao Q, Moghaddam-Taaheri P, Karlsson A and Asa-Awuku A. 
“Identification of toxic mold genes in aerosolized Stachybotrys.”  International Aerosol 
Conference, St. Louis, MO, September 2018. In preparation. (Poster) 
Moghaddam-Taaheri P and Karlsson AJ. "Bacterial inner membrane display for 
isolating intracellular antibodies that bind survivin." International Conference on 





[1] R.J. Kazlauskas, U.T. Bornscheuer (2009) Finding better protein engineering 
strategies, Nat. Chem. Biol. 5, 526–529. doi:10.1038/nchembio0809-526. 
[2] G. Güven, R. Prodanovic, U. Schwaneberg (2010) Protein engineering - an option 
for enzymatic biofuel cell design, Electroanalysis. 22, 765–775. 
doi:10.1002/elan.200980017. 
[3] O. Kirk, T.V. Borchert, C.C. Fuglsang (2002) Industrial enzyme applications, Curr. 
Opin. Biotechnol. 13, 345–351. doi:10.1016/S0958-1669(02)00328-2. 
[4] P.J. Carter (2011) Introduction to current and future protein therapeutics: A protein 
engineering perspective, Exp. Cell Res. 317, 1261–1269. 
doi:10.1016/j.yexcr.2011.02.013. 
[5] J. Maynard, G. Georgiou (2000) Antibody Engineering, Annu. Rev. Biomed. Eng.2, 
339-376. 
[6] P.J. Carter (2006) Potent antibody therapeutics by design, Nat. Rev. Immunol. 6, 
343–357. doi:10.1038/nri1837. 
[7] A.L. Nelson, E. Dhimolea, J.M. Reichert (2010) Development trends for human 
monoclonal antibody therapeutics, Nat. Rev. Drug Discov. 9, 767–774. 
doi:10.1038/nrd3229. 
[8] G. Walsh (2010) Biopharmaceutical benchmarks 2010, Nat. Biotechnol. 28, 910-
917. doi: 10.1038/nbt0910-917 
[9] G.S. Martin (2003) Cell signaling and cancer, Cancer Cell. 4, 167–174. 
doi:10.1016/S1535-6108(03)00216-2. 
[10] H.S. Bell, K.M. Ryan (2005) Intracellular signalling and cancer: complex pathways 
lead to multiple targets, Eur. J. Cancer. 41, 206–215. 
doi:10.1016/j.ejca.2004.10.022. 
[11] M. Mahlapuu, J. Håkansson, L. Ringstad, C. Björn (2016) Antimicrobial peptides: 
an emerging category of therapeutic agents, Front. Cell. Infect. Microbiol. 6, 194. 
doi:10.3389/fcimb.2016.00194. 
[12] M. Zasloff (2002) Antimicrobial peptides of multicellular organisms, Nature. 415, 
389–395. doi:10.1038/415389a. 
[13] Antibiotic Resistance Threats in the United States, 2013, U.S. Department of Health 
and Human Services Centers for Disease Control and Prevention, 2013. 
135 
 
[14] About Antimicrobial Resistance | Antibiotic/Antimicrobial Resistance | CDC, 
(2018). https://www.cdc.gov/drugresistance/about.html (accessed July 2, 2018). 
[15] S. Lutz (2010) Beyond directed evolution—semi-rational protein engineering and 
design, Curr. Opin. Biotechnol. 21, 734–743. doi:10.1016/j.copbio.2010.08.011. 
[16] P.A. Romero, F.H. Arnold (2009) Exploring protein fitness landscapes by directed 
evolution, Nat. Rev. Mol. Cell Biol. 10, 866–876. doi:10.1038/nrm2805. 
[17] K.T. O’Neil, R.H. Hoess (1995) Phage display: protein engineering by directed 
evolution, Curr. Opin. Struct. Biol. 5, 443–449. doi:10.1016/0959-440X(95)80027-
1. 
[18] E.T. Boder, K.D. Wittrup (2000) Yeast surface display for directed evolution of 
protein expression, affinity, and stability, Methods Enzymol., 328, 430-444. 
doi:10.1016/S0076-6879(00)28410-3. 
[19] S.A. Gai, K.D. Wittrup (2007)Yeast surface display for protein engineering and 
characterization, Curr. Opin. Struct. Biol. 17,467–473. 
doi:10.1016/j.sbi.2007.08.012. 
[20] D. Colby, B. Kellog, C. Graff, Y. Yeung, J. Swers, D. Wittrup (2004) Engineering 
antibody affinity by yeast surface display, Methods Enzymol., 388, 348-358. doi: 
10.1016/S0076-6879(04)88027-3 
[21] D. Gueorguieva, S. Li, N. Walsh, A. Mukherji, J. Tanha, S. Pandey (2006) 
Identification of single-domain, Bax-specific intrabodies that confer resistance to 
mammalian cells against oxidative-stress-induced apoptosis, The FASEB Journal. 
20, 2636–2638. 
[22] S. Zielonka, et al. (2014) Shark Attack; High affinity binding proteins derived from 
shark vNAR domains by stepwise in vitro affinity maturation, J. Biotech. 191, 236–
245. 
[23] E. Boder, K. Midelfort, K. Wittrup (2000) Directed evolution of antibody fragments 
with monovalent femtomolar antigen-binding affinity, Proc. Natl. Acad. Sci. 97, 
10701–10705. 
[24] M. Levisson, R. Spruijt, I. Winkel, S. Kengen, J. van der Oost (2014) Phage display 
of engineered binding proteins, Methods Mol. Biol. 1129, 211–229. doi: 
10.1007/978-1-62703-977-2_19. 
[25] J.J. VanAntwerp, K.D. Wittrup (2008) Fine affinity discrimination by yeast surface 
display and flow cytometry, Biotechnol. Prog. 16, 31–37. doi:10.1021/bp990133s. 
[26] G. Chao, W.L. Lau, B.J. Hackel, S.L. Sazinsky, S.M. Lippow, K.D. Wittrup (2006) 
Isolating and engineering human antibodies using yeast surface display, Nat. 
Protoc. 1, 755–768. doi:10.1038/nprot.2006.94. 
136 
 
[27] M.C. Kieke, E.V. Shusta, E.T. Boder, L. Teyton, K.D. Wittrup, D.M. Kranz (1999) 
Selection of functional T cell receptor mutants from a yeast surface-display library, 
Proc. Natl. Acad. Sci. 96, 5651–5656. doi:10.1073/pnas.96.10.5651. 
[28] D. Steiner, P. Forrer, M.T. Stumpp, A. Plückthun (2006) Signal sequences directing 
cotranslational translocation expand the range of proteins amenable to phage 
display, Nat. Biotechnol. 24, 823–831. doi:10.1038/nbt1218. 
[29] A.J. Karlsson, H.-K. Lim, H. Xu, M.A. Rocco, M.A. Bratkowski, A. Ke, M.P. 
DeLisa (2012) Engineering antibody fitness and function using membrane-anchored 
display of correctly folded proteins, J. Mol. Biol. 416, 94–107. 
doi:10.1016/j.jmb.2011.12.021. 
[30] S. Marshall, G. Lazar, A. Chirino, J. Desjarlis (2003) Rational design and 
engineering of therapeutic proteins, Drug Discov.Today. 8, 212-221. 
[31] Y. Chen, C.T. Mant, S.W. Farmer, R.E.W. Hancock, M.L. Vasil, R.S. Hodges 
(2005) Rational design of α-helical antimicrobial peptides with enhanced activities 
and ppecificity/therapeutic index, J. Biol. Chem. 280, 12316–12329. 
doi:10.1074/jbc.M413406200. 
[32] C. Loose, K. Jensen, I. Rigoutsos, G. Stephanopoulos (2006) A linguistic model for 
the rational design of antimicrobial peptides, Nature. 443, 867–869. 
doi:10.1038/nature05233. 
[33] S. Tangri, B.R. Mothe, J. Eisenbraun, J. Sidney, S. Southwood, K. Briggs, J. 
Zinckgraf, P. Bilsel, M. Newman, R. Chesnut, C. LiCalsi, A. Sette (2005) 
Rationally engineered therapeutic proteins with reduced immunogenicity, J. 
Immunol. 174, 3187–3196. doi:10.4049/jimmunol.174.6.3187. 
[34] A. Sircar, E. Kim, J. Gray (2009) RosettaAntibody: antibody variable region 
homology modeling server, Nucleic Acids Res. 37, W474-9. doi: 
10.1093/nar/gkp387 
[35] S. Lyskov, J.J. Gray (2008) The RosettaDock server for local protein-protein 
docking, Nucleic Acids Res. 36, W233–W238. doi:10.1093/nar/gkn216. 
[36] United States Cancer Statistics: 1999-2013 Incidence and Mortality Web-based 
Report, CDC. (2016). 
[37] R. Weinberg (2007)The Biology of Cancer, Garland Science. 
[38] R. Olie, et al. (2000) A novel antisense oligonucleotide targeting survivin 
expression induces apoptosis and sensitizes lung cancer cells to chemotherapy, 
Cancer Research. 60, 2805–2809. 
[39] K. Tanaka, et al. (2000) Expression of survivin and its relationship to loss of 
apoptosis in breast carcinomas, AARC. 6, 127–134. 
137 
 
[40] H. Kawasaki, et al. (1998) Inhibition of apoptosis by survivin predicts shorter 
survival rates in colorectal cancer, Cancer Research. 58, 5071–5074. 
[41] M. Zhang, D. Latham, M. Delaney, A. Chakravarti (2005) Survivin mediates 
resistance to antiandrogen therapy in prostate cancer, Oncogene. 24, 2474–2482. 
[42] C. Jeon, M. Kim, C. Kwak, H. Kim, J. Ku (2013) Prognostic role of survivin 
inbladder cancer: a systematic review and meta-analysis, PLoS ONE. 8, e76719. 
10.1371/journal.pone.0076719 
[43] C. Cheung, et al. (2013) Survivin – biology and potential as a therapeutic target in 
oncology, OncoTargets and therapy. 6, 1453–1462. 
[44] A. Sarela, R. Macadam, S. Farmery, A. Markham, P. Guillou (2000)  Expression of 
the antiapoptosis gene, Survivin, predicts death from recurrent colorectal carcinoma, 
Gut. 46, 645–650. 
[45] H. Kawasaki, et al. (2001)  Expression of survivin correlates with apoptosis, 
proliferation, and angiogenesis during human colorectal tumorigenesis, Cancer. 91, 
2026–2032. 
[46] C. Adida, et al. (1998) Developmentally regulated expression of the novel cancer 
anti-apoptosis gene survivin in human and mouse differentiation, The Amer. J. 
Pathology. 152, 43–49. 
[47] M. Coumar, F. Tsai, J. Kanwar, S. Sarvagalla, C. Cheung (2013) Treat cancers by 
targeting survivin: just a dream or future reality?, Cancer Treat. Rev., 39, 802–811. 
[48] M. Johnson, E. Howerth  (2004) A bifunctional inhibitor of apoptosis protein, Vet. 
Pathol., 41, 599–607. 
[49] G. Ambrosini, C. Adida, D. Altieri  (1997) A novel anti-apoptosis gene, survivin, 
expressed in cancer and lymphoma, Nat Med. 3, 917–921. 
[50] S. Chettiar, et al. (2013) Design, synthesis and biological studies of Survivin 
dimerization modulators that prolong mitotic cycle, Bioorg. & Med. Chem. Letters. 
23, 5429–5433. 
[51] D.C. Altieri (2003) Survivin, versatile modulation of cell division and apoptosis in 
cancer, Oncogene. 22, 8581–8589. doi:10.1038/sj.onc.1207113. 
[52] A.M. Aljaberi, J.R. Webster, S.P. Wheatley (2015)  Mitotic activity of survivin is 
regulated by acetylation at K129, Cell Cycle. 14, 1738–1747. 
doi:10.1080/15384101.2015.1033597. 
[53] M.A. Verdecia, H. Huang, E. Dutil, D.A. Kaiser, T. Hunter, J.P. Noel  (2000) 
Structure of the human anti-apoptotic protein survivin reveals a dimeric 
arrangement, Nat. Struct. Biol. 7, 7. 
138 
 
[54] F. Li, G. Ambrosini, E.Y. Chu, J. Plescia, S. Tognin, P.C. Marchisio, D.C. Altieri 
(1998) Control of apoptosis and mitotic spindle checkpoint by survivin, Nature. 
396, 580–584. doi:10.1038/25141. 
[55] L. Chantalat, et al. (2000) Crystal structure of human survivin reveals a bow tie 
shaped dimer with two unusual α-helical extensions, Mol. Cell. 6, 183–189. 
doi:10.1016/S1097-2765(00)00019-8. 
[56] T. Dohi, K. Okada, F. Xia, C.E. Wilford, T. Samuel, K. Welsh, H. Marusawa, H. 
Zou, R. Armstrong, S. Matsuzawa, G.S. Salvesen, J.C. Reed, D.C. Altieri (2004) An 
IAP-IAP complex inhibits apoptosis, J. Biol. Chem. 279, 34087–34090. 
doi:10.1074/jbc.C400236200. 
[57] D. Hu, S. Liu, L. Shi, C. Li, L. Wu, Z. Fan (2010) Cleavage of survivin by 
granzyme M triggers degradation of the survivin-X-linked inhibitor of apoptosis 
orotein (XIAP) complex to free caspase activity leading to cytolysis of target tumor 
Cells, J. Biol. Chem. 285, 18326–18335. doi:10.1074/jbc.M109.083170. 
[58] R. Moriai, N. Tsuji, M. Moriai, D. Kobayashi, N. Watanabe (2009) Survivin plays 
as a resistant factor against tamoxifen-induced apoptosis in human breast cancer 
cells, Breast Cancer Res. Treat. 117, 261–271. doi:10.1007/s10549-008-0164-5. 
[59] N.E. Weisser, J.C. Hall (2009) Applications of single-chain variable fragment 
antibodies in therapeutics and diagnostics, Biotechnol. Adv. 27,502–520. 
doi:10.1016/j.biotechadv.2009.04.004. 
[60] A. Messer, J. McLear (2006), The therapeutic potential of intrabodies in neurologic 
disorders, BioDrugs. 20,  327–333. 
[61] A. Wörn, A. Auf der Maur, D. Escher, A. Honegger, A. Barberis, A. Plückthun 
(2000) Correlation between in vitro stability and in vivo performance of anti-GCN4 
intrabodies as cytoplasmic inhibitors, J. Biol. Chem. 275, 2795–2803. 
doi:10.1074/jbc.275.4.2795. 
[62] R.C. Cumming, N.L. Andon, P.A. Haynes, M. Park, W.H. Fischer, D. Schubert 
(2004) Protein disulfide bond formation in the cytoplasm during oxidative stress, J. 
Biol. Chem. 279,  21749–21758. doi:10.1074/jbc.M312267200. 
[63] S.N. Joshi, D.C. Butler, A. Messer (2012) Fusion to a highly charged proteasomal 
retargeting sequence increases soluble cytoplasmic expression and efficacy of 
diverse anti-synuclein intrabodies, MAbs. 4, 686–693. doi:10.4161/mabs.21696. 
[64] M.P. DeLisa, D. Tullman, G. Georgiou (2003)  Folding quality control in the export 
of proteins by the bacterial twin-arginine translocation pathway, Proc. Natl. Acad. 
Sci. 100, 6115–6120. doi:10.1073/pnas.0937838100. 
139 
 
[65] A.C. Fisher, W. Kim, M.P. Delisa (2006)  Genetic selection for protein solubility 
enabled by the folding quality control feature of the twin‐arginine translocation 
pathway, Protein Sci. 15, 449–458. doi:10.1110/ps.051902606. 
[66] P. Martineau, P. Jones, G. Winter (1998)  Expression of an antibody fragment at 
high levels in the bacterial cytoplasm, J. Mol. Biol. 280,117–127. 
doi:10.1006/jmbi.1998.1840. 
[67] E.G. Bogsch, F. Sargent, N.R. Stanley, B.C. Berks, C. Robinson, T. Palmer (1998) 
An essential component of a novel bacterial protein export system with homologues 
in plastids and mitochondria, J. Biol. Chem. 273, 18003–18006. 
doi:10.1074/jbc.273.29.18003. 
[68] C. Tayapiwatana, R. Chotpadiwetkul, W. Kasinrerk (2006) A novel approach using 
streptavidin magnetic bead-sorted in vivo biotinylated survivin for monoclonal 
antibody production, J. Immunol. Methods. 317, 1–11. 
doi:10.1016/j.jim.2006.07.024. 
[69] R. Rauchenberger, E. Borges, E. Thomassen-Wolf, E. Rom, R. Adar, Y. Yaniv, M. 
Malka, I. Chumakov, S. Kotzer, D. Resnitzky, A. Knappik, S. Reiffert, J. Prassler, 
K. Jury, D. Waldherr, S. Bauer, T. Kretzschmar, A. Yayon, C. Rothe (2003) Human 
combinatorial Fab library yielding specific and functional antibodies against the 
human fibroblast growth factor receptor 3, J. Biol. Chem. 278,  38194–38205. 
doi:10.1074/jbc.M303164200. 
[70] H.J. de Haard, N. van Neer, A. Reurs, S.E. Hufton, R.C. Roovers, P. Henderikx, 
A.P. de Bruı̈ne, J.-W. Arends, H.R. Hoogenboom  (1999)  A large non-immunized 
human Fab fragment phage library that permits rapid isolation and kinetic analysis 
of high affinity antibodies, J. Biol. Chem. 274, 18218–18230. 
doi:10.1074/jbc.274.26.18218. 
[71] K.Y. Yau, M.A. Groves, S. Li, C. Sheedy, H. Lee, J. Tanha, C.R. MacKenzie, L. 
Jermutus, J.C. Hall (2003) Selection of hapten-specific single-domain antibodies 
from a non-immunized llama ribosome display library, J. Immunol. Methods. 281, 
161–175. doi:10.1016/j.jim.2003.07.011. 
[72] A. M. Levin, G. A. Weiss  (2006) Optimizing the affinity and specificity of proteins 
with molecular display, Mol. Biosyst. 2, 49–57. doi:10.1039/B511782H. 
[73] I. Liu, M. Liu, K. Shergill (2006) The effect of spheroplast formation on the 
transformation efficiency in escherichia coli DH5α, J. Exp. Microbiol. Immun. 9, 
81-85. 
[74] W.-K. Min, S.-G. Kim, J.-H. Seo (2015) Affinity maturation of single-chain 
variable fragment specific for aflatoxin B1 using yeast surface display, Food Chem. 
188,  604–611. doi:10.1016/j.foodchem.2015.04.117. 
140 
 
[75] T.S. Chen, H. Palacios, A.E. Keating  (2013) Structure-based redesign of the 
binding specificity of anti-apoptotic Bcl-xL, J. Mol. Biol. 425, 171–185. 
doi:10.1016/j.jmb.2012.11.009. 
[76] C.F. Barbas, J.D. Bain, D.M. Hoekstra, R.A. Lerner  (1992) Semisynthetic 
combinatorial antibody libraries: a chemical solution to the diversity problem., 
Proc. Natl. Acad. Sci. 89, 4457–4461. doi:10.1073/pnas.89.10.4457. 
[77] M.J. Feldhaus, R.W. Siegel, L.K. Opresko, J.R. Coleman, J.M.W. Feldhaus, Y.A. 
Yeung, J.R. Cochran, P. Heinzelman, D. Colby, J. Swers, C. Graff, H.S. Wiley, 
K.D. Wittrup (2003) Flow-cytometric isolation of human antibodies from a 
nonimmune Saccharomyces cerevisiae surface display library, Nat. Biotechnol. 21, 
163–170. doi:10.1038/nbt785. 
[78] G.M. Cherf, J.R. Cochran (2015) Applications of yeast surface display for protein 
engineering, Methods Mol. Bio.1319, 155–175. doi:10.1007/978-1-4939-2748-7_8. 
[79] J.A.V. Deventer, K.D. Wittrup (2014) Yeast surface display for antibody isolation: 
library construction, library screening, and affinity maturation, Methods Mol. Bio, 
1131, 151–181. doi:10.1007/978-1-62703-992-5_10. 
[80] A. Angelini, T.F. Chen, S. de Picciotto, N.J. Yang, A. Tzeng, M.S. Santos, J.A.V. 
Deventer, M.W. Traxlmayr, K.D. Wittrup (2015) Protein engineering and selection 
using yeast surface display, Methods Mol. Bio,1319, 3–36. doi:10.1007/978-1-4939-
2748-7_1. 
[81] C. McMahon, A.S. Baier, R. Pascolutti, M. Wegrecki, S. Zheng, J.X. Ong, S.C. 
Erlandson, D. Hilger, S.G.F. Rasmussen, A.M. Ring, A. Manglik, A.C. Kruse 
(2018) Yeast surface display platform for rapid discovery of conformationally 
selective nanobodies, Nat. Struct. Mol. Biol. 25, 289–296. doi:10.1038/s41594-018-
0028-6. 
[82] J. Hanes, C. Schaffitzel, A. Knappik, A. Plückthun (2000) Picomolar affinity 
antibodies from a fully synthetic naive library selected and evolved by ribosome 
display, Nat. Biotechnol. 18, 1287–1292. doi:10.1038/82407. 
[83] B. Wang, C.-H. Lee, E.L. Johnson, C.A. Kluwe, J.C. Cunningham, H. Tanno, R.M. 
Crooks, G. Georgiou, A.D. Ellington (2016) Discovery of high affinity anti-ricin 
antibodies by B cell receptor sequencing and by yeast display of combinatorial 
VH:VL libraries from immunized animals, MAbs. 8, 1035–1044. 
doi:10.1080/19420862.2016.1190059. 
[84] X. Yu, L. Qu, D.D. Bigner, V. Chandramohan (2017) Selection of novel affinity-
matured human chondroitin sulfate proteoglycan 4 antibody fragments by yeast 
display, Protein Eng. Des. Sel. 30, 639–647. doi:10.1093/protein/gzx038. 
141 
 
[85] M.M. Harmsen, H.J. De Haard (2007) Properties, production, and applications of 
camelid single-domain antibody fragments, Appl. Microbiol. Biotechnol. 77, 13–22. 
doi:10.1007/s00253-007-1142-2. 
[86] A.L. Marschall, S. Dübel, T. Böldicke (2015) Specific in vivo knockdown of protein 
function by intrabodies, MAbs. 7, 1010–1035. 
doi:10.1080/19420862.2015.1076601. 
[87] U. Rothbauer, K. Zolghadr, S. Tillib, D. Nowak, L. Schermelleh, A. Gahl, N. 
Backmann, K. Conrath, S. Muyldermans, M.C. Cardoso, H. Leonhardt (2006) 
Targeting and tracing antigens in live cells with fluorescent nanobodies, Nat. 
Methods. 3, 887–889. doi:10.1038/nmeth953. 
[88] R.H.J. van der Linden, L.G.J. Frenken, B. de Geus, M.M. Harmsen, R.C. Ruuls, W. 
Stok, L. de Ron, S. Wilson, P. Davis, C.T. Verrips (1999) Comparison of physical 
chemical properties of llama VHH antibody fragments and mouse monoclonal 
antibodies, Biochim. Biophys. Acta BBA - Protein Struct. Mol. Enzymol. 1431, 37–
46. doi:10.1016/S0167-4838(99)00030-8. 
[89] J. Tanha, G. Dubuc, T. Hirama, S.A. Narang, C.R. MacKenzie (2002) Selection by 
phage display of llama conventional VH fragments with heavy chain antibody VHH 
properties, J. Immunol. Methods. 263, 97–109. doi:10.1016/S0022-1759(02)00027-
3. 
[90] M.A. Ghahroudi, A. Desmyter, L. Wyns, R. Hamers, S. Muyldermans (1997) 
Selection and identification of single domain antibody fragments from camel heavy-
chain antibodies, FEBS Lett. 414, 521–526. doi:10.1016/S0014-5793(97)01062-4. 
[91] R. van der Linden, B. de Geus, W. Stok, W. Bos, D. van Wassenaar, T. Verrips, L. 
Frenken (2000) Induction of immune responses and molecular cloning of the heavy 
chain antibody repertoire of Lama glama, J. Immunol. Methods. 240, 185–195. 
doi:10.1016/S0022-1759(00)00188-5. 
[92] P. Verheesen, M.. ten Haaft, N. Lindner, C.. Verrips, J.J.. de Haard (2003) 
Beneficial properties of single-domain antibody fragments for application in 
immunoaffinity purification and immuno-perfusion chromatography, Biochim. 
Biophys. Acta BBA - Gen. Subj. 1624, 21–28. doi:10.1016/j.bbagen.2003.09.006. 
[93] E.R. Goldman, G.P. Anderson, J.L. Liu, J.B. Delehanty, L.J. Sherwood, L.E. 
Osborn, L.B. Cummins, A. Hayhurst (2006) Facile generation of heat-stable 
antiviral and antitoxin single domain antibodies from a semisynthetic llama library, 
Anal. Chem. 78, 8245–8255. doi:10.1021/ac0610053. 
[94] Y. Sun, B. Ban, A. Bradbury, G.A.S. Ansari, D.A. Blake (2016) Combining yeast 
display and competitive FACS to select rare hapten-specific clones from 




[95] E.T. Boder, K.D. Wittrup (1997) Yeast surface display for screening combinatorial 
polypeptide libraries, Nat. Biotechnol. 15, 553–557. doi:10.1038/nbt0697-553. 
[96] A. Pugsley (1993) The Complete General Secretory Pathway in Gram-Negative 
Bacteriat, Microbiol. Rev. 57, 59. 
[97] M.P. Rapoza, R.E. Webster (1993) The filamentous bacteriophage assembly 
proteins require the bacterial SecA protein for correct localization to the membrane., 
J. Bacteriol. 175, 1856–1859. doi:10.1128/jb.175.6.1856-1859.1993. 
[98] E. Mössner, H. Koch, A. Plückthun (2001) Fast selection of antibodies without 
antigen purification: adaptation of the protein fragment complementation assay to 
select antigen-antibody pairs1 1Edited by I. A. Wilson, J. Mol. Biol. 308, 115–122. 
doi:10.1006/jmbi.2001.4575. 
[99] J. Lloyd-Price, G. Abu-Ali, C. Huttenhower (2016) The healthy human microbiome, 
Genome Med. 8, 51. doi:10.1186/s13073-016-0307-y. 
[100] M.A. Pfaller, D.J. Diekema (2007) Epidemiology of invasive candidiasis: a 
persistent public health problem, Clin. Microbiol. Rev. 20, 133–163. 
doi:10.1128/CMR.00029-06. 
[101] P.G. Pappas, C.A. Kauffman, D.R. Andes, C.J. Clancy, K.A. Marr, L. Ostrosky-
Zeichner, A.C. Reboli, M.G. Schuster, J.A. Vazquez, T.J. Walsh, T.E. Zaoutis, J.D. 
Sobel (2016) Clinical Practice Guideline for the Management of Candidiasis: 2016 
Update by the Infectious Diseases Society of America, Clin. Infect. Dis. Off. Publ. 
Infect. Dis. Soc. Am. 62, e1–e50. doi:10.1093/cid/civ933. 
[102] M.B. Lohse, M. Gulati, A.D. Johnson, C.J. Nobile (2017) Development and 
regulation of single- and multi-species Candida albicans biofilms, Nat. Rev. 
Microbiol. 16, 19–31. doi:10.1038/nrmicro.2017.107. 
[103] P.K. Mukherjee, J. Chandra, D.M. Kuhn, M.A. Ghannoum (2003)  Mechanism of 
fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux 
pumps and membrane sterols, Infect. Immun. 71, 4333–4340. 
doi:10.1128/IAI.71.8.4333-4340.2003. 
[104] S.P. Hawser, L.J. Douglas (1995) Resistance of Candida albicans biofilms to 
antifungal agents in vitro, Antimicrob. Agents Chemother. 39, 2128–2131. 
doi:10.1128/AAC.39.9.2128. 
[105] G. Ramage, S. Bachmann, T.F. Patterson, B.L. Wickes, J.L. López-Ribot (2002) 
Investigation of multidrug efflux pumps in relation to fluconazole resistance in 
Candida albicans biofilms, J. Antimicrob. Chemother. 49, 973–980. 
doi:10.1093/jac/dkf049. 
[106] M.A. Jabra-Rizk, W.A. Falkler, T.F. Meiller (2004) Fungal biofilms and drug 
resistance, Emerg. Infect. Dis., 10, 14-19. doi:10.3201/eid1001.030119. 
143 
 
[107] K.C. Gray, D.S. Palacios, I. Dailey, M.M. Endo, B.E. Uno, B.C. Wilcock, M.D. 
Burke (2012)  Amphotericin primarily kills yeast by simply binding ergosterol, 
Proc. Natl. Acad. Sci. 109, 2234–2239. doi:10.1073/pnas.1117280109. 
[108] M.A. Ghannoum, L.B. Rice (1999) Antifungal agents: mode of action, 
mechanisms of resistance, and correlation of these mechanisms with bacterial 
resistance, Clin. Microbiol. Rev. 12, 501–517. 
[109] T. Xu, S.M. Levitz, R.D. Diamond, F.G. Oppenheim (1991) Anticandidal activity 
of major human salivary histatins., Infect. Immun. 59, 2549–2554. 
[110] P.A. Raj, E. Marcus, D.K. Sukumaran (1997) Structure of human salivary histatin 
5 in aqueous and nonaqueous solutions, Biopolymers. 45, 51–67. 
doi:10.1002/(SICI)1097-0282(199801)45:1<51::AID-BIP5>3.0.CO;2-Y. 
[111] O. Salvatori, S. Puri, S. Tati, M. Edgerton (2016) Innate immunity and saliva in 
Candida albicans–mediated oral diseases, J. Dent. Res. 95, 365–371. 
doi:10.1177/0022034515625222. 
[112] A.N. Amerongen, E.C.I. Veerman (2002)  Saliva – the defender of the oral cavity, 
Oral Dis. 8, 12–22. doi:10.1034/j.1601-0825.2002.1o816.x. 
[113] F.G. Oppenheim, T. Xu, F.M. McMillian, S.M. Levitz, R.D. Diamond, G.D. 
Offner, R.F. Troxler (1988) Histatins, a novel family of histidine-rich proteins in 
human parotid secretion. Isolation, characterization, primary structure, and 
fungistatic effects on Candida albicans., J. Biol. Chem. 263, 7472–7477. 
[114] T.F. Meiller, B. Hube, L. Schild, M.E. Shirtliff, M.A. Scheper, R. Winkler, A. 
Ton, M.A. Jabra-Rizk (2009) A novel immune evasion strategy of Candida 
albicans: proteolytic cleavage of a salivary antimicrobial peptide, PLoS ONE. 4. 
doi:10.1371/journal.pone.0005039. 
[115] S. Puri, M. Edgerton (2014) How does it kill?: understanding the candidacidal 
mechanism of salivary histatin 5, Eukaryot. Cell. 13, 958–964. 
doi:10.1128/EC.00095-14. 
[116] M. Edgerton, S.E. Koshlukova, T.E. Lo, B.G. Chrzan, R.M. Straubinger, P.A. Raj 
(1998) Candidacidal activity of salivary histatins: identification of a histatin 5-
binding protein on Candida albicans, J. Biol. Chem. 273, 20438–20447. 
doi:10.1074/jbc.273.32.20438. 
[117] C.R. Pusateri, E.A. Monaco, M. Edgerton (2009) Sensitivity of Candida albicans 
biofilm cells grown on denture acrylic to antifungal proteins and chlorhexidine, 
Arch. Oral Biol. 54, 588–594. doi:10.1016/j.archoralbio.2009.01.016. 
[118] S.A. Khan, P.L. Fidel, A.A. Thunayyan, S. Varlotta, T.F. Meiller, M.A. Jabra-
Rizk (2013) Impaired histatin-5 levels and salivary antimicrobial activity against C. 
144 
 
albicans in HIV infectedindividuals, J. AIDS Clin. Res. 4. doi:10.4172/2155-
6113.1000193. 
[119] S.R. Torres, A. Garzino‐Demo, T.F. Meiller, V. Meeks, M.A. Jabra‐Rizk (2009) 
Salivary histatin-5 and oral fungal colonisation in HIV+ individuals, Mycoses. 52, 
11–15. doi:10.1111/j.1439-0507.2008.01602.x. 
[120] A.B. Mochon, H. Liu (2008) The antimicrobial peptide histatin-5 causes a 
spatially restricted disruption on the Candida albicans surface, allowing rapid entry 
of the peptide into the cytoplasm, PLoS Pathog. 4, e1000190. 
doi:10.1371/journal.ppat.1000190. 
[121] D.M. Rothstein, P. Spacciapoli, L.T. Tran, T. Xu, F.D. Roberts, M. Dalla Serra, 
D.K. Buxton, F.G. Oppenheim, P. Friden(2001) Anticandida activity is retained in 
p-113, a 12-amino-acid fragment of histatin 5, Antimicrob. Agents Chemother. 45, 
1367–1373. doi:10.1128/AAC.45.5.1367-1373.2001. 
[122] H. Situ, S.V. Balasubramanian, L.A. Bobek (2000) Role of alpha-helical 
conformation of histatin-5 in candidacidal activity examined by proline variants., 
Biochim. Biophys. Acta. 1475, 377–382. doi:10.1016/S0304-4165(00)00096-9. 
[123] J. Driscoll, C. Duan, Y. Zuo, T. Xu, R. Troxler, F.G. Oppenheim (1996) 
Candidacidal activity of human salivary histatin recombinant variants produced by 
site-directed mutagenesis, Gene. 177, 29–34. doi:10.1016/0378-1119(96)00265-X. 
[124] P.A. Raj, M. Edgerton, M.J. Levine(1990) Salivary histatin 5: dependence of 
sequence, chain length, and helical conformation for candidacidal activity, J. Biol. 
Chem. 265, 3898–3905. 
[125] E.J. Helmerhorst, W. Van’t Hof, E.C. Veerman, I. Simoons-Smit, A.V. Nieuw 
Amerongen (1997) Synthetic histatin analogues with broad-spectrum antimicrobial 
activity, Biochem. J. 326, 39–45. 
[126] E.J. Helmerhorst, W. van’t Hof, P. Breeuwer, E.C.I. Veerman, T. Abee, R.F. 
Troxler, A.V.N. Amerongen, F.G. Oppenheim (2001) Characterization of histatin 5 
with respect to amphipathicity, hydrophobicity, and effects on cell and 
mitochondrial membrane integrity excludes a candidacidal mechanism of pore 
formation, J. Biol. Chem. 276, 5643–5649. doi:10.1074/jbc.M008229200. 
[127] A.L.A. Ruissen, J. Groenink, E.J. Helmerhorst, E. Walgreen-Weterings, W. van’t 
Hof, E.C.I. Veerman, A.V.N. Amerongen (2001) Effects of histatin 5 and derived 
peptides on Candida albicans, Biochem. J. 356, 361–368. doi:10.1042/bj3560361. 
[128] X.S. Li, J.N. Sun, K. Okamoto-Shibayama, M. Edgerton (2006) Candida albicans 
cell wall Ssa proteins bind and facilitate import of salivary histatin 5 required for 
toxicity, J. Biol. Chem. 281, 22453–22463. doi:10.1074/jbc.M604064200. 
145 
 
[129] E.J. Helmerhorst, P. Breeuwer, W. van ‘t Hof, E. Walgreen-Weterings, L.C.J.M. 
Oomen, E.C.I. Veerman, A.V.N. Amerongen, T. Abee (1999)  The cellular target of 
histatin 5 on Candida albicans is the energized mitochondrion, J. Biol. Chem. 274, 
7286–7291. doi:10.1074/jbc.274.11.7286. 
[130] O. Bochenska, M. Rapala-Kozik, N. Wolak, W. Aoki, M. Ueda, A. Kozik(2016) 
The action of ten secreted aspartic proteases of pathogenic yeast Candida albicans 
on major human salivary antimicrobial peptide, histatin 5, Acta Biochim. Pol. 63, 
403–410. doi:10.18388/abp.2016_1318. 
[131] A. da Silva Dantas, K.K. Lee, I. Raziunaite, K. Schaefer, J. Wagener, B. Yadav, 
N.A. Gow (2016) Cell biology of Candida albicans–host interactions, Curr. Opin. 
Microbiol. 34, 111–118. doi:10.1016/j.mib.2016.08.006. 
[132] A. Albrecht, A. Felk, I. Pichova, J.R. Naglik, M. Schaller, P. de Groot, D. 
MacCallum, F.C. Odds, W. Schäfer, F. Klis, M. Monod, B. Hube (2006) 
Glycosylphosphatidylinositol-anchored proteases of Candida albicans target 
proteins necessary for both cellular processes and host-pathogen interactions, J. 
Biol. Chem. 281, 688–694. doi:10.1074/jbc.M509297200. 
[133] J.R. Naglik, S.J. Challacombe, B. Hube (2003) Candida albicans secreted 
aspartyl proteinases in virulence and pathogenesis, Microbiol. Mol. Biol. Rev. 67, 
400–428. doi:10.1128/MMBR.67.3.400-428.2003. 
[134] W. Aoki, N. Kitahara, N. Miura, H. Morisaka, Y. Yamamoto, K. Kuroda, M. 
Ueda (2011) Comprehensive characterization of secreted aspartic proteases encoded 
by a virulence gene family in Candida albicans, J. Biochem. (Tokyo). 150, 431–
438. doi:10.1093/jb/mvr073. 
[135] L. Schild, A. Heyken, P.W.J. de Groot, E. Hiller, M. Mock, C. de Koster, U. 
Horn, S. Rupp, B. Hube (2011) Proteolytic cleavage of covalently linked cell wall 
proteins by Candida albicans sap9 and sap10, Eukaryot. Cell. 10, 98–109. 
doi:10.1128/EC.00210-10. 
[136] M.B. Zepelin, S. Beggah, K. Boggian, D. Sanglard, M. Monod (2002) The 
expression of the secreted aspartyl proteinases Sap4 to Sap6 from Candida albicans 
in murine macrophages, Mol. Microbiol. 28, 543–554. doi:10.1046/j.1365-
2958.1998.00815.x. 
[137] J.R. Naglik, D. Moyes, J. Makwana, P. Kanzaria, E. Tsichlaki, G. Weindl, A.R. 
Tappuni, C.A. Rodgers, A.J. Woodman, S.J. Challacombe, M. Schaller, B. Hube 
(2008)  Quantitative expression of the Candida albicans secreted aspartyl proteinase 
gene family in human oral and vaginal candidiasis, Microbiol. Read. Engl. 154, 
3266–3280. doi:10.1099/mic.0.2008/022293-0. 
[138] O. Bochenska, M. Rapala-Kozik, N. Wolak, W. Kamysz, D. Grzywacz, W. Aoki, 
M. Ueda, A. Kozik (2015) Inactivation of human kininogen-derived antimicrobial 
146 
 
peptides by secreted aspartic proteases produced by the pathogenic yeast Candida 
albicans, Biol. Chem. 396. doi:10.1515/hsz-2015-0167. 
[139] G. Koelsch, J. Tang, J.A. Loy, M. Monod, K. Jackson, S.I. Foundling, X. Lin 
(2000) Enzymic characteristics of secreted aspartic proteases of Candida albicans, 
Biochim. Biophys. Acta BBA - Protein Struct. Mol. Enzymol. 1480, 117–131. 
doi:10.1016/S0167-4838(00)00068-6. 
[140] S. Ikonomova, Protein engineering approaches to improving diagnosis and 
treatment of Candida albicans infections, PhD Dissertation, University of 
Maryland, 2017. 
[141] L. Mathé, P. Van Dijck (2013) Recent insights into Candida albicans biofilm 
resistance mechanisms, Curr. Genet. 59, 251–264. doi:10.1007/s00294-013-0400-3. 
[142] G. Baillie, L.J. Douglas (1999) Candida biofilms and their susceptibility to 
antifungal agents, in: R. Doyle (Ed.), Methods Enzymol., 310, 644–656. 
[143] L.J. Douglas (2003) Candida biofilms and their role in infection, Trends 
Microbiol. 11, 30–36. doi:10.1016/S0966-842X(02)00002-1. 
[144] S.P. Hawser, L.J. Douglas (1994) Biofilm formation by Candida species on the 
surface of catheter materials in vitro, Infect. Immun. 62, 915-921. 
[145] P. Sudbery, N. Gow, J. Berman (2004) The distinct morphogenic states of 
Candida albicans, Trends Microbiol. 12, 317–324. doi:10.1016/j.tim.2004.05.008. 
[146] C.A. Kumamoto, M.D. Vinces (2005) Contributions of hyphae and hypha-co-
regulated genes to Candida albicans virulence, Cell. Microbiol., 7,1546–1554. 
doi:10.1111/j.1462-5822.2005.00616.x. 
[147] M.B. Lohse, A.D. Johnson (2009) White–opaque switching in Candida albicans, 
Curr. Opin. Microbiol. 12, 650–654. doi:10.1016/j.mib.2009.09.010. 
[148] M.A. Al-Fattani, L.J. Douglas (2006) Biofilm matrix of Candida albicans and 
Candida tropicalis: chemical composition and role in drug resistance, J. Med. 
Microbiol. 55, 999–1008. doi:10.1099/jmm.0.46569-0. 
[149] K.Y. Lum, S.T. Tay, C.F. Le, V.S. Lee, N.H. Sabri, R.D. Velayuthan, H. Hassan, 
S.D. Sekaran (2015) Activity of novel synthetic peptides against Candida albicans, 
Sci. Rep. 5, 9657. doi:10.1038/srep09657. 
[150] A.J. Karlsson, W.C. Pomerantz, K.J. Neilsen, S.H. Gellman, S.P. Palecek (2009) 
Effect of sequence and structural properties on 14-Helical β-Peptide activity against 




[151] A.J. Karlsson, R.M. Flessner, S.H. Gellman, D.M. Lynn, S.P. Palecek (2010) 
Polyelectrolyte multilayers fabricated from antifungal β-peptides: design of surfaces 
that exhibit antifungal activity against Candida albicans, Biomacromolecules. 11, 
2321–2328. doi:10.1021/bm100424s. 
[152] L.L. Burrows, M. Stark, C. Chan, E. Glukhov, S. Sinnadurai, C.M. Deber (2006) 
Activity of novel non-amphipathic cationic antimicrobial peptides against Candida 
species, J. Antimicrob. Chemother. 57, 899–907. doi:10.1093/jac/dkl056. 
[153] P.-W. Tsai, C.-Y. Yang, H.-T. Chang, C.-Y. Lan (2011) Human antimicrobial 
peptide ll-37 inhibits adhesion of Candida albicans by interacting with yeast cell-
wall carbohydrates, PLoS ONE. 6, e17755. doi:10.1371/journal.pone.0017755. 
[154] M.J.S. Mendes Giannini, T. Bernardi, L. Scorzoni, A.M. Fusco-Almeida, J.C.O. 
Sardi (2013) Candida species: current epidemiology, pathogenicity, biofilm 
formation, natural antifungal products and new therapeutic options, J. Med. 
Microbiol. 62, 10–24. doi:10.1099/jmm.0.045054-0. 
[155] M.M. Weerasekera, G.K. Wijesinghe, T.A. Jayarathna, C.P. Gunasekara, N. 
Fernando, N. Kottegoda, L.P. Samaranayake (2016) Culture media profoundly 
affect Candida albicans and Candida tropicalis growth, adhesion and biofilm 
development, Mem. Inst. Oswaldo Cruz. 111, 697–702. doi:10.1590/0074-
02760160294. 
[156] N. Raman, M.-R. Lee, S.P. Palecek, D.M. Lynn (2014)  Polymer multilayers 
loaded with antifungal β-peptides kill planktonic Candida albicans and reduce 
formation of fungal biofilms on the surfaces of flexible catheter tubes, J. Controlled 
Release. 191, 54–62. doi:10.1016/j.jconrel.2014.05.026. 
[157] O. Etienne, C. Gasnier, C. Taddei, J.-C. Voegel, D. Aunis, P. Schaaf, M.-H. Metz-
Boutigue, A.-L. Bolcato-Bellemin, C. Egles (2005) Antifungal coating by 
biofunctionalized polyelectrolyte multilayered films, Biomaterials. 26, 6704–6712. 
doi:10.1016/j.biomaterials.2005.04.068. 
[158] K. Proba, A. Wörn, A. Honegger, A. Plückthun (1998) Antibody scFv fragments 
without disulfide bonds, made by molecular evolution, J. Mol. Biol. 275,  245–253. 
doi:10.1006/jmbi.1997.1457. 
[159] P. Moghaddam-Taaheri, A.J. Karlsson (2018)  Protein labeling in live cells for 
immunological applications, Bioconjug. Chem. 29, 680–685. 
doi:10.1021/acs.bioconjchem.7b00722. 
[160] S.P. Ikonomova, Z. He, A.J. Karlsson (2016) A simple and robust approach to 





[161] J. Cruz, M. Mihailescu, G. Wiedman, K. Herman, P.C. Searson, W.C. Wimley, K. 
Hristova (2013) A membrane-translocating peptide penetrates into bilayers without 
significant bilayer perturbations, Biophys. J. 104, 2419–2428. 
doi:10.1016/j.bpj.2013.04.043. 
[162] J. Bürck, P. Wadhwani, S. Fanghänel, A.S. Ulrich (2016) Oriented circular 
dichroism: a method to characterize membrane-active peptides in oriented lipid 
bilayers, Acc. Chem. Res. 49, 184–192. doi:10.1021/acs.accounts.5b00346. 
 
